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Abstract 
The work presented in this thesis aims to extend our understanding of 
the controlling mechanisms that influence the plasma concentration of 
lipoprotein(a) [Lp(a)]. The techniques of apo(a) genotyping and apo(a) 
phenotyping are used to study Lp(a) in different ethnic and genetic groups to 
achieve this end. In chapter 3 the effective use of a commercially available 
monoclonal antibody is demonstrated. Two primary antibodies were compared 
and apo(a) isoform analysis was performed using an immunoblotting method. 
When equal quantities of Lp(a) were loaded approximately equal signal 
intensities were obtained, irrespective of apo(a) isoform size. Serial dilutions of 
samples with known Lp(a) level and a single expressing apo(a) isoform were 
used to determine the detection limit of the system. With both monoclonals it 
was possible to detect 0.05 mg. dL-l Lp(a). 
Distributions of plasma Lp(a) concentrations exhibit marked inter-racial 
differences. Apo(a), the unique constituent of Lp(a), is highly polymorphic in 
length due to allelic variations in the number of kringle 4 (K-4)-encoding 
sequences. Plasma Lp(a) concentrations are inversely related to the number of 
K-4 repeats in the apo(a) alleles. To determine the contribution of this length 
variation to the inter-racial variation in plasma Lp(a) levels, the APO(a) allele 
size, glycoprotein size, and plasma Lp(a) concentrations in Caucasians, Chinese 
and African-Americans were compared in chapter 4. Caucasians and African-
Americans had very different distributions of plasma Lp(a) concentrations yet 
there was no significant difference in the overall frequency distributions of their 
APO( a) alleles. Over the entire size spectrum of apo(a) alleles, the plasma Lp(a) 
levels were higher in African-Americans than in Caucasians. Conversely, 
Caucasians and Chinese had similar plasma Lp(a) concentrations but 
significantly different APO( a) allele size distributions. Therefore, inter-racial 
differences in the plasma concentrations of Lp(a) are not due to differences in 
the frequency distributions of APO( a) alleles. The relationship between APO( a) 
allele size and the presence of detectable plasma apo(a) protein in plasma were 
also examined. APO( a) alleles associated with no detectable plasma protein 
were not of uniformly large size, as had been expected, but were distributed 
over the entire size spectrum. From this analysis, it was concluded that there is 
no common "null" allele at the APO( a) locus. 
xv 
The role of the low density lipoprotein (LDL) receptor in the control of 
plasma Lp(a) concentrations remains controversial. To investigate if a reduction 
in LDL receptor activity is associated with alteration in the plasma 
concentrations of Lp(a), the apo(a) phenotype and plasma lipid levels have been 
studied in families with familial hypercholesterolemia (FH). In normal 
Caucasian families it has previously been shown that 90% of the inter-
individual variation in plasma Lp(a) levels is attributable to sequences linked to 
the APO( a) gene; this is reflected in the fact that sibling pairs who inherit 
APO(a) alleles identical by descent (ibd) had very similar plasma levels of Lp(a) 
(r=0.95). In chapter 5, plasma Lp(a) levels are compared in siblings from 9 
families with FH. In the non-FH (n=15), and FH sibling pairs (n=lO) the 
plasma Lp(a) levels were very similar. The plasma Lp(a) levels in the sibling 
pairs with the same apo(a) phenotype and with APO(a) alleles ibd in which one 
member had FH and one member did not (n=12), were significantly different 
[median plasma Lp(a) 22.0 vs. 12.0 mg. dL-I, p=0.005], which would be 
expected if the LDL receptor played an important role in the control of plasma 
Lp(a) levels, as it does for LDL. 
Apo B-67 is a truncated form of apoB previously described in a large 
Amish kindred. The mutation is associated with apoB levels that are 25% of 
normal, which result from decreased production of both apoB-lOO and apoB-
67. To determine the impact of decreased apoB-lOO production on plasma 
Lp(a) levels families with this form of familial hypobetalipoproteinaemia (FHB) 
were studied. In chapter 6, plasma Lp(a) levels are compared in siblings from 
these FHB families. In the non-FHB (n=13), and FHB sibling pairs (n=6) the 
plasma Lp(a) levels were very similar. The plasma Lp(a) levels in the sibling 
pairs with the same apo(a) phenotype and with APO(a) alleles ibd in which one 
member had FHB and one member did not (n=13), were significantly different 
[median plasma Lp(a) 4.6 vs. 1.8 mg. dL-I, p=O.003], which would be 
expected if the APOB gene played an important role in the control of plasma 
Lp(a) levels. 
In chapter 7 an overall review of the major findings reported in this 
thesis is presented. 
Chapter 1 Introduction 
The factor present in the serum of positive human reactors was called Lp(a) 
factor, where Lp is an abbreviation for Lipo-protein. 
KAre Berg, 1963. 
1.1 Introduction 
Lipoprotein(a) [Lp(a)] is a cholesteryl-ester rich lipoprotein that 
resembles low density lipoprotein (LDL), but has distinctive structural, 
epidemiological, and genetic properties. Discovered and named by Berg in 
1963, Lp(a) stimulated relatively little interest for almost 25 years despite early 
reports of its association with coronary heart disease (CHD). Now, however, 
there is a renewed and rapidly growing interest in this lipoprotein, due to 
mounting evidence linking high plasma concentrations of Lp(a) with increased 
risk of coronary and cerebrovascular atherosclerosis. In addition, the molecular 
genetic analysis of the APO( a) gene has provided new insight into the genetic 
control of Lp(a) levels. 
1.2. Lp(a) and apo(a) structure 
1.2.1 Lp(a) structure 
Lp(a) has two components: a particle of LDL, to which is attached a 
large, hydrophilic, glycoprotein, apolipoprotein(a) [apo(a)] [Figure 1.1]. 
Apo(a) is attached to the apoB-lOO of LDL by a single disulphide bridge 
(Gaubatz et al., 1983; Utermann & Weber, 1983; Sommer et al., 1991), but 
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LDL 
4 4 Apo (a) 
FIGURE 1.1. Structure of Lp(a) 
Plasminogen 
Apo(a) 
98 100------75·85 ------ 91 94 
% sequence identity 
FIGURE 1.2. 
87 
Compari on of plasminogen and apo(a) cDNAs. SS-signal sequence; T - tail 
region; 1-5 - kringle 1 to k:ringle 5; P-protease domain. Adapted from McLean 
et al. (1987). 
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other non-covalent, hydrophobic interactions may also participate in the 
association of apo(a) with LDL (Fless et aI., 1985; Chiesa et aI., 1992; Ye et 
aI., 1988). Lp(a) has a higher density (d= 1.027 - 1.100 g. mL-l) and mass 
(4.6-5.6 x 106 Daltons) than LDL (En holm et aI., 1972; Sattler et aI., 1991). 
The lipid composition of Lp(a) is similar to that of LDL, but Lp(a) has a 4-fold 
higher carbohydrate content than LDL due to extensive glycosylation of the 
apo(a) protein. Lp(a) has pre-B migration on agarose gel electrophoresis and 
has been alternatively referred to as the "sinking pre-B lipoprotein". The 
physical characteristics of Lp(a) and LDL are compared in table 1.1. 
As early as 1973, it was recognized that there was significant inter-
individual heterogeneity in the density of Lp(a) (Harvie & Schultz, 1973). 
These differences in Lp(a) density are now known to be due to variations in the 
size of the apo(a) component of Lp(a) (Fless et aI., 1984; Kraft et at, 1992; 
Reblin et ai., 1992). As expected, the higher molecular weight of the apo(a) 
isoform, the denser the Lp(a) particle (Fless et aI., 1984; Pfaffinger et aI., 
1991). It was Utermann (1989) who made the seminal observation that apo(a) 
varied in size over a wide range (400-700 kDa) and that the size variation was 
inherited as a stable Mendelian trait (Utermann et aI., 1988a). This size 
polymorphism has provided an important molecular tool with which to study 
the genetics of Lp(a) [section 1.5.3]. 
1.2.2 Apo(a) protein and cDNA structure 
The apo(a) cDNA shares a high degree of sequence identity with that of 
plasminogen, a key zymogen in the fibrinolytic system (McLean et aI., 1987) 
[Figure 1.2]. In the 5' flanking and signal sequence regions, the two cDNAs 
are practically identical in sequence. In plasminogen, the signal sequence is 
followed by a so-called tail region, five cysteine-rich domains refelTed to as 
kringles (K), numbered 1-5, and a protease domain. The sequences 
cOlTesponding to the tail region and Kl to K3 in plasminogen are not found in 
human apo(a). The K4-encoding sequence, which is present as a single copy in 
plasminogen, is repeated 12 to 51 times in apo(a) (Lackner et aI., 1993). 
In the single human apo(a) cDNA that has been characterized to date, 
there was a total of 37 K4 repeats (McLean et aI., 1987). Twenty-four of the 
37 repeats shared the same sequence (Type A repeats). Four repeats, the Type 
B repeats, differed from the Type A repeats by only 3 silent nucleotide 
Table 1.1. Comparison of the physical characteristics of LDL and Lp(a) 
LDL 
Synonym LpB 
Electrophoretic mobility (agarose) jJ 
Buoyant density (g. mL-I) 1.019-1.063 
Molecular mass (Da) 2.4 x 106 
Molecular diameter (A) 210 
Plasma To.s (days) 2.5-3.0 
Fractional catabolic rate (pools. day-I) 0.3-0.5 
Protein (g. moP) 550,000 
Free cholesterol (mol. moP) 725 
Cholesteryl ester (mol. moP) 1,900 
Triglyceride (mol. mol-I) 220 
Phospholipid (mol. mol-I) 1,000 
Lipid: protein mass 3.5 
Da, Dalton; A, dngstrom 
Adapted from MBewu & Durrington (1990). 
Lp(a) 
Sinking pre jJ 
prejJl 
1.027-1.100 
4.6-5.6 x 106 
250 
3.0-3.5 
0.3 
-850,000-1,250,000 
750 
2,000 
350 
1,110 
2.2 
?" 
::::! 
-: 
~ 
'" ~. 
~ 
~ 
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substitutions. The remaining repeats, K4J and K430 - K437 differed from the 
Type A repeats by between 11 and 71 nucleotides. 
Each 342 base pair K4 sequence encodes 114 amino acids including six 
conserved cysteine residues that form three intra-kringle disulphide linkages. 
The penultimate K4-like repeat, K436, contains a free cysteine residue thought 
to be the site of attachment of apo(a) to apoB-IOO (McLean et aI., 1987). The 
exact cysteine residue in apoB-IOO to which apo(a) is bound has not been 
conclusively demonstrated. Since apo(a) does not associate with apoB48, the 
site of attachment probably resides within the C-terminal half of apoB-IOO. 
Physicochemical studies suggest that the residue responsible is at position 3734 
(Coleman et aI., 1990; Guevara et aI., 1993a). 
To prove that the single unpaired cysteine (position 4057) in K436 of 
apo(a) is involved in this covalent linkage with apoB-IOO, two groups have 
altered this residue by ill vitro mutagenesis (Koschinsky et al 1993; Brunner et 
al 1993). When the cysteine was replaced with a serine, the resultant 
recombinant apo(a) glycoprotein failed to associate with human LDL in vitro. 
The final K4 repeat, K437, most closely resembles the K4 repeat of 
plasminogen. This repeat has been proposed as the site of attachment of apo(a) 
to lysine-rich proteins, such as fibrin (Guevara et aI., 1993b; Scanu et aI., 
1993). 
Each K4 repeat in apo(a), unlike plasminogen, contains a consensus 
sequence for the attachment of a single N-linked sugar, and six O-linked 
sugars. Exactly which of these potential glycosylation sites are used is not 
known. Approximately 30% of the mass of apo(a) is carbohydrate, which is 
10-fold higher than the relative sugar content of plasminogen (Fless et aI., 
1986). 
Immediately following the tandem array of K4 sequences, apo(a) 
contains a sequence that is homologous to K5 of plasminogen. In 
plasminogen, this region contains a cleavage site that permits activation by 
tissue-type plasminogen activator (tPA) or urokinase. Apo(a), however, is not 
activated because the amino acid sequence at the cleavage site is not conselved 
(McLean et aI., 1987). Although the protease domain of apo(a) shares 88% 
amino acid identity with plasminogen, apo(a) has no known serine protease 
activity. 
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1.2.3 APO( a) gene structure 
The APO(a) gene resides on the long ann of chromosome 6 (6q26-27) 
within 50 kb of the plasminogen gene and close to two other APO( a) - like 
genes (Murray et aI., 1987; Malgaretti et aI., 1992, Magnaghi et aI., 1994) 
[Figure 1.3]. 
Although the apo(a) cDNA was cloned in 1987, the APO(a) gene and its 
5' flanking region have only recently been isolated. The cloning and 
characterization of the APO( a) gene proved difficult because the gene is large, 
highly repetitive, and strikingly similar to genes encoding other members of the 
plasminogen gene family. A breakthrough was made by Malgaretti et aI. (1992) 
who isolated a yeast artificial chromosome (Y AC) with a -470 kb insert that 
included the entire plasminogen gene as well as the 5' region of the APO( a) 
gene. The APO(a) and plasminogen genes are oriented in a head-to-head 
fashion within 50 kb of each other and are flanked by APO( a)- and 
plasminogen- like sequences, neither of which have yet been fully characterized 
(Magnaghi et al., 1994) [Figure 1.3]. However, it has been shown recently 
that one of these pseudogenes, the apo(a)-related gene C is transcribed in 
human liver (Byrne et aI., 1994) and that loss of a splice donor site at a skipped 
exon in this gene leads to the transcription of a mRNA that encodes a protein 
consisting of a single kringle domain (Byrne et aI., 1995). A total of 1.4 kb of 
the 5' flanking region of the APO( a) gene was sequenced and there was a high 
degree of similarity with the corresponding region of the plasminogen gene 
wi thin the first 712 base pairs. 
The 5' flanking region was also characterized by Wade et al. (1993) 
who noted multiple interleukin-6 responsive elements. This is of potential 
interest since Lp(a) has been proposed as an acute phase reactant (Maeda et aI., 
1989). Consensus sequences of a number of hepatocyte transcription elements, 
hepatocyte nuclear factor 1 a (HNF-1 a), C/EBP, and LF-Al, were also 
identified but it has not yet been determined which, if any, of these elements are 
functionally important in vivo, although positive regulation of APO( a) gene 
transcription has recently been shown ill vitro to be dependent on the binding 
of HNF-1 a to a regulatory element situated downstream of the mRNA start site 
(Wade et aI., 1994). In addition, it is not known whether all the sequences 
necessary for APO(a) transcription and regulation are contained within the 
sequenced regions. 
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Protease 
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PMG-like 
Schematic of the APO(a) - plasminogen gene cluster and the kringle 4 (K4) 
region of the APO( a) gene. The APO( a) gene maps to the tip of the long arm 
of chromosome 6 (6q27), and is located within 50 kb of the plasminogen gene. 
The APO(a) gene has four structural domains: a signal sequence (SS), which is 
nearly identical to that of plasminogen; a K4 region, which contains 12 to 51 
copies of the K4 repeat sequence; a single copy of kringle 5 (K5), which has 
alternatively been referred to as KII and finally, the protease domain. 
Two different nomenclatures have been used to designate the non-identical K4 
repeats. The original numbering system put forth by McLean et al. (1987) or an 
alternative system in which the different types of K4 repeats are numbered 
consecutively (KI - KlO) (Morrisett et aI., 1990). In the latter system, K41 is 
referred to as K I, the A and B repeats as K2 repeats, and so on. Reproduced 
from Gaw & Hobbs (1994). 
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In vitro studies using variable lengths of the 5' untranslated region of 
the APO( a) gene spliced to a luciferase reporter gene have revealed that only 
the portion of the APO( a) gene from position -98 to + 130 is required to direct 
liver-specific transcription of the gene (Wade et aI., 1994). Overexpression of 
HNF-1 a in a HepG2 cell culture system resulted in significant stimulation of 
reporter gene transcription. This result suggests that positive transcriptional 
regulation of the APO( a) gene may be dependent on the binding of HNF-1 a to 
a regulatory element situated downstream of the mRNA start site. Furthermore, 
Wade and his colleagues (1994) have hypothesised the existence of an as yet 
unidentified protein, which may down-regulate APO(a) transcription by 
binding to a discrete sequence within the 5' untranslated region. 
However, the 5' untranslated regions of the apo(a) gene studied so far 
have relatively weak promoter activity and it remains to be seen whether the 
region identified by Wade and his colleagues (1993, 1994) is indeed the long 
sought after apoCa) promoter. 
1.3 Metabolism 
1.3.1 Synthesis of Lp(a) 
ApoCa) is synthesized almost exclusively in the liver (Tomlinson et aI., 
1989) and over 95% of the apolipoprotein circulates in plasma coupled to 
lipoprotein particles (Gries et al., 1987). Metabolic studies suggest that Lp(a), 
unlike LDL, is not derived from a triglyceride-rich precursor particle (Krempler 
et aI., 1979). However, lipoproteins that contain both apo(a) and apoE have 
been identified in both the VLDL and IDL density intervals using apoE 
immunoaffinity chromatography (Bard et aI., 1992). If Lp(a) were initially 
secreted as part of VLDL it would be expected that apo(a) would accumulate in 
the VLDL or IDL fractions in individuals with lipoprotein lipase deficiency or 
Type III hyperlipoproteinaemia. Sandholzer et aI. (1992a) have demonstrated 
that this is not the case. 
Small amounts of apo(a) associate with triglyceride-rich particles, 
including chylomicron remnants and VLDL, after a high fat meal (Bersot et aI., 
1986; Pfaffinger et al. 1991; Cohn et aI., 1991). The larger molecular weight 
forms of apo(a) appear to have a higher affinity for these particles (Pfaffinger et 
aI., 1991). Neither the metabolic fate nor the pathological significance of these 
particles is known. 
Introduction 9 
It is likely that apo(a) is secreted independently of apoB-l 00 and joins 
the LDL particle extracellularly. This hypothesis is supported by two lines of 
evidence. First, in a series of elegant biosynthetic studies of Lp(a) in cultured 
baboon hepatocytes White and her colleagues have demonstrated that there is no 
detectable intracellular apo(a)-apoB-lOO complex (White et aI., 1993), and that 
Lp(a) assembly can occur at the hepatocyte cell surface (White & Lanford, 
1994). These workers found that newly synthesised apo(a) binds to the 
hepatocyte surface and from this location can be captured by apoB-containing 
lipoproteins to produce Lp(a). The second line of evidence comes from a selies 
of important experiments conducted by Chiesa et al. (1992) who developed a 
mouse line expressing a human apo(a) transgene. 
1.3.2 Development of an experimental animal model for Lp(a) 
The elucidation of the metabolism of Lp(a) has been hindered by the 
lack of a convenient animal model. Plasma Lp(a) has a very unusual species 
distribution [see section 1.5.1] and none of the usual laboratory animals have 
circulating Lp(a). Therefore, major efforts have been made to develop a mouse 
model in which to study the metabolism, genetics, and atherogenicity of Lp(a). 
Transgenic mice were recently engineered to express human apo(a) in 
plasma (Chiesa et aI., 1992). In these mice, over 95% of the apo(a) circulated 
free of lipoproteins. An intact Lp(a) particle could be produced by infusion of 
human, but not mouse, LDL. From these studies it was clear that the 
development of a mouse expressing human Lp(a) would require the co-
expression of human apo(a) together with human apoB-IOO. Recently, this 
goal has been achieved by crossing a mouse expressing human apoB with an 
apo(a) transgenic mouse (Linton et aI., 1993; Callow et aI., 1994). The effect 
of this cross on the migration of plasma apo(a) in a non-denaturing 
polyacrylamide gel is shown in Figure 1.4. In mice expressing only apo(a), the 
protein migrates rapidly, indicating that it is not attached to LDL. In the 
offspring that express both transgenes, the immunoreactive apo(a) is retarded, 
and travels at the same position as authentic human Lp(a). This result indicates 
that human apo(a) forms a stable complex with human apoB-100, but not 
mouse apoB-lOO. 
These double transgenic mice are now being used for metabolic and 
atherogenicity studies (Callow et aI., 1995) as well as possible pharmacological 
investigations into potential Lp(a) lowering drugs. 
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Figure 1.4. 
Apo(a) distribution in plasma of mice expressing either or both human apo(a) 
and apoB transgenes. Plasma (l~l) from an apo(a) transgenic mouse (lane 1), 
an apoB transgenic mouse (lane 2), and their offspring (lanes 3-8) were loaded 
onto a 4% non-denaturing polyacrylamide gel. A total of 0.2 ~l of human 
plasma (h) and 1 ~l of apo(a) transgenic mouse plasma (m) were included on 
the gel as positive controls. After electrophoresis, immunoblotting was 
peIformed using an apo(a) specific monoclonal antibody 1A2, conjugated to 
horseradish peroxidase. This method has previously been shown to separate 
free apo(a) from lipoprotein bound apo(a). In the two offspring expressing 
both human apo(a) and apoB u'ansgenes (lanes 5 and 6) the apo(a) migrated 
only a short distance into the gel, to the same level as human Lp(a), indicating 
the lipoprotein association of apo(a) in these mice. Modified from Linton et al 
(1993). 
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1.3.3 Clearance of Lp(a) 
Lp(a) turnover studies suggest that the rate of Lp(a) production, rather 
than catabolism, is the major determinant of the plasma Lp(a) concentration 
(Krempler et aI., 1983; Rader et aI., 1993). The predominant mechanism by 
which Lp(a) is cleared from the circulation remains controversial. Lp(a) can 
bind to, and be internalized via the LDL receptor, as demonstrated by the rapid 
catabolism of Lp(a) in mice overexpressing the LDL receptor transgene 
(Hofmann et aI., 1990). However, the physiological significance of this 
observation is questionable. III vitro studies of LDL receptor mediated binding 
and uptake of Lp(a) by cultured cells have produced conflicting results (Floren 
et aI., 1981; Hofmann et aI., 1990; Krempler et aI., 1983; Armstrong et aI., 
1985); this may in part be due to genetic heterogeneity in the Lp(a) particles, 
variations in the preparation and purity of the Lp(a), interactions between Lp(a) 
and LDL (Kostner, 1993), and differences in the cell types examined. 
In vivo studies suggest that the LDL receptor probably does not playa 
major role in the catabolism of plasma Lp(a). Pharmacological agents that 
significantly modify LDL receptor activity, such as bile acid sequestrant resins 
or HMG-CoA reductase inhibitors, have no appreciable effect on the plasma 
concentration of Lp(a) (Vessby et aI., 1982; Thiery et aI., 1988; JUrgens et aI., 
1989; Kostner et aI., 1989; Wiklund et aI., 1990). Hypothyroidism, which is 
associated with a decrease in LDL receptor activity (Salter et aI., 1991) and 
elevation in plasma concentrations of LDL, is not associated with a significant 
change in plasma Lp(a) levels (Klausen et aI., 1992a). Moreover, the fractional 
catabolic rate (FCR) of 125I-labelled Lp(a) is no different from normal in 
individuals heterozygous for an LDL receptor mutation (Knight et aI., 1991). 
Utermann et aI. (1989) reported that individuals with familial 
hypercholesterolaemia (FH) had higher plasma concentrations of Lp(a) than 
non-FH individuals. These findings were supported by the results of other 
studies (Wiklund et aI., 1990; Leitersdorf et aI., 1991; Mbewu et aI., 1991). 
However, more recent FH family studies suggest that the previously observed 
association between FH and higher plasma levels of Lp(a) was an artifact due to 
selection bias, as previously suggested (Scanu 1991). There was no 
association between FH and plasma concentration of Lp(a) in three human 
family studies (Ghiselli et aI., 1992; Soutar et al., 1991; Hegele et aI., 1990), as 
well as in a simian pedigree with FH (Neven et aI., 1990). 
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1.4 Factors affecting Lp(a) concentrations 
When Lp(a) was initially identified in 1963, it was thought to be present 
in only -35% of all individuals (Berg, 1963). Harvie & Schultz (1970) were 
the first to suggest that Lp(a) was a quantitative trait and present in the plasma 
of most, if not all. individuals. Albers & Hazzard (1974) subsequently 
developed an immunoassay, which demonstrated that plasma Lp(a) 
concentrations vary over a very wide range. 
Plasma levels of Lp(a) are relatively low at birth and gradually increase 
to adult levels over the first few months of life (Van Bielv liet et aI.. 1991, 
Wang et aI., 1992). Levels are similar in men and women and do not increase 
with age (Sandkamp et aI., 1990). as do plasma concentrations of LDL-
cholesterol. The one exception is postmenopausal women who have a -15-
50% higher plasma concentration of Lp(a) than premenopausal women 
(Heinrich et aI., 1991; Jenner et aI.. 1993). 
Unlike plasma LDL-cholesterol levels. the plasma concentrations of 
Lp(a) are remarkably stable in any given individual and are not significantly 
related to body mass index (Sundell et aI., 1989). changes in weight (Giavarina 
et aI. 1992. Corsetti et aI.. 1991). or exercise (Lobo et aI., 1992, Mankowitz et 
aI.. 1992). Plasma levels of Lp(a) are also unaffected by changes in dietary 
composition (Albers et aI.. 1977; Brown et aI., 1991) with one major 
exception. Mensink et al. (1992) reported that plasma Lp(a) levels were raised 
when trans C18: 1 replaced either oleic, linoleic, or stearic acids in the diet. 
Nestel et al. (1992) compared diets containing up to 2.4 or 6.7 en% as trails 
fatty acids and found that plasma total cholesterol, LDL-cholesterol, and Lp(a) 
concentrations were higher on the trans fatty acid diets. In addition, heavy 
alcohol ingestion, especially if accompanied by alcoholic liver disease, lowers 
plasma Lp(a) levels (Marth et al., 1992). 
Plasma Lp(a) concentrations do not correlate with levels of other 
lipoproteins (Boyer et aI., 1990) or with indirect indicators of whole body 
cholesterol synthesis (Boomsma et aI., 1993). Approximately one-third of the 
mass of the Lp(a) particle is cholesteryl-ester, so only very high plasma 
concentrations of Lp(a) significantly affect either the plasma level of total or 
LDL-cholesterol. 
It has been suggested that Lp(a) is an acute phase reactant (Maeda et aI., 
1989). Lp(a) has been reported to increase dramatically in concentration after 
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Table 1.2 Published healthy adult plasma or serum Lp(a) levels in different 
ethnic groups. 
Ethnic group n Lp(a) Lp(a) Method Reference 
Mean (SO) Median 
(mg. dL-l) (mg. dL-l) 
CAUCASIAN 
American 242 16.4 ELISA Haffner et at 1992a 
American 134 16.3 EIA Guyton ct a1. 1985 
Tyrolean 279 14.1 (19.4) EID Sandho1zer et a1. 1991 
Icelandic 184 13.5 (17.7) EID Sandho1zer et a1. 1991 
Hungarian 202 8.3 (11.0) EID Sandho1zer ct a1. 1991 
Belgian 60 16.0 8.0 ELISA Cobbaert+KesteloOI 1991 
French 81 10.7 (15.2) 7.0 EIA Parra et a1. 1987 
Gennan 166 18.7 (23.1) 8.5 ELISA Helmhold ct a1. 1991 
AFRICAN 
African-Amer. 105 32.5 EIA Guyton et at 1985 
Sudanese 105 45.7 (25_9) EID Sandholzer et a1. 1991 
Nigerian 60 17.8 13.4 ELISA Cobbaert+Kcsteloot 1991 
Congoese 81 23.9 (20.2) 20.8 EIA Parra ct a1. 1987 
Seychellois 12,110 31.9 (36.2) RIA Bovet et aI. 1991 
Ghanaian 190 36.2 (31.5) 26_0 ELISA Helmhold et a1. 1991 
San 67 21.1 (19.3) 15.2 ELISA Helmhold et a1. 1991 
ASIAN 
Chinese (Sing) 112 7.2 (13.1) EID Sandholzer et a1. 1991 
Chinese 60 14.2 8_9 ELISA Cobbaert+Kesteloot 1991 
Chinese 88 22.9 (18.3) 15.3 ELISA Helmhold et a1. 1991 
Korean 60 12.1 9.9 ELISA Cobbaert+ Kesteloot 1991 
Korean 250 14.9 12.0 ELISA Kim et aI. 1992 
Indian 143 20.1 (15.9) EID Sandholzer et a1. 1991 
Malay/Singap. 125 12.9 (17.9) EID Sandholzer et a1. 1991 
Japanese 34 13.1 (11.6) ELISA Yamasaki et a1. 1992 
Tibetan 60 9_2 4.9 ELISA Cobbaert+ Kesteloot 1991 
EID, electroimmunodiffusion; EIA, electroimmunoassay; ELISA, enzyme 
linked immunosorbent assay; RIA, radioimmunoassay. 
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The distribution of plasma Lp(a) concentrations in (A) Gennans (8) Chinese 
and (C) Ghanaians. Adapted from Helmhold et al. (1991). 
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myocardial infarction and surgical operations, though no large controlled 
longitudinal studies have been performed to confilm this report. 
1.4.1 Racial differences in plasma Lp(a) concentrations 
In all popUlations studied to date, the plasma levels of Lp(a) vary over a 
wide range, from <0.1 mg. dL-1 to >100 mg. dL-1 (total Lp(a) mass). There 
are important racial differences in the distribution of plasma Lp(a) 
concentrations [Figure 1.5, Table 1.2]. In Caucasians the distribution of 
plasma Lp(a) concentrations are highly skewed towards lower levels 
(Sandholzer et aI., 1991, Guyton et aI., 1985), and greater than 65% of 
Caucasians have levels less than 20 mg. dL -1. In African popUlations, the 
distribution of plasma Lp(a) levels tends to be more Gaussian (Guyton et aI., 
1985, Helmhold et aI., 1991, Parra et aI., 1987, Sandholzer et aI., 1991, Bovet 
et aI., 1991). 
On average, individuals of African descent have an Lp(a) level that is 2-
3 fold higher than Caucasians. In African-Americans there is some skewing in 
the distribution of plasma Lp(a) towards lower levels, which is most likely due 
to genetic admixture with Caucasians (Guyton et aI., 1985; Chakraborty et aI., 
1992). 
The distributions of plasma Lp(a) levels in Asian populations are very 
similar to those of Caucasians (Yamasaki et aI., 1992, Cobbaert & Kesteloot, 
1992; Kim et aI., 1992), though two studies reported significantly lower plasma 
Lp(a) levels in Chinese (Sandholzer et aI., 1991; Cobbaert & Kesteloot, 1992). 
These conflicting results may be due to regional ethnic variations within the 
Asian population or to methodological differences in the handling of the blood 
samples prior to analysis. 
1.4.2 Plasma Lp(a) levels and renal disease 
Chronic renal failure is associated with significant elevations in plasma 
Lp(a) levels. It is not clear how much of the elevation is due to renal 
insufficiency per se or to the dialysis procedure (Haffner et aI., 1992b; Irish et 
aI., 1992; Dieplinger et aI., 1993). Plasma Lp(a) levels plunge over 50% 
within one week of renal transplantation (Black & Wilcken, 1992) presumably 
due to the associated improvement in renal function. However, plasma Lp(a) 
levels also fall after cardiac transplant (despite coincident elevations of LDL-
cholesterol and HDL-cholesterol), suggesting that the administration of 
immunosuppressive agents could contribute to the reduction in plasma Lp(a) 
concentrations seen after renal transplantation (Farmer et aI., 1991). 
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Plasma Lp(a) levels also tend to be elevated in patients with proteinuria 
(Black & Wilcken, 1992; Kanidi et aI., 1989). In nephrotic syndrome, the 
increase in plasma Lp(a) levels does not correlate with the levels of the other 
apoB-containing lipoproteins. In a small sample of patients with minimal 
change disease, there was a direct relationship between the plasma Lp(a) levels 
and the amount of protein excreted in the urine. Conversely, there was an 
inverse correlation between the plasma Lp(a) and the levels of proteinuria in the 
patients with membranoproliferative disease (Karadi et ai., 1989). 
Unfortunately, the medications taken by the study patients were not reported, so 
the observed differences in plasma Lp(a) levels may be pharmacological effects. 
1.4.3 Plasma Lp(a) levels and diabetes mellitus 
Initial reports found plasma Lp(a) levels elevated in poorly controlled 
diabetics (Bruckert et aI., 1990; Haffner et aI., 1991; Levitsky et aI., 1991; 
Joven & Vilella, 1991). Subsequent studies have not consistently demonstrated 
elevations in plasma Lp(a) levels in either Type I or Type II diabetes, in the 
absence of renal disease (Velho et aI., 1993; Heller et aI., 1993; Klausen et aI., 
1992b). 
1.5 Evolution and genetics 
1.5.1 Species distribution of Lp(a) 
Lp(a) has an unusual species distribution. It is a major cholesterol-
can"ying lipoprotein of the European hedgehog (a hibernating insectivore) 
(Laplaud et aI., 1988), yet it has not been found in any other mammals except 
old world monkeys (Azrolan et aI., 1991) and great apes (Makino et aI., 1989). 
The hedgehog APO(a) gene has not yet been cloned and characterized, but 
partial characterization of the 3' region of a rhesus monkey apo(a) cDNA 
revealed a structure very similar to that of the human, though the rhesus gene 
does not contain the K5 repeat (Tomlinson et aI., 1989). 
1.5.2 Evolution of the APO( a) gene 
The APO( a) gene is located within 50 kb of the plasminogen gene and 
almost certainly evolved as the result of gene duplication followed by a 
subsequent deletional event and intragenic amplification. It is perplexing that 
the APO( a) gene is not present continuously in the evolutionary tree. 
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Presumably the gene has either evolved twice or has been regained after being 
deleted from the genome. 
Sequence comparison between the human apo(a) and plasminogen 
cDNA in the 3' untranslated region suggests the two human genes diverged 
around the same time that the old and new world monkeys diverged: -40 
million years ago (McLean et aI., 1987). However, Pesole and colleagues 
(1994) have more recently estimated the separation of the two genes by 
duplication to date back to -90 million years ago, immediately before the 
radiation of the mammals. The strikingly high degree of sequence identity that 
has been maintained within regions of the APO(a) and plasminogen genes, 
especially at the 5' end, is likely due to frequent gene conversion events 
between the two closely linked loci. 
Apo(a) is a member of a superfamily of plasma proteins and shares 
numerous protein motifs with proteins of the coagulation cascade, fibrinolytic 
system, as well as selected growth factors (Lawn, 1992). These shared 
sequence motifs have fueled much speculation on the physiological role of 
Lp(a) including a suggestion that it may playa role in wound repair by 
delivering cholesterol to regenerating tissues (Brown & Goldstein, 1987). 
1.5.3 Human genetics of plasma Lp(a) concentration 
Using qualitative assays, Lp(a) was shown to be an inherited trait with 
an apparent autosomal dominant inheritance pattern (Schultz et aI., 1968; 
Heiberg & Berg, 1974; Berg & Mohr. 1963). When more sensitive assays 
were developed, it became clear that Lp(a) was a quantitative rather than 
qualitative trait (Schultz et al., 1974; Albers et al.. 1974). Early family studies 
examining the segregation of plasma Lp(a) suggested a limited number of genes 
contributed to its plasma level (Sing et al.. 1974; Morton et aI., 1985; Hasstedt 
et al.. 1983; Hewitt et al., 1982; Iselius et al., 1981). Qualitative analysis of 
plasma Lp(a) levels in twins revealed a strikingly high heritability index (0.98) 
(Hewitt et al.. 1977). Later, quantitative analysis of plasma Lp(a) 
concentrations confirmed the high concordance of levels in identical twins 
(Austin et aI., 1992; Boomsma et aI., 1993). 
The observation that the plasma level of Lp(a) tends to be inversely 
related to the size of the apo(a) isoforms (Utermann et aI., 1987) thrust the 
APO( a) gene to the forefront as a potential major candidate gene for controlling 
plasma Lp(a) concentrations. Subsequently, plasma Lp(a) levels were shown 
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to co-segregate with a sequence polymorphism closely linked to the APO( a) 
gene, which further implicated the APO( a) locus as a major determinant of 
plasma Lp(a) concentrations (Drayna et aI., 1988). 
1.5.4 Apo(a) isoform determination 
Various immunoblotting techniques have been developed to analyze the 
size of the apo(a) isoforms. SDS-polyacrylamide and agarose gel 
electrophoresis have both been used to size-fractionate reduced plasma proteins 
prior to immunoblotting with an apo(a)-specific antibody (Utermann et aI., 
1987; Kamboh et aI., 1991). Initially, six apo(a) isoforms that ranged in 
molecular mass from 400-700 kDa were identified and classified according to 
their mobility relative to apoB-l 00 (-513 kDa): F (fast), B (migration similar to 
apoB-lOO), and S I-S4 (progressively slower migration than apoB-lOO) 
(Utermann et aI., 1987). Approximately 49% of individuals had no identifiable 
apo(a) using this method and in only a minority of subjects could two apo(a) 
isoforms be detected (Utermann et aI., 1987). With improved techniques, 
apo(a) was identified in almost every individual, but the isoforms were still not 
in Hardy-Weinberg equilibrium, which suggests that not all APO(a) gene 
products were detected equally (Gaubatz et aI., 1991). 
There are several technical problems associated with analyzing such a 
large glycoprotein by immunoblotting. First, the ability to size-fractionate large 
glycoproteins is limited using SDS-PAGE gels. Kamboh et ai. (1991) reported 
greatly improved resolving capacity by using agarose gel electrophoresis for 
size fractionation. Optimization of the size-fractionation and immunoblotting 
procedures has resulted in the resolution of 34 isoforms ranging in size from 
300 to 850 kDa (Lackner et aI., 1993; Marcovina et aI., 1993b) [Figure 1.6]. 
Second, isoforms associated with low levels of apo(a) were often not detected, 
especially in heterozygous individuals expressing different amounts of each 
isoform. Finally, isoforms of higher molecular weight do not transfer as well 
during immunoblotting and so may go undetected. 
1.5.5 Apo(a) isoform size polymorphism and plasma 
concentration of Lp(a) 
As previously noted, the apparent molecular mass of apo(a) isoforms 
tends to be inversely related to the plasma concentration of Lp(a) (Utermann et 
aI., 1987) [Figure 1.7]. It has been estimated that approximately 42% of the 
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Immunoblot analysis of apo(a) isoforms in human plasma. A total of 7 - 15 1-11 of plasma from each individual was subjected to electrophoresis 
on a horizonta12% agarose gel. The plasma proteins were blotted onto a supported nitrocellulose membrane and inununoblotted with an apo(a) 
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variability in plasma Lp(a) level between unrelated individuals is attributable to 
the size polymorphism in the apo(a) protein (Boerwinkle et al., 1989; Gaubatz 
et aI., 1990). The frequency distribution of isoforms in part accounts for the 
skewed distribution of plasma Lp(a) concentrations in the Caucasian population; 
the larger isoforms (S I-S4), which tend to be associated with lower plasma 
levels of Lp(a), are most common in Caucasian populations, whereas, the 
smaller isoforms (F and B), which are associated with higher plasma 
concentrations of Lp(a), are less common (Utermann et al., 1988b). 
The mechanism responsible for this relationship is still not known, 
although there is some evidence that it is not due to differential catabolism. 
Apo(a) isoforms of varying size are apparently catabolized at similar rates 
(Rader et ai., 1993). Nor can the relationship be completely explained by 
differences in hepatic mRNA levels. In primates, the amount of hepatic apo(a) 
mRNA tends to correlate with plasma concentration of Lp(a), but a number of 
exceptions have been described (Azrolan et aI., 1991; Hixson et aI., 1989). 
Interestingly, no correlation was found between apo(a) mRNA length and 
hepatic apo(a) mRNA levels. This suggests that factors other than the APO(a) 
gene size affect apo(a) mRNA levels (Azrolan et ai., 1991; Hixson et aI., 
1989). 
There are important exceptions to this relationship between apo(a) 
isoform size and plasma concentration of Lp(a). For example, the frequency 
distribution of apo(a) isoforms is not dramatically different when Caucasians 
are compared to Africans, despite the fact that Africans have higher plasma 
concentrations of Lp(a) (Sandholzer et aI., 1991). Also, within populations, 
individuals with apo(a) isoforms of the same size (whether large or small) can 
have very different plasma levels of Lp(a) (Boerwinkle et aI., 1989; Lackner et 
aI., 1991). 
1.5.6 Molecular analysis of apo(a) polymorphism 
The molecular mechanism responsible for the size variation in apo(a) 
was first suggested by the structure of the apo(a) cDNA. McLean et ai. (1987) 
hypothesized that the variations in the size of the apo(a) protein were due to 
differences in the numbers of K4 repeats in the APO(a) gene. In support of 
this suggestion, the size of the hepatic apo(a) mRNA was shown to correlate 
with the size of the apo(a) isoforms in rhesus monkeys, baboons, and man 
(Hixson et aI., 1989; Azrolan et aI., 1991; Koschinsky et aI., 1990). 
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Direct proof that the apo(a) size variation was due to differences in the 
number of K4 repeats awaited the development of a method to analyze the 
APO(a) gene directly. Lackner et ai. (1991.1993) demonstrated that a KpllI or 
HpaI restriction fragment containing the common (i.e., Type A & B) K4 repeats 
varied in size between alleles. Size fractionation of the restriction fragments by 
pulsed-field gel electrophoresis and Southern blotting revealed that their size 
correlated directly with the size of the apo(a) isoforms. Thus. the major size 
variation in apo(a) isoforms was shown to be due to variations in the number of 
K4 repeats in the APO(a) gene and not to postranslational modifications. To 
date, 34 fragments of different sizes have been resolved using these methods 
(Lackner et aI., 1993) [Figure 1.8]. Sttikingly. 94% of individuals examined 
were heterozygous and thus had two APO( a) alleles of different sizes. In 
contrast to the observed distribution of apo(a) isoforms, the APO( a) allele 
frequencies. as determined by pulsed-field gel electrophoresis, were in Hardy-
Weinberg equilibrium. 
Individuals with APO( a) alleles of identical size can have very disparate 
plasma Lp(a) levels (Lackner et aI.. 1991). Family studies have shown that 
these differences are due to sequence differences linked to the APO( a) gene, 
other than the number of K4 repeats, and not to the effect of other genes or 
environmental factors (Boerwinkle et aI., 1992). 
1.5.7 Molecular mechanisms and implication of APO( a) 
polymorphism. 
The APO(a) gene is amongst the most highly polymorphic loci yet 
described in the human genome outside the histocompatability complex. The 
high degree of length polymorphism in the APO(a) gene can be attributed to 
homologous recombination and unequal exchange. There is evidence that both 
inter- and intra-chromosomal exchanges occur frequently within the Type A and 
B kringle repeats (Cohen et aI., 1993; Lackner et al., 1993). Only a single 
spontaneously generated APO( a) allele of new length has been identified and 
characterized at a molecular level thus far. The analysis was consistent with the 
allele being the result of sister chromatid exchange during mitosis. or a gene 
conversion event during meiosis (Lackner et aI.. 1993). 
Not only are there many APO(a) alleles of different le~gth, but it is now 
clear that APO( a) alleles of the same size do not necessanly have the same 
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FIGURE 1.8. 
Southern blot analysis of HpaI-digested genomic DNA size-fractionated by pulsed-field gel electrophoresis. High molecular weight genomic 
DNA (1-2 Ilg) was digested with HpaI and size-fractionated using pulsed-field electrophoresis. After transfer to a nylon membrane by 
Southern blotting, the filter was hybridized with a K4-APO( a)-specific probe. The HpaI sites that define this fragment are located immediately 
5' of the first exon of K4[ and in the intron of K431 • The fragment sizes vary between 28 to 250 kilobases depending on the total number of 
K4-encoding sequences in the APO(a) allele which have been estimated to range between 12 and 51 (APO(a)K12-APO(a)K51). Adapted from 
Lackner et al. (1993) . 
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sequence (Cohen et aI., 1993). Based on the analysis of both APO(a) gene 
structure and sequence, there are > 100 identifiable different APO(a) alleles in 
the normal populations. This dramatically high degree of both sequence and 
length polymorphism in the APO( a) gene begs the question of whether the 
physiological role of apo(a) is vestigial [section 1.10]. 
1.5.8 The APO( a) gene is a major determinant of plasma 
Lp(a) levels 
The high degree of size polymorphism of the APO( a) gene allowed 
detailed segregation analysis of this gene in families [Figure 1.9]. If the 
APO( a) gene is an important determinant of plasma Lp(a) levels, then siblings 
who inherit the same APO( a) alleles from their parents would be expected to 
have similar plasma concentrations of Lp(a). Conversely, if genes other than the 
APO(a) gene significantly affect plasma Lp(a) levels, it would be expected that 
the levels of Lp(a) would vary between sibling pairs with identical 
APO( a)alleles. The degree of similarity in plasma Lp(a) levels in sibling pairs 
with identical APO(a) alleles (and only a 25% chance of having identical genes 
at any other locus) can be used to estimate the contribution of the APO( a) gene 
to plasma levels of Lp(a). Siblings who inherited the same APO(a) alleles from 
each parent had very similar plasma concentrations of Lp(a) (r=0.95) which 
was in dramatic contrast to siblings who inherited no APO(a) alleles in common 
(r =-0.23) (Boerwinkle et aI., 1992). From this analysis, it was estimated that 
>90% of the inter-individual variation in plasma Lp(a) can be attributed to 
sequence differences at, or closely linked to the APO(a) locus (Boerwinkle et 
aI., 1992). 
The exact sequences at the APO( a) locus that determine the plasma 
concentration of Lp(a) have not been delineated. It is paradoxical that a single 
gene can predominate in the control of this widely varying quantitative trait. It 
is likely, given the polymorphic nature of the APO( a) gene, and the wide range 
in plasma concentrations of Lp(a), that the plasma Lp(a) levels are determined 
by a complex interaction of multiple sequence differences at the APO(a) locus. 
1.6 Association of Lp(a) levels & atherosclerosis 
The first paper to report an association between the presence of Lp(a) in 
plasma with coronary heart disease (CHO) was made shOltly after the discovery 
of Lp(a) (Renninger et aI.. 1965). Later. Kostner et al. (1981) compared 
plasma levels of Lp(a) in 36 normolipaemic men (ranging in age from 40-60 
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Segregation of APO( a) alleles and Lp(a) plasma concentrations in a family. 
High molecular weight genomic DNA was digested with KpnI and size-
fractionated by pulsed-field gel electrophoresis as described (Lackner et aI., 
1993). The circles and squares denote females and males, respectively. The 
first two lanes of the autoradiogram show results of the analysis of the parents, 
and the subsequent four lanes demonstrate the Mendelian inheritance of the 
KpnI restriction fragments to the offspling. Below the blot are the apo(a) 
genotypes and plasma Lp(a) concentrations. The latter are the mean of two 
separate determinations on different plasma samples by an ELISA assay. 
Adapted from Lackner et al. (1991). 
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years) with a history of a myocardial infarction to 55 age- and sex-matched 
controls, and found that a higher percentage of patients than controls had an 
Lp(a) level greater than 30 mg. dL-I (44% vs. 26%). These early findings 
suggest that the risk conferred by high plasma levels of Lp(a) was independent 
of other lipoprotein-related risk factors. Numerous subsequent reports have 
con finned the results of these earlier studies. 
1.6.1 Epidemiology of Lp(a) and coronary atherosclerosis 
Elevations of plasma levels of Lp(a) (over 20-30 mg. dL-I or 0.07-0.1 
Jlmol. L-i) have been estimated to confer a 1.5- to 3- fold increased risk for the 
presence of coronary atherosclerosis in both Caucasian and Oriental men 
(Albers et aI., 1977; Armstrong et aI., 1986; Sandholzer et aI., 1992b; Rhoads 
et aI., 1986). This association is independent of the contribution of other 
plasma lipoprotein concentrations to coronary risk (Sandkamp et aI., 1990). 
Moreover, plasma levels of Lp(a), together with a history of prior 
atherosclerotic events, were found to be the best predictors of subsequent 
vascular events (Cressman et aI., 1992) in chronic haemodialysis patients. 
The association between elevations in plasma Lp(a) and the presence of 
ischaemic heart disease is most robust in younger age groups. Rhoads et al. 
(1986) compared plasma Lp(a) concentrations in 303 Japanese-Hawaiian men 
with a history of myocardial infarction to those in 408 population-based 
controls, and found the odds ratio of having had a myocardial infarction was 
2.5-fold higher in those men under age 60 who had a plasma Lp(a) level in the 
top quartile. In this study, the population attributable risk of having an MI, if 
the Lp(a) was in the top quartile, was 28% for men under 60 years, whereas it 
was only 5% for men older than 70. 
1.6.2 Lp(a) and severity of CHD 
Not only are high plasma concentrations of Lp(a) associated with the 
presence of CHD, but they are also directly related to its severity. This effect 
was found to be independent of the plasma concentration of LDL-cholesterol. 
Dahlen et al. (1986) evaluated 307 Caucasians and found a direct relationship 
between the level of plasma Lp(a) and the severity of CHD, as assessed by 
coronary angiography. Similarly, Budde and his colleagues (1994) studied 118 
male patients undergoing coronary angiography and found that plasma Lp(a) 
levels con·elated with number, severity and length-extension of atheromatous 
lesions. In women and men aged less than 55, the same direct relationship 
between plasma concentration of Lp(a) and severity of CHD held true; 
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however, the relationship was not observed in males over the age of 55. These 
findings again indicate that plasma Lp(a) levels are a better predictor of CHD in 
younger men. 
1. 6.3 Lp(a) and restenosis 
Elevated plasma Lp(a) levels have been reported to be associated with an 
increased incidence of re-stenosis after coronary artery bypass surgery (Hoff et 
aI., 1988) and percutaneous transluminal coronary angioplasty (PTCA) (Hearn 
et aI., 1992). However, Johansson et al. (1992) found no relationship between 
restenosis after PTCA and plasma Lp(a) concentrations. A prospective study in 
which all subjects, irrespective of clinical outcome, are re-evaluated by 
angiography is required to determine if a high plasma level of Lp(a) is indeed a 
risk factor for restenosis. 
1.6.4 Interaction of elevated plasma Lp(a) and LDL 
concentrations 
Although an isolated increase in plasma Lp(a) concentration has been 
associated with an increase in risk of myocardial infarction (Kostner et aI., 
1981), it appears that this risk is compounded when coupled with elevated 
levels of LDL-cholesterol. Armstrong et al. (1986) measured plasma Lp(a) 
levels in a sample of 428 Caucasian men (age 40-60) with CHD (at least one 
major coronary vessel occluded >50%) documented by angiography as well as 
in 142 individuals who had no evidence of CHD. Individuals who had plasma 
Lp(a) levels over 30 mg. dL-l had an odds ratio of having CHD of 2.7 when 
compared to those with an Lp(a) less than 5 mg. dL-l. The odds ratio was not 
modified by other CHD risk factors, such as smoking, hypertension, or 
decreased plasma levels of HDL-cholesteroI. Only plasma concentration of 
LDL-cholesterol significantly affected the odds ratio. In individuals with 
plasma Lp(a) concentrations >30 mg. dL-l, and LDL-cholesterollevels greater 
than the median, the odds ratio rose from 2.7 to 6.3. 
These results were supported by three studies that found that FH 
heterozygotes with CHD have significantly higher plasma Lp(a) levels than 
those without clinical evidence of CHD (Houlston et aI., 1988; Seed et aI., 
1990; Wiklund et al., 1990). However, in one study in which there were age-
and sex-matched controls, no significant relationship was found between the 
plasma Lp(a) levels and the presence or absence of CHD in FH heterozygotes 
I ntroductiol/ 28 
(Mbewu et aI., 1991). Therefore, at this time it is debatable whether elevated 
levels of plasma Lp(a) are a prognostic indicator of ischaemic heart disease in 
patients with FH. 
1.6.5 Lp(a) and family history of CUD 
There is an association between the plasma level of Lp(a) and a parental 
history of CHD (Hoefler et aI., 1988; Kostner & Grillhofer, 1991, and 
Durrington et aI., 1988). Durrington and his colleagues (1988) compared 41 
men who had suffered a myocardial infarction to 78 controls and found the best 
predictors of CHD were plasma concentrations of 1) apoB-lOO, 2) apoAI and 
3) the presence of a positive parental history of myocardial infarction. The 
plasma Lp(a) level could be substituted for the parental history of myocardial 
infarction as a risk factor; no additional benefit was derived from knowledge of 
a parental history of myocardial infarctions if the plasma Lp(a) level was 
known. The results of their study are again consistent with the highly heritable 
nature of plasma Lp(a) levels. 
1.6.6 Prospective studies of cun and Lp(a) 
Several prospective studies have examined the effect of plasma Lp(a) on 
the incidence of coronary events [Table 1.3]. In an early uncontrolled study, 
plasma Lp(a) levels were measured in 232 Swedish males (age 50-53) with no 
overt atherosclerotic disease. The patients were followed for 11 years, and 
there was a 2-3 fold higher incidence of myocardial infarction and stroke in 
those with high plasma concentrations of Lp(a) (Dahlen et aI., 1991). A larger 
prospective case-control study of middle aged men (Rosengren et aI., 1990) 
also revealed an association between elevated Lp(a) levels and coronary events. 
Two other major prospective studies, however, failed to find an 
association between high plasma levels of Lp(a) and coronary events: the 
Helsinki Heart Study and the US Physicians' Health StUdy. In a subgroup 
analysis of the Helsinki Heart Study, 138 individuals who had suffered a 
myocardial infarction during the study were compared with 130 controls 
(Jauhiainen et aI., 1991). There was no significant difference in the distribution 
of plasma Lp(a) concentrations in these two groups. The discrepant findings of 
this study remain to be explained, but it does not appear to be due to survival 
bias (i.e., the lack of association of cardiac events with plasma Lp(a) 
concentration is not explained by a bias incurred if individuals with high Lp(a) 
died before or during the course of the study and were therefore not represented 
in the analysis). 
Table 1.3. Summary of controlled prospective studies of Lp(a) and CHD. 
Study CUD positi ve Controls 
participants 
Rosengren et al. (1990) 26M* 109 M 
lauhiainen et al. (1991) 138M 130 M 
Coleman et al. (1992) 51 F 201 F 
Siggurdson et al. (1992) 104M 1228 M 
Ridker et al. (1993) 296M 296M 
Wald et al. (1994) 229M 1145 M 
Schaefer et al. (1994) 233M 390M 
Cremer et al. (1994) 107M 5364M 
*M, male; F, female; TC, plasma total cholesterol concentration 
Adapted from Rader et al. (1994). 
Lp(a) association 
with CUD 
Higher in affected 
participants P=O.OI 
No difference P=O.37 
Higher in affected 
participants P=O.15 
Higher in affected 
participants P<O.05 
No difference P=0.88 
Higher in affected 
participants P<O.05 
Higher in affected 
participants P<O.02 
Higher in affected 
participants P<O.OOI 
Relative to lipids 
Independent of TC 
LDL also not different 
No better than TC 
Independent of TC & apoB 
TC also not significantly different 
Independent of TC 
Independent of LDL 
Lp(a) 5th most important risk factor 
after LDL-C. family history of MI. 
plasma fibrinogen. and HDL-C. 
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The Helsinki Heart Study is not the only Finnish report that failed to 
demonstrate a relationship between plasma Lp(a) levels and CHD. When 
plasma Lp(a) levels in Finnish individuals with and without angiographic 
evidence of CHO were compared, no significant difference was found 
(Nieminen et aI., 1992). 
Another population in which plasma Lp(a) levels have not been shown 
to be a risk factor for CHD are individuals of African descent. On average, 
African-Americans have two-fold higher plasma concentrations than do 
Caucasians (Utermann, 1989; Guyton et al., 1985), and yet appear not to have 
a corresponding increase in incidence of CHD (National Center for Health 
Statistics, 1990; Keil et aI., 1993). Sorrentino et al. (1992) found no 
significant difference in plasma concentration of Lp(a) in African-Americans 
with and without CHD, as documented by coronary angiography. Moreover, 
plasma levels of Lp(a) are good predictors of parental CHO in Caucasians, but 
not in African-American children (Srinivasan et aI., 1991). 
The lack of association between high plasma concentrations of Lp(a) 
and CHD in both Finns and African-Americans needs to be verified with 
additional studies. If confirmed, elucidation of the reason for this difference 
should provide insights into the mechanism responsible for the atherosclerotic 
effects of Lp(a). In the African-American population there may be apo(a) alleles 
of different sequence, which generate high plasma concentrations of Lp(a), but 
do not contain the epitope responsible for its atherogenicity. Alternatively, there 
may be another ethnic-specific factor(s) that protects African-Americans from 
the atherogenic effects of Lp(a). 
The second major prospective case-control study that failed to find any 
evidence of association between plasma Lp(a) concentration and risk of future 
myocardial infarction was the US Physicians' Health Study (Ridker et aI., 
1993). While this was the largest prospective study of its kind to date, it has 
been the subject of criticism (Gaw, 1994). 
Neither the racial breakdown nor the age range of the nested study 
group was reported. This is important because, as stated above [section 1.4.1], 
it has been well recognized that ethnic origin plays a significant role in the 
determination of plasma Lp(a) concentrations (Helmhold et aI., 1991). The age 
distribution of the groups would not necessarily have affected the Lp(a) levels 
but may have significantly influenced the observed association between plasma 
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Lp(a) concentration and risk of myocardial infarction. Previous studies have 
reported that the association between plasma Lp(a) levels and risk of myocardial 
infarction is stronger in younger individuals (Rhoads et aI., 1986). Plasma 
LDL-cholesterollevels of cases and controls were omitted from the paper and in 
view of the P value (0.06) for the comparison of plasma total cholesterol 
between the two groups it would have been interesting to see if the LDL-
cholesterol levels were significantly different, as they should have been. If they 
were not, then the authors might have considered reporting this lack of 
association between another widely recognized lipid risk factor and myocardial 
infarction. Alternatively. it may be concluded that there was something atypical 
about their study group. 
A similar sized prospective study of a cohort from the Lipid Research 
Clinics Coronary Primary Prevention Trial (Schaefer et aI., 1994) did identify 
elevated plasma Lp(a) levels as an independent risk factor for CHD in 
hypercholesterolaemic Caucasian males. 
The most impressive prospective study to date has been the Gottingen 
Risk Incidence and Prevalence Study (GRIPS) (Cremer et aI., 1994). In this 
study approximately 6,000 males aged between 40-59.9 years with no overt 
evidence of CHD were followed for 5 years. The primary end-point in this 
study was myocardial infarction, fatal or non-fatal. Over the study period 107 
subjects with myocardial infarction were recorded and compared with a control 
group of 5,364. These groups, as expected. differed significantly in plasma 
LDL-cholesterol (4.7 VS. 3.7 mmol. L-l, p<O.OOl) and HDL-cholesterol (1.1 
VS. 1.3 mmol. L-l, p<O.OOI), but they also exhibited a statistically significant 
difference in plasma Lp(a) (18 VS. 9 mg. dL-l, p<O.OOI). The association 
between plasma Lp(a) level and the incidence of myocardial infarction in 
GRIPS is shown in figure 1.10. 
U sing multivariate logistic regression analysis the authors of GRIPS 
were able to rank the different risk factors in order of importance. In this 
scheme plasma Lp(a) proved to be an important CHD risk factor ranking 5th 
behind LDL-cholesterol, family history of myocardial infarction, fibrinogen, 
and HDL-cholesterol. 
Therefore, at the present time the balance of evidence is in favour of a 
positive and independent association between plasma Lp(a) concentration and 
risk of CHD [Table 1.3]. Taken together these studies do not completely clarify 
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FIGURE 1.10. 
Gottingen Risk Incidence and Prevalence Study (GRIPS). The impact of 
plasma Lp(a) concentration at baseline on the incidence of myocardial infarction 
during a 5 year follow up. Adapted from Cremer et al. (1994). 
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the association between plasma Lp(a) levels and CHD risk, but they do offer 
some important pointers, viz. patient characteristics such as gender, ethnic 
origin and age must be taken into account in any future study. The apparently 
discrepant findings from the prospective studies may at least in part be 
explained by the failure of some investigators to follow this advice. 
1.6.7 Cerebrovascular and peripheral vascular disease and Lp(a) 
High plasma concentrations of Lp(a) have been found to be associated 
with atherosclerotic involvement of vessels other than the coronary arteries, 
including both cerebral and peripheral vessels (Pedro-Botet et aI., 1982; Jovicic 
et aI., 1993; Cambillau et aI., 1992; Koltringer & Jiirgens, 1985; Murai et aI., 
1986; NorrgMd et aI., 1991). Plasma LpCa) levels have been found to be 
significantly higher in individuals who have had strokes - either embolic or 
thrombotic (Woo et aI., 1991). 
1. 7 Atherosclerosis & Lp(a) 
The most direct evidence that apoCa) itself has an atherogenic role comes 
from the analysis of mice expressing the human apo(a) transgene. Fat-fed mice 
expressing human apoCa) had a 40-fold higher mean area of lipid staining in the 
aorta than did control animals. Importantly, only those animals maintained on a 
high fat diet developed lesions. Over 95% of the apoCa) in these mice circulated 
free of lipoproteins, yet in the atherosclerotic lesions the apo(a) not only co-
localized with the lipid, but also with mouse apoB-IOO (Lawn et al., 1992). 
Whether apo(a) forms a weak association with mouse lipoproteins and escorts 
them into the lesion or whether apo(a) binds first and then traps LDL has not 
been determined. The relevance of this result to man is unclear since there is 
little to no free apo(a) circulating in human plasma. Now that the double 
(apo(a)/apoB-lOO) transgenics are available (Linton et al 1993), the 
atherogenicity of whole LpCa), has been studied in inbred mice (Callow et aI., 
1995). In this study, mice with plasma Lp(a) were compared to mice only 
expressing the apo(a) transgene and were found to have 2.5 times the number 
of proximal aortic fatty streak lesions and 8 times the number in non-transgenic 
control animals. 
The early pathological studies of Walton et aI., (1974) revealed that 
Lp(a) is present in human atherosclerotic lesions. Immunohistochemical studies 
of human aorta and venous saphenous grafts have demonstrated that Lp(a) is 
located predominantly in the extracellular subendothelial space. The apo(a) is 
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found largely intact and is associated with apoB-lOO though free apo(a) and 
lipid poor apo(a)-apoB-lOO complexes are also found (Pepin et aI., 1991; 
Cushing et aI., 1989; Rath et aI., 1989). The amount of apo(a) in arterial 
biopsy specimens tends to correlate with plasma Lp(a) concentration (Rath et 
aI., 1989; Nachman et aI., 1991). 
The mechanism by which Lp(a) traverses the endothelium is not known, 
but it has been shown to bind several components of the intimal matrix 
including glycosaminoglycans (Bihara-Varga et aI., 1988), fibrinogen, 
crosslinked fibrin, and fibronectin (Harpel et aI., 1989; Loscalzo et aI., 1990; 
Rouy et aI., 1992; Smith & Cochran, 1990; Salonen et aI., 1989). Furthermore, 
reducing agents, including homocysteine, enhance the binding of Lp(a) to fibrin 
(Harpel et aI., 1992). 
The binding of Lp(a) to lysine rich proteins such as fibrin has received 
considerable attention (Guevara et ai., 1993b; Scanu et aI., 1993). As 
described above in section 1.2.2 this binding is thought to be mediated through 
the last K4 unit, K437, although other K4 units may be involved (Miles & Plow 
1990). 
The exact role Lp(a) plays in the development of arterial plaques has not 
been elucidated. III vitro studies have implicated Lp(a) as both a proatherogenic 
and antifibrinolytic agent. Lp(a) may be an innocent bystander that becomes 
trapped in the atherosclerotic lesion, thus contributing its cholesteryl-ester-rich 
cargo to the developing plaque. Alternatively, Lp(a) may interfere with the 
physiological role of plasminogen by molecular mimicry and thus promote 
thrombosis (Hajjar et aI., 1989; Miles et aI., 1989). These effects, for which 
there is only ill vitro evidence, are summarized in Figure 1.11. and are listed 
below:. 
I.Lp(a) may contribute to the development of foam cells in atherosclerotic 
lesions. Native Lp(a) and recombinant apo(a) bind ill vitro to cultured mouse 
macrophages, but are only internalized if the macrophages are pre-loaded with 
cholesterol (Zioncheck et aI., 1991; Bottalico et aI., 1993). Native Lp(a) is 
not internalized through the macrophage scavenger receptor. However, if the 
lysine residues in Lp(a) are modified using malondialdehyde it becomes a 
ligand for this receptor (Haberland et aI.. 1992). Lp(a) can also undergo 
oxidation. though not as readily as LDL (Sattler et aI., 1991). 
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2. At high concentrations, Lp(a) competes in vitro with plasminogen binding to 
the surlace of human umbilical vein endothelial cells, platelets, and a human 
monocyte cell line (Miles et al., 1989; Ha.iiar et al., 1989; Ezratty et al .. 1993) 
3. Lp(a) can compete in vitro with the activation of plasminogen by either 
streptokinase or tPA (Edelberg et al., 1990; Simon et al., 1991) 
4. Lp(a) competes in vitro with plasminogen for binding to fibrinogen or fibrin 
(Edelberg et al., 1990; Rouy et al., 1992; Loscalzo et al. 1990; Harper & 
Saunders. 1981; Leerink et al., 1991) 
5. Lp(a) promotes plasmin inhibition by <X2 antiplasmin (Edelberg & Pizzo, 
1992). 
6. Lp(a), by interlering with plasminogen activation, decreases the conversion 
of inactive transforming growth factor B (TGFB) to active TGFB. TGFB acts 
as an antimitogen on smooth muscle cells. In vitro studies have demonstrated 
that additions of high concentrations of Lp(a) are associated with smooth 
muscle cell proliferation and migration (Kojima et al., 1991; Grainger et al., 
1993). 
Most of these ill vitro effects require very high concentrations of Lp(a), 
which brings their physiological significance into question. It may be argued, 
however, that the concentrations of Lp(a) are much higher in the atherosclerotic 
lesion, and that plasma levels do not reflect these tissue concentrations. 
There is little in vivo evidence that Lp(a) is prothrombotic. If Lp(a) 
interferes with plasminogen activation, it may be expected that thrombolytic 
therapy would be less effective in patients with high plasma concentrations of 
Lp(a), but this appears not to be the case (Von Hodenberg et al., 1991; 
Armstrong et al., 1991). Individuals with high plasma concentration of Lp(a) 
have not been noted to have a higher incidence of venous thrombosis. 
A single study suggests that Lp(a) may be anti-thrombolytic in vivo. 
Moliterno et al. (1993) measured plasma Lp(a) concentrations in individuals 
who had sustained a myocardial infarction and had obtained coronary 
arteriograms at least one week after the event to assess the patency of the 
infarction-related artery. Prior studies have found that approximately half of all 
infarction-related arteries recanalize soon after the event (DeWood et al., 1980; 
Bertrand et al., 1979). Those survivors who failed to recanalize the occluded 
coronary artery had significantly higher plasma Lp(a) concentrations compared 
to those in which the artery had regained patency. 
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1.8 Clinical chemistry 
1.8.1 Measurement of plasma Lp(a) concentrations 
The measurement of plasma Lp(a) requires less stringent conditions for 
sample collection than other lipoproteins. It is not necessary that a fasting 
sample be collected, since Lp(a) concentrations are not significantly different in 
the fasting or fed state (Pfaffinger et aI., 1991; Panteghini & Pagani, 1993). 
The plasma or serum can be stored at 4°C for up to two weeks without loss of 
antigenicity. Reports vary as to effects of long-tenn storage on the maintenance 
of the integrity of the Lp(a) particle, but some methods, such as radio-
immunodiffusion assays, are particularly sensitive to the effects of long-term 
storage (Craig et aI., 1992). It appears that storage at -200C is equivalent to 
-70°C, and Lp(a) is stable for up to three months at both temperatures. It has 
been reported that serum Lp(a) concentrations are even stable in samples stored 
at -200C for many years. lauhianen and colleagues (1991) noted no significant 
reduction in the immunogenicity of the particle in the serum samples of the same 
individuals either assayed freshly or in samples stored at 5.5, 7.5 or 8.5 years. 
A variety of methods have been developed to measure plasma Lp(a) 
concentrations, including quantitative immunoelectrophoresis (Berg, 1994), 
radio-immunoassay (Albers et aI., 1977), radioimmunodiffusion (Albers & 
Hazzard, 1974), rate nephelometry (Gillery et aI., 1993) fluorescent 
immunoassay (JUrgens et aI., 1992, Kottke & Bren, 1994), and the most 
commonly used method, the enzyme-linked immunosorbent assay (ELISA) 
(Albers et aI., 1990). 
In most ELISA assay systems the first antibody, which is used to 
capture the Lp(a) particle, is usually a polyclonal antibody to apo(a). The 
second antibody, the detecting antibody, can either be an anti-apo(a) 
monoclonal antibody or an anti-human apoB-100 antibody. An advantage of 
using apoB-100 as the detecting antibody is that Lp(a) concentrations can then 
be expressed in molar units (i.e., number of particles), rather than total 
lipoprotein mass. Most assays have an intra-assay coefficient of variation (CV) 
of less than 5% and an inter-assay CV of -10%. 
As yet, there has been no consensus on the method used to express the 
results, and presently the plasma concentrations are reported as moles. L-l, mg 
apo(a). dL-l, or mg Lp(a). dL-l. Given the high degree of polymorphism in 
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apo(a) mass, it may be argued that molar rather than mass units would be 
preferable. 
Both monoclonal and polyclonal anti-Lp(a) antibodies may cross react 
with plasminogen or LOL. Any new antibody must be rigorously screened for 
these potential interactions and any new assay system must document this 
potential source of error (Berg, 1994). A further potential source of analytical 
error is the presence of interferants in the plasma. Pharmacological agents that 
alter the immunogenicity of Lp(a), such as thiols and cysteine-containing 
compounds, have been shown to interfere with the assay (Scanu et aI., 1992). 
The measurement of plasma Lp(a) concentrations is made more difficult 
by the highly polymorphic nature of apo(a) (Grinstead & Ellefson, 1988). It 
has not been conclusively demonstrated that any of the antibodies currently used 
react equally with all the apo(a) isoforms of different size. Many of the 
antibodies employed in the assays are directed against an epitope within the K4 
sequences, which can vary in number over a 4-fold range. Efforts are being 
directed to develop antibodies to apo(a) that react with only one epitope in the 
apo(a) protein, such as in the protease domain. 
There are no agreed primary reference materials or reference methods 
for the measurement of Lp(a) (Marz et aI., 1993; Albers et aI., 1990). A 
standard serum is needed for calibration and to permit comparisons between 
laboratories. The dissemination of a reference standard may be facilitated by 
using lyophilized samples, which have been stabilized by the addition of 
sucrose (Borgue et aI., 1993) but this has yet to be fully validated. To address 
the many problems of standardisation (Labeur et aI., 1994) the International 
Federation of Clinical Chemists has recently established a Working Group on 
Lp(a) Standardisation (personal communication, G. Siest, 1994). 
Due to the highly skewed distribution of plasma Lp(a) concentrations, a 
population-based reference interval is not appropriate. Since there is no 
standardized method to measure plasma Lp(a) level or a unified approach to the 
expression of the results, there can be no consensus on the cut-off point above 
which an individual is deemed at risk. 
1.8.2 Apo(a) isoform phenotyping and apo(a) genotyping 
The pulsed-field gel analysis of the APO( a) gene, as described above, 
allows for the analysis of APO(a) alleles that produce little or no apo(a) protein 
and has clarified the relationship between APO( a) gene structure and the apo(a) 
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isofonn size. Refinements of this analysis have indicated that the length of the 
APO(a) gene is even more variable than originally appreciated. The high degree 
of length polymorphism in the APO( a) gene is reflected by a similarly high 
degree of size polymorphism in the apo(a) glycoprotein. Most recent reviews 
refer to the work of Lackner et al. (1993) and Marcovina et al. (1993b) and cite 
the fact that 34 different apo(a) isofonns have been described, Undoubtedly, as 
the methodology improves and more subjects are analyzed, additional APO(a) 
alleles and isofonns will be identified and this number will increase. 
There is currently no evidence, however, that the analysis of APO( a) 
gene structure provides useful additional information for decision making in 
patient care. Similarly, apo(a) phenotyping by immunoblot analysis has no 
significant role, as yet, in routine patient management. 
1.9 Intervention 
Cross-sectional studies, but not all prospective studies, have 
demonstrated that high concentrations of plasma Lp(a) are associated with 
coronary atherosclerosis in Caucasians, but no studies have demonstrated that 
lowering plasma concentrations of Lp(a) is associated with a reduction in CHD 
morbidity or mortality. Intervention studies will not be immediately 
forthcoming, since few available pharmacological agents lower Lp(a). 
1.9.1 Pharmacological agents 
Hypolipidaemic agents that interfere with lipoprotein synthesis have a 
more pronounced effect on plasma Lp(a) levels than those that accelerate the 
clearance of the lipoprotein. Agents that up-regulate the LDL receptor, such as 
bile acid sequestrant resins or HMG Co-A reductase inhibitors, significantly 
lower the plasma concentrations of LDL-cholesterol, but have little or no 
appreciable effect on the plasma concentration of Lp(a) (Vessby et aI., 1982; 
Thiery et a!., 1988; Jurgens et al., 1989; Kostner et a!., 1989). Other agents 
that lower LDL and VLDL-cholesterol, such as the fibric acid derivatives and 
probucol, have no effect on Lp(a) (Albers et aI., 1975; Maeda et aI., 1989). 
The administration of nicotinic acid interferes with the hepatic secretion 
of lipoproteins, causing a fall in not only plasma VLDL and LDL-cholesterol 
concentrations, but also Lp(a) (Gurakar et aI., 1985; Carlson et aI., 1989; 
Noma et aI., 1990) [Figure 1.12]. Doses of nicotinic acid as low as 500 mg 
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Effects of nicotinic acid (4g. dol) on serum Lp(a) concentration. Reduction in 
serum Lp(a) is (A) inversely correlated with serum triglyceride concentration 
and (B) directly correlated with the percentage reduction of LDL-C. Data from 
Carlson et al. (1989) 
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(sustained-release) are associated with a significant fall in plasma Lp(a) 
concentration (Lepre et aI., 1992). The degree to which the plasma Lp(a) 
concentration falls is proportional to the initial plasma Lp(a) level (Carlson et 
aI., 1989); therefore, individuals with higher plasma levels have a more 
significant response to therapy. The decrease in plasma Lp(a) concentration 
tends to correlate with the decrease in plasma LDL-cholesterol. Paradoxically, 
in hypertriglyceridaemic individuals the plasma Lp(a) level may increase on 
nicotinic acid therapy. 
For reasons that are not clear, administration of anabolic and androgenic 
steroids (stanozolol and danazol) to women (Albers et aI., 1984; Crook et aI., 
1992; Hiraga et aI., 1992; Henriksson et aI., 1992) are associated with up to 
50% lowering of plasma Lp(a) levels. High dose oestrogen administration to 
elderly men resulted in a -50% lowering of plasma Lp(a) levels (Henriksson et 
aI., 1992; Hiraga et aI., 1992) though when lower doses were administered to 
women there was a less significant fall in plasma Lp(a) concentrations (Lobo et 
aI., 1992). The effects of postmenopausal hormone replacement therapy on 
plasma Lp(a) levels have also been studied. Sacks et al. (1994) report 
beneficial falls in plasma Lp(a) of 14% and 16% with 0.625 and 1.25 mg of 
conjugated oestrogen respectively. 
An initial report suggested that administration of N-acetylcysteine, a 
reducing agent, was associated with a marked reduction in plasma Lp(a) levels 
(Gavish & Breslow, 1991). The authors speculated that the mechanism by 
which this agent lowered plasma Lp(a) levels was by dissociating apo(a) from 
the LDL moiety. However, a follow-up study failed to confirm this result 
(Kroon et aI., 1991). Whether or not it is advisable to use this strategy to lower 
plasma Lp(a) levels is not clear. It is not known how the free apo(a) is cleared 
and this moiety may be in itself particularly atherogenic (Lawn et aI., 1992). 
Thus, there are only three medications that have been convincingly 
shown to lower the plasma level of Lp(a) in some patients - nicotinic acid, 
oestrogens, and anabolic steroids. Since these medications all have multiple 
effects on the other classes of lipoproteins, it is not possible to lower the plasma 
Lp(a) concentration selectively without changing the levels of other 
lipoproteins. Therefore, it will be difficult to design a study to assess the 
independent effect of lowering plasma Lp(a) levels on coronary risk. 
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1.9.2 Plasmapheresis and Lp(a) 
The plasma concentration of Lp(a), like LDL, can be dramatically 
lowered (30-50%) by either plasma exchange (Schenck et a1., 1988) or LDL-
apheresis (Armstrong et aI., 1989; Ritter et aI., 1990). Indeed the efficiency 
with which this procedure strips the plasma of Lp(a) has prompted GroB and 
colleagues (1994) to suggest it as a preparative method for isolating Lp(a). The 
therapeutic utility of this method to lower plasma levels of Lp(a) is 
questionable, however, given its inconvenience and expense. 
1.9.3 Guidelines for therapeutic intervention 
Despite numerous gaps in our knowledge and our relative inability to 
lower the plasma levels of this lipoprotein effectively, there is sufficient 
evidence to warrant measuring the plasma concentration of Lp(a) in Caucasian 
patients with ischaemic heart disease or with a strong family history CHD. It 
remains controversial whether Caucasians with elevated plasma Lp(a) levels, 
who are otherwise normolipaemic, should be treated with medications directed 
at lowering plasma levels of Lp(a). If a hyperlipidaemic individual also has a 
high plasma Lp(a) level, treatment with nicotinic acid might be preferable to 
other lipid-lowering medications. Oestrogen replacement therapy should be 
encouraged in post-menopausal women with high Lp(a) levels. Finally, in 
individuals with high plasma concentrations of Lp(a), the other known risk 
factors for ischaemic heart disease should be aggressively treated, especially 
any elevations in plasma LDL-cholesterollevels. 
1.10 Lp(a)· molecular folly or design 
The APO( a) locus is arguably the most highly polymorphic in the 
human genome outside of the histocompatibility complex. More than 100 
identifiably distinct APO( a) alleles are present in the Caucasian population 
alone. The variability includes not only the number of kringle repeats, but also 
differences in sequence (Cohen et aI., 1993). This high degree of 
polymorphism must raise the question as to whether the apo(a) protein performs 
any useful function. 
To date, Lp(a) has no known physiological role. Individuals who have 
little to no Lp(a) in their plasma appear to be healthy. Moreover, most 
mammals have no detectable apo(a) protein or APO( a) gene, suggesting that 
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apo(a) does not have an essential function. However, it is possible that apo(a) 
has an intracellular or autocrine role and its presence in plasma is a consequence 
of cellular leakage. If this scenario were true, the association of apo(a) with 
LDL in plasma would simply be a marriage arranged blindly by the forces of 
physical chemistry. Alternatively, apo(a) may confer selective advantage in 
only certain populations. As stated above [section 1.4.1] individuals of African 
descent have 2-3 fold higher plasma levels of Lp(a) than either Caucasians or 
Chinese. These inter-ethnic differences may provide a clue as to a possible 
function for Lp(a). Lp(a) may perhaps provide protection against an infectious 
agent found in Africa, much in the same way that sickle cell trait provides 
selective advantage against falciparum malaria. 
Alternatively, apo(a) may have no physiological relevance and simply be 
the result of a series of genetic and molecular mishaps. The plasminogen gene 
locus appears to be highly recombinogenic; giving rise not only to the APO(a) 
gene, but also to numerous other related genes. It is likely that the APO( a) gene 
is the product of a duplication event that may have occurred more than once, as 
evidenced by its presence in the hedgehog, the old world monkey lineage, but 
no intermediary species. Interestingly, in all animals that express apo(a), the 
protein is polymorphic in size, again attesting to the highly recombinogenic 
nature of this region of the genome. 
Arguing in favour of a physiological role for Lp(a) is the high degree of 
sequence conservation in the coding regions of the APO(a) gene, excluding the 
common K4 and K5 regions. If apo(a) has a function, it is likely to be 
mediated by the sequences that are conserved among individuals and between 
species. For this reason, it would be instructive to compare the sequences of the 
unique K4 repeats and the protease domain in the hedgehog and man. 
Thus, despite advances in our knowledge of Lp(a), important new 
pieces to the puzzle need to be put in place before "the mysteries of Lp(a)" as 
defined by Utermann (1989) can be solved. 
1.11 General aims of this thesis 
It will be clear from the above literature review that while much 
important and fundamental information exists on Lp(a) there are also 
considerable gaps. Most of the work presented in this thesis was peliormed in 
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the Department of Molecular Genetics, Dallas, Texas under the leadership of 
Drs. Michael S. Brown and Joseph L. Goldstein and in the team headed by Dr. 
Helen H. Hobbs. In these laboratories a major initiative is underway to 
understand the mechanisms that control plasma Lp(a) concentrations and the 
contribution of Lp(a) to atherogenesis. Much of this work is currently 
dominated by the study of murine models. My contribution to this work as 
presented in this thesis is concerned primarily with studies performed in human 
subjects. 
In the following chapters I present a series of experiments performed 
using the techniques of high resolution apo(a) phenotyping in conjunction with 
apo(a) genotyping. As a preliminary, I present a study briefly characterising the 
monoclonal antibodies used in the apo(a) phenotyping studies and a description 
of developmental work performed to validate this method. 
Next, a study is presented detailing a comparative analysis of the 
APO( a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three 
ethnic groups viz. Caucasians, Chinese, and African-Americans. This study 
uses the above methods to elucidate underlying mechanisms of plasma Lp(a) 
level control and to shed light on human evolutionary patterns. 
The remainder of the experimental work focusses on the impact of 
candidate genes other than APO( a) on the plasma concentrations of Lp(a). 
Using sib-pair analyses the controversial effects of the LDL receptor gene were 
explored by studying kindreds with familial hypercholesterolaemia. Similarly, 
the effects of the apoB gene were studied in kindreds with 
hypobetalipoproteinaemia. 
The thesis concludes with a discussion of the importance of the detailed 
characterisation of Lp(a). A case is made for the adoption of high resolution 
apo(a) phenotyping in future research initiatives aimed at the study of Lp(a), 
whether these be biochemical, metabolic, clinical or epidemiological. 
Chapter 2 Materials and Methods 
On my way to the Whim I slowly walked toward the Clare Bridge, 
staring up at the gothic pinnacles of the King's College Chapel that stood out 
sharply against the spring sky. I briefly stopped and looked over at the perfect 
Georgian features of the recently cleaned Gibbs Building, thinking that much of 
our success was due to the long uneventful periods when we walked among the 
colleges or unobtrusively read the new books that came into Heffer's 
Bookstore. 
Just do it 
2.1 Introduction 
James D. Watson, (1962 Nobel Laureate) 
The Double Helix 1968 
Joe Goldstein, (1985 Nobel Laureate) 
Nike promotional slogan, and personal motto 
In this thesis four separate but related studies are presented. The general 
methods of plasma Lp(a) analysis, apoCa) phenotyping by high resolution 
immunoblotting, and apo(a) genotyping by pulsed-field gel electrophoresis and 
Southern blotting are described here in detail. Other methods, principally 
plasma lipid and lipoprotein analysis, apoB phenotyping and genotyping, and 
LDL receptor genotyping are crucial to the studies presented but were not 
performed by the author. These assays were performed by collaborators in the 
laboratories stated below and the methods used are outlined here for 
completeness. 
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2.2 Materials 
All reagents used were of analytical grade and the names and addresses 
of all suppliers are shown in appendix 1 together with the manufacturers or 
suppliers of all hardware and software used in this work. 
2.3 Plasma lipid and lipoprotein analysis 
These were assayed using a variety of chemical, enzymatic, centrifugal 
and immunoassay techniques as described in detail below. 
2.3. 1 Plasma lipid assays 
Total cholesterol and triglyceride were determined in fresh, whole 
plasma and lipoprotein preparations by enzymatic colorimetric assays according 
to the protocols of the Lipid Research Clinics Program (1982). For the subjects 
described in chapter 4 these assays were performed in the laboratory of Dr. 
Scott Grundy (University of Texas, Southwestern Medical Center, Dallas, TX), 
while those related to the work described in chapter 5 and 6 were performed in 
the laboratories of Dr. Paul Hopkins (Cardiovascular Genetics Research Center, 
University of Utah, Salt Lake City, UT) and Dr Francine Welty (Institute for 
Prevention of Cardiovascular Disease, Deaconess Hospital, Boston, MA) 
respectively. 
Total cholesterol was assayed using the cholesterol oxidase method, the 
principal of which is shown below: 
Cholesteryl esters + H20 Cholesterol esterase > Cholesterol + RCOOH 
Cholesterol + 02 Cholesterol oxidase > ~4-cholestenone +H20 2 
2 H202 + 4-aminophenazone + phenol POD > 4-(p-benzoquinone-mono-
imino)- henazone + 4 H20. 
Triglyceride was assayed using an enzymatic method the principal of 
which is shown below: 
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Triglyceride+ 3 H20 Lipase > glycerol + 3 RCOOH 
glycerol + ATP GK > glycerol-3-phosphate+ ADP 
glycerol-3-phosphate + 02 GPO > dihydroxyacetone phosphate + H202 
H202 + 4-aminophenazone + 4-chlorophenol Peroxidase > 4-(p-
benzo uinone-mono-imino)- henazone + 2H20 + HC!. 
The resultant colour changes were measured spectrophotometrically at 505 nm. 
2.3.2 Beta quantification 
Lipoprotein classes were prepared by a combination of 
ultracentrifugation and selective precipitation, using standard methodologies 
(Lipid Research Clinics Program 1982). VLDL were separated as a floating 
fraction. The infranatant was then treated with heparin/Mn2+ (at a final 
concentration of 1.3 g. mL- 1 heparin and 0.092M Mn2+) to precipitate LDL and 
leave HDL in solution (Warnick & Albers 1978). The cholesterol content of 
whole plasma, of the top (VLDL), and bottom (LDL and HDL) fractions, and 
of the heparin/Mn2+ supernatant (HDL) were measured as described above. 
Ultracentrifugation. 
Five mL of plasma was placed in an Ultra-clear tube (l3x64 mm) (Beckman 
Instruments, Fullerton, CA) and overlayered with 2 mL of d 1.006 g. mL-l 
solution. Tubes were capped and centrifuged overnight at 35,000 rpm (4°C) in 
a Beckman 50.4 rotor, then sliced 25 mm from the top and the supernatant 
collected into a 3 mL volumetric flask. The contents of the bottom fraction were 
transferred to a 5.0 mL volumetric flask, the tube washed with saline, the wash 
added to the flask, and the volume adjusted to 5.0 mL with 0.15M NaCl. 
Precipitation of LDL. 
An aliquot (1.0 mL) of the bottom fraction was placed in a Beckman centrifuge 
tube and 50 JlL of precipitating reagent [9.56 g MnCh.4 H20 + 1.05 g 
(approximately 5x105 units) heparin sodium salt in 25 mL 0.15M NaCl] were 
added and mixed. The mixture was kept at 4°C for 15 min then centrifuged at 
10,000 rpm for 30 min, and the supernatant separated immediately for 
cholesterol analysis. 
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2.4 Plasma Lp(a) assay 
Plasma Lp(a) concentrations were determined in the different studies 
presented in this thesis using 3 diferent ELISA systems. This was done for two 
reasons. Firstly. during the course of this work the ELISA system used in the 
Dallas laboratory changed. and secondly Lp(a) measurements in the FH families 
from Utah had already been performed locally and were not repeated. It is 
important to note that at no time in this work is any comparison made between 
values for plasma Lp(a) concentrations obtained from more than one assay. 
Only comparisons of plasma Lp(a) concentrations measured by the same assay 
system are made. Therefore. the confounding effects of the lack of inter-assay 
standardisation. which may be considerable. are avoided. 
2.4.1 Lp(a) ELISA 1 
Plasma Lp(a) concentrations in the hypobetalipoproteinaemia family 
members were determined in the Northwest Lipid Research Laboratory. 
University of Washington. Seattle. WA according to the ELISA protocol of 
Marcovina and her colleagues (1995). 
Blood was collected into vacutainers (Becton Dickinson. Lincoln Park. 
NJ) containing K2EDT A as anti-coagulant to give a final concentration of 1 mg. 
mL -I. Plasma was obtained from each of the blood samples by low speed 
centrifugation. lOOOg (4°C) and stored at -80°C. Approximately 7 days after 
collection the samples were shipped on dry ice by express courier to the Seattle 
laboratory. The ELISA measurements were performed as follows. First. flat-
bottomed polystyrene microtitre plates (Nunc. Immunoplate Maxisorp. 
Intermountain Scientific. Bountiful. UT) were coated with lOOf..lL of coating 
buffer (O.IM NaHC03. pH 9.6) containing 0.5f..lg MAb a-6. The plates were 
gently shaken for lh at room temperature and then incubated overnight at 4°C. 
The unbound antibody was removed by washing the plates three times using an 
automated plate washer (Dynatech. Chantilly. VA) with phosphate buffered 
saline (PBS). pH 7.4. The remaining binding sites were blocked by the 
addition of 300f..lL PBS containing 30g. L-I bovine serum albumin (BSA). 
incubated for 1 h at room temperature and washed as before. The plates were 
then sealed and stored at 4°C until used. After equilibrating the plates at room 
temperature for 30min. lOOf..lL of standard. quality controls or plasma samples. 
appropriately diluted in PBS containing Ig. L-l BSA and O.5mL. L-I Tween 
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20, were added to the wells and incubated for Ih at 28°C in an incubator-shaker 
(Innova 4000, New Brunswick Scientific, Edison, NJ). After washing, 100llL 
of appropriate dilutions of either HRPO-conjugated MAb a-5 or MAb a-40, or a 
goat anti-human apoB, was added to each well and incubated as before for Ih at 
28°C. Wells were washed and colour was developed by adding 100llL of 
substrate (hydrogen peroxide) and chromogen (O-phenylenediamine 
dihydrochloride). The enzyme reaction was allowed to proceed for 15 min at 
room temperature, stopped by adding 100llL of 1M H2S04 and the absorbance 
read at 495nm using an automated micro titre plate reader (Molecular Devices, 
Menlo Park, CA). Standard curves were generated by plotting the absorbance 
against Lp(a) concentration by linear regression. Values for sample 
concentrations were obtained by interpolating their absorbance from the 
standard curve. 
2.4.2 Lp(a) ELISA 2 
Plasma Lp(a) concentrations in the FH family members were determined 
in the Cardiovascular Genetics Research Center, University of Utah, Salt Lake 
City, UT, using a commercially available ELISA kit: MACRATM Lp(a) (Temmo 
Medical Corp. Elkton, MD). Briefly, this assay involves the incubation of 
plasma samples at room temperature in microtitre plate wells pre-coated with a 
capture monoclonal anti-Lp(a) antibody. The wells are washed and incubated 
with a polyclonal anti-Lp(a) antibody conjugated to horseradish peroxidase. 
The unbound enzyme conjugate is removed by washing the wells using an 
automated plate washer, as above. Following a 20rnin incubation with enzyme 
substrate (hydrogen peroxide) and chromogen (O-phenylenediamine 
dihydrochloride) the reaction was stopped with 2N H2S04 and the absorbance 
read at 492nm using an automated plate reader, as above. Standard curves were 
prepared as above by plotting the absorbance against the Lp(a) concentration. 
The absorbance is directly proportional to the plasma Lp(a) concentration within 
the working range of the assay, which is quoted by the manufacturer as 0.8-80 
mgLp(a). dL-l. 
2.4.3 Lp(a) ELISA 3 
In the studies on inter-ethnic variation of Lp(a) concentration presented 
in chapter 4, the Lp(a) assay system used was an ELISA described by Menzel 
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et at., (1990). This assay was performed by the commercial laboratory, 
GeneScreen (Dallas, TX). 
Fasting venous blood was collected into vacutainers contalfllflg 
K2EDT A as anti-coagulant to give a final concentration of 1 mg. mL-I. Plasma 
was obtained from each of the blood samples by low speed centrifugation, 
1000g (4°C) and stored at -80°C and plasma Lp(a) concentrations were 
measured within two months of collection. The capture antibody used in the 
assay to coat the microtitre plate wells was a polyclonal rabbit anti-human Lp(a) 
antibody. The detection antibody was a mouse monoclonal anti-human apo(a) 
anti body, IgG-l A 2. The hy bridoma cell line was provided by Dr. Gerd 
Utermann (University of Innsbruck, Innsbruck, Austria) and this was injected 
into mice in the Dallas laboratories where IgG-l A2 was prepared and purified 
for use in-house and by GeneScreen. This antibody does not cross react with 
plasminogen and was conjugated to horseradish peroxidase before use using the 
protocol outlined in section 2.5 below. This antibody was also used in the 
apo(a) immunoblotting method to determine apo(a) phenotype. 
2.5 Apo (a) isoform determination by immunoblotting 
Apo(a) isoform analysis was performed using a modification of the 
immunoblotting method described by Kamboh et a1. (1991) A 12.5 ~l aliquot 
of plasma was mixed with 30 ~l reducing buffer [1 :2: 10 ratio of 13-
mercaptoethanol, 0.5% (w/v) bromophenol blue in 5% (v/v) glycerol, 5% (w/v) 
SDS] and boiled for 5 min. A 10 ~l aliquot of this mixture was loaded onto a 
2% agarose (Ultra Pure DNA Grade Agarose, Bio-Rad, Hercules, CA) gel (15 
cm x 25 cm) in 90 mM Tris-HCl, 90 mM boric acid, 2 mM Na2EDT A and 
0.1 % (w/v) SDS. A mixture of equal quantities of 5 apo(a) isoforms, with 14, 
18, 24, 30 and 34 K-4 repeats, from fully characterized subjects were run on 
each gel as size standards. 
Electrophoresis was performed in a horizontal gel apparatus (BRL Life 
Technologies, Gaithersburg, MO) in 45 mM Tris-HC1, 45 mM boric acid, 2 
mM Na2EDTA and 0.1 % (w/v) SDS for 17 h at a constant 100 V at 4°C. After 
electrophoresis, proteins were transferred to a supported nitrocellulose 
membrane (Hybond™-C extra, Amersham, Arlington Heights, IL) by 
electroblotting using a Hoefer Transphor Cell (Hoefer Scientific Instruments, 
San Francisco, CA) at 90 V for 3 h in 10 mM Tris-HCI, 40 mM glycine and 5% 
(v/v) methanol at 4 0C. Prior to electroblotting the gel was soaked in pre-chilled 
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transfer buffer for 5-10 min and the membrane was soaked first in distilled 
water for 1 min and then pre-chilled transfer buffer for 5 min. 
After electroblotting the membrane was incubated in blocking solution 
[TBS (0.5 M NaCI and 35 mM Tris-HCI, pH 7.4), 5% (w/v) powdered 
skimmed milk and 0.2% (v/v) Tween 20] on a rocking platfOlID, for 1 h prior to 
a 30 min incubation in TBS plus 1 % (v/v) NP-40 and either 34~g. 100mL-I of 
IA2 or 4F3. After incubation with the first antibody the membrane was washed 
four times for 10 min each in 100 ml washing buffer [TBS plus 1 % (v/v) NP-
40,0.5% (w/v) deoxycholic acid and 0.1 % (w/v) SDS] on a rocking platform. 
The membrane was then incubated with a 1: 10,000 dilution of an 
appropriate species-specific affinity purified secondary antibody conjugated to 
horseradish peroxidase. In the case of lA2 and 4F3 this was a sheep anti-
mouse peroxidase linked antibody (Cat # NA931 Amersham). The four cycle 
wash procedure was then repeated and the membrane was developed by using 
ECLTM Western blot detection reagents (Amersham) and subjected to 
autoradiography using Reflection film (Dupont, Willmington, DE) for 10 sec to 
10 min. 
The ECLTM Western blot detection system is a commercially available 
enhanced chemiluminescence system. The plinciple of the ECLTM Western blot 
detection system is illustrated in figure 2.1. Briefly the enhanced 
chemiluminescence is achieved by performing the oxidation of the cyclic 
diacylhydrazide, luminol, by horseradish peroxidase (HRPO) in the presence of 
chemical enhancers such as phenols. This has the effect of increasing the light 
emission by approximately 1,000 fold. The light signal produced by this 
reaction peaks after 5-20 min and decays slowly thereafter with a half-life of 
approximately 60 min. An example of the high resolution apo(a) phenotyping 
blot obtained by this method is shown in figure 1.6. 
2.5.1 Conjugation of monoclonal antibodies 
Mouse monoclonal antibody IgG-l A2 used in the apo(a) 
immunoblotting system was conjugated to HRPO using the method of Nakane 
& Kawaoi (1974). This method joins the enzyme to the FC region of the IgG 
antibody using sodium m-periodate as a "linker" and was performed as follows: 
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Protein Nitrocellulose membrane 
Primary antibody 
r '" LUMINOL 
+ 
" Enhancer .I 
Figure 2.1 
HRPO conjugated 
secondary antibody 
---- Peracid 
Oxidised form 
of enzyme 
LIGHT 
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... 
Oxidised 
product 
Autoradiography film 
Principle of the ECLTM Western blot detection system. This system is a light 
emitting, non-radioactive method for detection of irnmobilised specific antigens, 
conjugated directly or indirectly with horseradish peroxidase (HRPO) -labelled 
antibodies. Adapted from ECLTM Western blot protocol booklet, Amersham 
International pic (1995). 
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a) Lyophilised IgG-IA2 antibody (4mg) was dissolved in dH20 (500~L) and 
dialysed against IOmM NaHC03 (pH 8.5) overnight at 4°C. 
b) HRPO (2mg) was dissolved in dH20 (500~L) to which was added 50~L 
O.2M sodium m-periodate (NaI04). This mixture was then dialysed against 
ImM sodium acetate (pH 4.5) overnight at 4°C. 
c) After dialysis the pH of the antibody solution and of the HRPO solution 
were adjusted to 9.5 with O.5N NaOH and O.2M Na2C03 respectively. 
d) The two solutions were then combined and mixed on a rocking platform for 
2h at room temperature. 
e) The reaction was stopped by adding 50 ~L sodium borohydride (NaBf4) 
(4mg. mL-l) and the solution allowed to stand for 2h at 4°C. 
f) The solution was dialysed against 75mM Na2HP04, 75mM NaCI and 
18mM KH2P04 overnight at 4°C. 
g) The conjugate was tested using an optimisation ELISA and stored at 4°C for 
up to 6 months. 
2.6 Apo(a) genotype determination by pulsed-field gel 
electrophoresis and genomic blotting 
The sizes of the APO( a) alleles studied were confirmed by apo(a) 
genotyping using pulsed-field gel electrophoresis by a modification (Gaw et aI., 
1994) of the procedures originally described by Lackner et al. (1991). 
2.6.1 Cellular agarose plug preparation 
Leukocytes were isolated from whole blood using LeucoPrep tubes 
(Becton, Dickinson) as described by the manufacturer. The leukocytes were 
diluted in PBS to a final concentration of 2 x 107 cells. mL- 1 and placed on ice. 
A 1 % (w/v) solution of low melting point (LMP) agarose in PBS was prepared 
and cooled to 3TC. Equal volumes of LMP agarose and cell solutions were 
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mixed gently and 150/lL of cellular-agarose mixture was injected into an ice-
cold plug mold (Beckman). This mold was tightly wrapped in plastic film and 
incubated on ice for at least 30 min. The mold was unwrapped and the plugs 
were discharged by gentle shaking. The plugs were incubated in 0.5M 
Na2EDTA (pH 8.0). 1 % (w/v) SOS (Bio-Rad), 2 mg. mL-i Proteinase K 
(Boehringer Mannheim) for 48h at 55°C. The plugs were washed with 
0.04mg. mL-l phenylmethylsulphonyl fluoride (PMSF, stock 40mg. mL-I in 
isopropanol) in 1 x TE buffer (lmM Na2 EDTA, 10 mM Tris-HCI, pH 8.0) at 
5YC twice for 30min each. The plugs were stored in 0.5 M Na2EDT A, (pH 
8.0) at 4°C. 
2.6.2 Restriction digest and electrophoresis 
The agarose-cellular plug was washed twice for 30min in 1 x TE. A 3-4 
mm segment was cut using a sterile razor blade and incubated twice for 2 h each 
with 100 units KpllI or HpaI (New England Biolabs, Beverly, MA) in 70 IlL of 
the buffer suggested by the manufacturer (Lackner et aI., 1991, Boerwinkle et 
aI., 1992). 
The plugs were rinsed with 1 x TE buffer and loaded into the wells of a 
1 % (w/v) agarose gel (without ethidium bromide). The wells were then sealed 
with molten 1 % (w/v) agarose. The gel was subjected to transverse alternating 
gel electrophoresis using a GeneLine n™ apparatus (Beckman) containing 1 x 
T AFE II buffer (0.5mM EDTA[free acid], 4.35mM acetic acid, lOmMTris [pH 
8.0]) pre-chilled to 14°C. The pulse times were 4 sec for 30 min followed by 6 
sec pulses (150 volts/350 mAmps) for 18h. Low range PPO markers (New 
England Biolabs) were used as size standards. 
After electrophoresis the gel was stained with 0.5/lg. mL-l ethidium 
bromide for lOmin and photographed in UV light. The gel was rinsed with 
dH20 for lOmin and soaked in denaturation buffer (1.5M NaCI, 0.5M NaOH) 
twice for 30min. The size-fractionated DNA was blotted to a nylon membrane 
(leN, Biomedicals, Irvine, CA) by southern blotting overnight in lOx SSC. 
After transfer the blot was baked for 2h at 80°C in a vacuum oven. 
2.6.3 Single stranded M13 probe preparation 
Lackner and her colleagues (1991) previously subcloned an APO( a)-
specific K4 probe by amplifying the K4 encoding sequences from the human 
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APO( a) gene using the polymerase chain reaction (PCR). A single 4.2 kb band 
was indentified and this fragment was purified, digested with PstI and cloned 
into PstI restricted and dephosphorylated bacteliophage M13-mp18 DNA. The 
clones containing inserts were sequenced and one, designated MP-I shared 15 
bases of sequence identity with the lower strand of the apo(a) cDNA. 
This probe was made in the Dept. of Molecular Genetics, Dallas, Texas 
and was made freely available to me. The probe was prepared according to 
standard protocols as shown in figure 2.2 (Sambrook et aI, 1989) and 
radiolabelled prior to use according to the protocol of Church & Gilbert (1984). 
2.6.4 Hybridisation 
The filter was prehybridised for 2h at 42°C in a rotating incubator in the 
following buffer: 25mL 100% formamide, 5mL 100 x Denhardt's solution, 
12.5mL 20 x SSPE, 5mL 10% (w/v) SDS (filtered), 1.5mL dH20, and 1mL 
denatured salmon sperm (lOOmg. mL-l). The filter was then probed with 6 x 
106 cpm. mL-I) of MP-l, an [a-32P]dCTP radiolabelled human apo(a) K4-
specific single-stranded fragment at 42°C overnight as previously described 
(section 2.6.3 and Lackner et aI., 1991). 
2.6.5 Washing and exposure 
The filter was washed in 500mL of 2 x SSC, 1 % (w/v) SDS at room 
temperature for 15min on a shaker. The filter was then gently scrubbed with a 
sponge and placed in lL 0.5 x SSC, 1 % (w/v) SDS and incubated at 68°C for 
30min. The filter was exposed to X-OMATTM AR film (Eastman Kodak, 
Rochester, NY) with an intensifying screen (Lightening Plus Dupont Co., 
Wilmington, DE) for 16 hat -80T. The APO(a) alleles were designated by the 
estimated number of kringle 4-encoding sequences per allele (APO(a) K-12 to 
APO( a) K-Sl (Lackner et aI., 1993). Examples of the Southern blots obtained 
by this method are shown in figures 1.8 and 1.9. 
2.7 LD L receptor genetic analysis 
The diagnoses of familial hyperchoiesterolaemia in the family members 
described in chapter 5 were made in the Cardiovascular Genetics Research 
Center, University of Utah, Salt Lake City, UT by Dr. Paul Hopkins and his 
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Clone the target sequences Into an appropriate bacteriophage M13 or phagemld vector 
Isolate Single-stranded DNA carrying the target sequences 
\ universal primer 
Using universal primer, synthesize radiolabeled DNA 
complementary to the sequences of interest 
Klenow fragment of E. coli 
DNA polymerase I 
three unlabeled dNTPs 
one 32P-labeled dNTP 
Digest the DNA with a restriction enzyme that cleaves 
at the distal end of the sequences of interest 
Separate the radiolabeled probe from the unlabeled template by gel electrophoresis, 
for example, through a polyacrylamide gel under denaturing conditions 
unlabeled 
template DNA 
radiolabeled 
probe DNA 
fragments derived 
from 3' terminus 
of radiolabeled DNA 
Figure 2.2. 
-
radiolabeled markers 
Principle of the synthesis of probes from single-stranded DNA vectors such a 
M13. Adapted from Sambrook et al. (1989). 
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colleagues. The methods used were those detailed in Emi et ai. (1991). Briefly 
these were as follows. Venous blood was collected after a 12-16 h fast and 
genomic DNA was prepared from peripheral lymphocytes as decribed by 
Cavanee et al. (1984). DNA polymorphisms at the LDL receptor locus were 
characterised by digesting genomic DNA with the restriction endonucleases Nco 
I, Msp I, or Pvu II (New England Biolabs). LDL receptor haplotypes were 
formed by combining the alleles of the three restriction fragment length 
polymorphisms (RFLPs). The LDL receptor cDNA clone pHHI was used to 
detect Nco I and Msp I diallelic RFLPs on Southern Blots (Cavanee et aI., 
1984; Kotze et ai., 1987; Geisel et aI., 1987). The other probe used for 
phenotyping was the LDL receptor genomic clone pRHPI7, which detects a 
Pvu II diallelic RFLP (Hegele et aI., 1988). 
The plasma LDL-cholesterol levels of subjects were compared to the 
95th percentile of their age and sex reference values (Lipid Research Clinics 
Program, 1980). Emi and colleagues (1991) have previously demonstrated that 
a high LDL-cholesterol phenotype segregated with these markers at the LDL 
receptor locus without recombination, with a maximum log of the odds score of 
4.74, which corresponds to an odds ratio greater than 1 in 50,000. 
2.8 Apo 8 genetic analysis 
The diagnoses of hypobetalipoproteinaemia (apoB-67) in the family 
members described in chapter 6 were made in the Institute for Prevention of 
Cardiovascular Disease, Deaconess Hospital, Boston, MA by Dr. Francine 
Welty and her colleagues, using the following methods. 
Venous blood samples were obtained after a 14h fast from family 
members. The blood was collected into vacutainers containing K2EDT A as 
anti-coagulant to give a final concentration of 1 mg. mL-I. Plasma was 
obtained from each of the blood samples by low speed centrifugation, WOOg 
(40 C). Plasma total cholesterol, triglyceride, LDL-cholesterol and HDL 
cholesterol concentrations were measured according to LRC protocols as 
described above (section 2.3.2). The lipoproteins were further characterized 
and the patients' DNA analysed as described elsewhere (Welty et al., 1991). 
The VLDL (d< 1.006 glml), IDL (d 1.006-1.025 glml), LDL Cd 1.025-
1.063 g. mL-I), and HDL (d 1.063-1.21 g. mL-I) fractions were isolated from 
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fresh fasting venous plasma by ultracentrifugation (Havel et ai.. 1955). The 
total protein content of these fractions were determined by a protein assay using 
bovine serum albumin as a standard (Lowry et ai.. 1951). The apolipoprotein 
content of each lipoprotein fraction was then determined using 3-12% gradient 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on gels stained with 
either 0.1 % Coomasie Brilliant Blue R-250 or silver. 
The SDS-PAGE revealed a truncated apoB species migrating identical to 
the apoB-67 previously described (Welty et aI.. 1991). To determine the 
precise mutation in the APOB gene responsible for the apoB-67 phenotype. an 
842 bp segment of ex on 26 of the APOB gene (apoB cDNA nucleotides 9013-
9854) was amplified using PCR with the following oliginucleotide primers: 
B67 5'-TGT CCA ATA AGA TCA AT A GCA AAC ACC T AA GA-3' 
(apoB cDNA nucleotides 9004-9035) 
B67-2 5'-CTG AAA AAT CTC ACG ACG AGC TCC CCA GGA CC-3' 
(complemetary to apoB cDNA nucleotides 9832-9863) 
Genomic DNA (0.5 Jlg) prepared from peripheral white blood cells was 
amplified using Taq polymerase (New England Biolabs) with denaturation. 
annealing and extension conditions of 96°C for Imin, 62°C for Imin, and 72°C 
for 2min for 3 cycles and then 96°C for 30sec. 62°C for Imin. and 72°C for 
2min. for 27 cycles respectively. 
DNA sequencing of the first apoB-67 kindred revealed a deletion of an 
adenine at eDNA 9327 (Welty et ai.. 1991). This frameshift mutation converted 
a lysine to an arginine, followed by a premature stop codon (TAG). Analysis 
of the genetic map revealed that this mutation deleted an Mboll restriction site at 
cDNA 9339. 12 bp 3' of the apoB-67 mutation. To determine the precise 
mutation in the apoB gene responsible for apoB-67 in the other kindreds, the 
amplified DNA from the pro bands in each kindred was purified using column 
chromatography (Qiagen, Irvine, CA) and then digested with MboII (New 
England Biolabs) at 3TC overnight, in the buffer suggested by the 
manufacturer. The products were then subjected to electrophoresis on an 8% 
polyacrylamide gel for 3 h and stained with ethidium bromide. 
After the mutation responsible for the apoB-67 phenotype was 
determined in each kindred. other family members were apoB phenotyped by 
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simply analysing freshly prepared lipoprotein samples by SDS-PAGE as 
described above. 
2.9 Ethical considerations 
All subjects gave informed written consent to the studies which met with 
the requirements of the Ethical Committees of the University of Texas 
Southwestern Medical Center, Dallas, Texas, USA, the Cardiovascular 
Genetics Research Center, University of Utah, Salt Lake City, UT, USA, or 
the Institute for Prevention of Cardiovascular Disease, Deaconess Hospital, 
Boston, MA, USA, as appropriate. 
2.10 Statistical methods 
In the ethnic studies described in chapter 4, the overall shape of the 
distribution of plasma Lp(a) concentrations was compared between popUlations 
using the two-sample Kolmogorov-Smirnov test (Conover, 1980). The 
distributions of plasma Lp(a), were clearly not normally distributed. therefore. 
non-parametric rank-sum tests and Kruskal-Wallis tests (Conover. 1980) were 
used to compare median Lp(a) levels between racial groups. 
Because of the large number of apo(a) phenotypes relative to the 
numbers of individuals in this sample. traditional chi-square goodness-of-fit test 
and chi-square tests of independence were inappropriate. A goodness-of-fit test 
to Hardy-Weinberg expectations was carried out using a computerized 
permutation algorithm described by Guo & Thompson (1992). Comparisons of 
apo(a) isoform and phenotype frequencies among races were carried out using a 
Monte Carlo simulation method to derive p-values for Fisher's exact test (Guo 
& Thompson. 1989). 
The relationship between the apo(a) polymorphism and plasma Lp(a) 
concentrations was analyzed in several ways. The contribution of the apo(a) 
genotypes to the inter-individual variance in plasma Lp(a) concentrations was 
estimated using the adjusted R2 from an analysis of variance (Neter et aI., 
1990). The Spearman's rank correlation (Conover. 1980) between the sum of 
the number of K-4 repeats represented in an individual's genotype and their 
plasma Lp(a) level was calculated. These rank correlations were compared 
between popUlations using Fisher's z-transformation. 
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In the sibling pair analyses described in chapters 5 and 6 the plasma 
Lp(a) concentrations were not normally distributed but were highly skewed 
towards lower plasma levels. Therefore, a comparison of median plasma Lp(a) 
concentrations was made between sibling groups using the non-parametric test 
of significance, the Wilcoxon signed rank test. As previously used in a similar 
analysis by Boerwinkle et al (1992) all analyses were performed on the raw and 
square-root transformed data. For each analysis, the primary inferences were 
identical irrespective of which data format was used. 
Even though the sibships described in chapters 5 and 6 were often larger 
than size two, the above methods have been shown to be valid when 
overlapping sibling pairs are analysed as though they were independent (Amos 
et aI., 1989). 
Chapter 3 
Characterization of antibodies/or use in high 
resolution apo(a) phenotyping by immunoblot 
analysis 
The rapidity of change and the speed with which new situations are created 
follow the impetuous and heedless pace of man rather than the deliberate pace of 
nature. 
Rachel Carson, Silent Spring, 1962. 
3.1 Study Design 
The studies described in this thesis rely in part on the quality of the high 
resolution immunoblotting technique used for apo(a) phenotyping. The 
preliminary study described in this chapter was designed to assess this assay 
system and in particular to answer the following questions: 
a) What is the sensitivity of the assay? 
b) In view of the highly polymorphic nature of the apo(a) glycoprotein is the 
detection of apo(a) proportional to the size of the number of K4 repeats in the 
apo(a) protein? 
c) How does the IgG-IA2 anti-Lp(a) antibody used in these studies compare 
with another commercially available anti-Lp(a) monoclonal? 
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3.2 Introduction 
High resolution apo(a) phenotyping has been used in conjunction with 
apo(a) genotyping to help elucidate underlying mechanisms of plasma Lp(a) 
level control (Gaw et ai., 1994). High resolution apo(a) phenotyping has also 
been reported with in-house monoclonal antibodies as an indirect means of 
assessing apo(a) allele frequencies in different populations (Marcovina et aI., 
1993b). With increasing interest in the Lp(a) field more laboratories are now 
establishing apo(a) phenotyping methods. Despite the use of such methods in a 
number of laboratories throughout the world a series of problems remain 
unanswered. Principle among these are the questions of specificity and 
sensitivity of the antibodies used and the availablity of good anti-apo(a) 
monoclonals that can be used in a high resolution system. To help answer these 
questions the following evaluation was performed to study the specificity and 
sensitivity of the antibody used in the other studies reported in this thesis 
comparing it with one of the few other available anti-Lp(a) monoclonal 
antibodies available commercially. 
3.3 Study protocols 
3.3.1 Subjects 
From a survey of 500 individuals carried out in the University of Texas 
Southwestern Medical Centre at Dallas, a panel of 9 subjects were selected who 
had a single expressing APO(a) allele ranging in size from 14 - 34 K-4 repeats 
and who had a detectable plasma Lp(a) level. Blood sampling of human 
volunteers was approved by the University of Texas Southwestern Medical 
Center Institutional Review Board. 
3.3.2 Plasma Lp(a) assay 
Fasting venous blood samples were collected into Vacutainer Tubes 
(Becton Dickinson & Co. Rutherford, NJ) containing Na2EDT A. Plasma was 
isolated by low speed centrifugation at 1000 x g for 15 min at 4°C, aliquotted 
and stored at -80 DC for up to six months until Lp(a) assay or apo(a) 
phenotyping were performed. Lp(a) levels have been shown to be stable up to 
7 years in samples stored at -20°C (Jauhiainen et al., 1991). Plasma Lp(a) 
concentrations were measured in the Northwest Lipid Research Laboratory, 
Seattle, WA using an in-house enzyme-linked immunosorbent sandwich assay 
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(ELISA) system described in chapter 2 and in detail elsewhere (Marcovina et 
aI., 1995). This assay does not use either of the antibodies studied in the in the 
apo(a) phenotyping system as reponed here. 
3.3.3 Anti.Lp(a) monoclonal antibodies 
Two primary antibodies were studied for characterisation and use in 
high resolution apo(a) phenotyping. 
1. IgG-IA2 is a mouse monoclonal developed in the laboratory of Dr. Gerd 
Utermann (University of InnsbrUck, Austria) and kindly made available 
for the comparison, but which is now commercially available from 
Boehringer Mannheim. This antibody is directed against the common K-
4 repeat, i.e., type A and type B K-4 repeat (Gaw et aI., 1994) and has 
been used in a number of previous studies by ourselves and others for 
Lp(a) ELISA (Menzel et al 1990), and low (Utermann, 1989) and high 
resolution phenotyping (Lackner et aI., 1993; Gaw et aI., 1994). 
2. 4F3 is a commercially available purified mouse monc1onal antibody raised 
against human apo(a) (Cappel Cat #59408) previously only used for 
immunodetection of apo(a) in transgenic animals (Callow et aI., 1994). 
The epitope in apo(a) to which this antibody is directed is not known. 
Because 4F3 only reacts with denatured apo(a) a potential site is in the K-
4 repetivie region (Organon-Teknikal Biotechnology Research Institute, 
Rockville MD, personal communication). 
3.3.4 Apo(a) isoform determination by immunoblotting 
Apo(a) isoform analysis was performed using a modification of the 
immunoblotting method described by Kamboh et aI. (1991) exactly as described 
in chapter 2, methods section 2.5 above. 
3.3.5 Apo(a) genotype determination by pulsed·field gel 
electrophoresis and genomic blotting 
The sizes of the APO(a) alleles in those subjects used in this study were 
confirmed by apo(a) genotyping using pulsed-field gel electrophoresis by a 
modification of the procedures originally described by Lackner and her 
colleagues (1991), and exactly as described elsewhere (Gaw et aI., 1994). The 
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APO( a) alleles were designated by the estimated number of K -4-encoding 
sequences per allele (APO(a) K-J2 to APO(a) K-5J) (Lackner et aI., 1993) as 
described in chapter 2. 
3.4 RESULTS 
3.4.1 Specificity/equivalence of response with different 
apo(a) isoforms 
Plasma samples from the panel of 9 subjects ranging in plasma Lp(a) 
concentration from 5-88 mg. dL-l, who had a single expressing apo(a) allele 
were diluted with mouse plasma to render all samples with an equivalent Lp(a) 
level (5 mg. dL-i). Mouse plasma was used as the diluent because wild type 
mice have no plasma Lp(a). Equal volumes were loaded on to the SDS-agarose 
gel as described in the methods and after electrophoresis was immunoblotted 
with each of the antibodies. 
Figure 1 shows the results of two different experiments using the same 
samples immunoblotted with either of the plimary antibodies. Clearly, equal 
quantities of plasma Lp(a) yield approximately equal intensities of signal 
irrespective of apo(a) isoform size. This was also the case when different 
antibody dilutions were tried (data not shown). 
Because the apo(a) protein is composed of a chain of very similar 
kringle-4 repeat domains and because the primary antibodies used are thought to 
have epitopes in these repeat regions it may have been expected that larger 
isoforms would have more binding sites and would therefore yield a relatively 
stronger signal, but this was not the case. Both antibodies showed an 
equivalence of signal when apo(a) isofonns of very different sizes were 
studied. The reasons for this remain to be determined by further studies of the 
primary antibodies, 1A2 and 4F3 
3.4.2 Sensitivity 
Serial dilutions of samples with known Lp(a) level and single 
expressing apo(a) isoform. Previously the detection limit of the lA2 antibody 
in our immunoblotting system was reported as 0.1 mg. dL-i of Lp(a) (Gaw et 
aI., 1994). 
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Figure 3.1. 
Immunoblot analysis of apo(a) isoforms in human plasma. Plasma samples 
from 9 subjects with a single expressing apo(a) allele were diluted with mouse 
plasma to make the Lp(a) concentrations in each sample the same (5 mg. dL-1). 
A total of 12.5 J.ll of each diluted plasma was subjected to electrophoresis on a 
horizontal 2% SDS-agarose gel. The plasma proteins were blotted onto a 
nitrocellulose membrane and immunoblotted with an apo(a) specific monoclonal 
antibody (lA2 on the left panel and 4F3 on the right panel). The signals were 
developed using the EeL system with a 5 min exposure time. The number of 
lcringle 4 repeats for each apo(a) isoform is given and 'n' denoted null allele. A 
mixture of equal quantities of 5 apo(a) isoforms, with 14, 18,24,30 and 34 K-
4 repeats, from fully characterized subjects were run on each gel as size 
standards. 
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Figure 3.2. 
Irnmunoblot analysis of apo(a) isofonns in serial dilutions of human plasma 
from a individual with a single expressing apo(a) allele. The sample was loaded 
neat (first lane in each panel with a concentration of 7.5 mg.dL-1) and diluted 
with mouse plasma to yield Lp(a) concentrations of 1.8, 0.75, 0.28, 0.05 and 
0.02 mg.dL-1. A total of 12.5 J.ll of each diluted plasma was subjected to 
electrophoresis on a horizontal 2% SDS-agarose gel. The plasma proteins were 
blotted onto a nitrocellulose membrane and immunoblotted with an apo(a) 
specific monoclonal antibody (lA2 on the left panel and 4F3 on the right panel). 
The signals were developed using the ECLTM Western blot detection system 
with a 16 hour exposure time. 
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With the very long exposures shown in figure 2 levels can be detected down to 
0.05 mg. dL-I Lp(a) using both lA2 or 4F3 antibodies. In practice all blots are 
subjected to short and long (i.e., overnight) exposures in order to determine 
whether an isoform is present or not. The definition of the 'null allele' must, 
however, remain an operational one as discussed elsewhere (Gaw et aI., 1994, 
and chapter 4). 
3.5 DISCUSSION 
Because of the enormous heterogeneity in the size of the apo(a) 
glycoprotein, simple measurement of the plasma Lp(a) concentration does not 
provide a full assessment of Lp(a) phenotype. Originally apo(a) phenotyping 
was performed using an SOS-polyacrylamide gel electrophoresis (SOS-PAGE) 
system by Utermann (1989). With their system 5 apo(a) isoforms were 
resolved which together with a putative null allele gave 6 apo(a) phenotypes. 
These were designated B (equalling apoB-lOO mobility), F (faster than apoB-
100) and Sl, S2, S3 and S4 (slower than apoB-lOO by varying degrees).This 
SOS -PAGE system was modified by others and the resolution was improved 
resulting in the identification of 9 (Soutar et aI., 1991) then 28 (Perombelon et 
aI., 1994) apo(a) isoforms. 
Not until Kamboh and his colleagues (1991) suggested the use of an 
SOS-agarose matrix was it possible to resolve many more apo(a) isoforms. 
Using this system first 23 (Callow et aI., 1994) then 34 apo(a) isoforms were 
resolved (Lackner et aI., 1993, Marcovina et aI., 1993b). Further screening 
and perhaps improved methodology will undoubtedly identify further apo(a) 
isoforms of different size. It should be noted that both high and low resolution 
apo(a) phenotyping systems only resolve apo(a) isoforms on the basis of size. 
A further level of heterogeneity was uncovered when apo(a) isoforms of the 
same size were found to be different in sequence (Cohen et aI., 1993). 
Although significant progress in our understanding of the biology of 
Lp(a) has been made using high resolution apo(a) phenotyping (Lackner et aI., 
1993; Gaw et aI., 1994; Marcovina et aI., 1993b), it remains to be seen whether 
this method has a place in the assessment of the patient by the clinical chemistry 
laboratory. However, one thing is certain: further research on the 
pathophysiological role of Lp(a) in human disease is needed. Such research 
performed without access to high resolution apo(a) phenotyping either alone or 
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in conjunction with apo(a) genotyping is likely to be severely limited in its 
impact and its relevance. The availability of good commercially produced 
antibodies for this purpose should make these assays more widely available for 
improved clinical research. 
Chapter 4 
Comparative Analysis of the APO(a) Gene, Apo( a) 
Glycoprotein and Plasma Concentrations of Lp(a) 
in Three Ethnic Groups 
Here individuals of all nations are melted into a new race of men, whose 
labours and posterity will one day cause great changes in the world. 
1. Hector St. John de Crevecoeur, 1782. 
Letters from an American F mmer 
4.1 Study background 
It has been previously estimated that in Caucasians, approximately 90% 
of the inter-individual variation in plasma Lp(a) levels is explained by sequence 
differences at, or closely linked, to the APO( a) locus (Boerwinkle et aI., 1992). 
This finding, however, has not been extended to other racial groups to date, 
which is important since the distributions of plasma Lp(a) levels exhibit marked 
inter-racial variability. 
In Caucasians and Chinese, the distribution of plasma Lp(a) is highly 
skewed towards lower levels (Utermann, 1989; Albers et aI., 1990; Marcovina 
et aI., 1993a, 1993b; Sandholzer et al., 1991). However, in Africans and 
African-Americans, the distribution curve of plasma Lp(a) levels has a more 
Gaussian shape (Scanu & Fless, 1990; Marcovina et al., 1993a, 1993b; Parra et 
aI., 1987; Helmhold et al., 1991) and on average, African-Americans have 2-3 
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fold higher plasma concentrations of Lp(a) than either Caucasians or Chinese. 
The factors responsible for the racial differences in distribution of Lp(a) levels 
have not been identified. but previous studies have suggested that differences in 
apo(a) isoform size distributions are not solely responsible (Marcovina et ai., 
1993a. 1993b; Sandholzer et ai., 1991; Helmhold et ai., 1991). The use of 
apo(a) isoforms in such studies is problematic, however, because standard 
immunoblotting methods cannot detect protein products from all APO( a) alleles. 
In fact. in only one out of eleven ethnic groups, in which APO( a) allele 
frequencies have been calculated, were the alleles in Hardy-Weinberg 
equilibrium (Sandholzer et aI., 1991; Helmhold et aI., 1991). 
In this study, high resolution apo(a) genotyping and phenotyping 
systems have been used to evaluate the relationship between APO( a) gene 
structure, apo(a) glycoprotein size, and plasma concentrations of Lp(a) in three 
racial groups: Caucasians, Chinese, and African-Americans. This is the first 
study in which APO( a) gene structure, apo(a) glycoprotein size and plasma 
Lp(a) levels have been simultaneously analyzed in any population. 
4.2 Subject characteristics 
Venous blood samples were obtained from 174 unrelated American 
Caucasians (86 men, 88 women), 101 unrelated Chinese (46 men, 55 women), 
and 106 unrelated African-Americans (20 men, 86 women). All subjects were 
selected at random from healthy individuals living in the Dallas-Fort Worth 
area. The only selection criteria were that all Caucasians and African-Americans 
had to be born in the United States and all Chinese had to be born in Mainland 
China or Taiwan. Four Caucasians, 17 Chinese and 12 African-Americans 
were post-menopausal at the time of sampling. A description of the 
characteristics of the three sample groups is given in Table 4.1. while the 
individual plasma Lp(a), apo(a) phenotype and apo(a) genotype of all subjects 
is given in appendix II. There was no significant difference in the ages, or 
plasma levels of total cholesterol or LDL-cholesterol of the 3 groups. The 
African-Americans had slightly lower plasma concentrations of triglyceride and 
higher concentrations of high density lipoprotein HDL-cholesterol than the 
other two racial groups. 
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4.3 Plasma Lp(a) distributions 
The distribution of plasma Lp(a) concentrations in each of the three 
racial groups is shown in Figure 4.1. The charactetistics of the distributions of 
plasma Lp(a) levels were compared in the three populations [Table 4.2J. In all 
populations, the plasma Lp(a) concentrations varied over a wide range. As 
reported previously, (Marcovina et aI., 1993a, 1993b; Sandholzer et aI., 1991; 
Helmhold et aI., 1991), the plasma levels of Lp(a) were more highly skewed 
towards the lower range in the Chinese (skew=3.77) and Caucasians 
(skew=1.33) than in the African-Americans (skew=O.84). There was only a 
marginal statistical difference between the overall distribution of plasma Lp(a) 
levels (Kolmogorov-Smirnov, p=0.06) between the Chinese and Caucasians; 
the distributions in both populations were significantly different from the 
African-Americans. (p<O.OOl). In the Caucasians and Chinese, more than 45% 
of the individuals had plasma Lp(a) concentrations less than 9 mg. dL-l 
whereas only 12% of the African-Ameticans had plasma Lp(a) levels in this 
range. In the African-Americans, the distribution of plasma Lp(a) 
concentrations was relatively uniform up to approximately 50 mg. dL -I, 
whereas in the other two populations there was a dramatic decrease over this 
range [Figure 4.1]. 
Since plasma Lp(a) concentrations in the three populations were not 
normally distributed, the median rather than mean plasma Lp(a) concentrations 
was used to compare levels. There was no significant difference in median 
plasma Lp(a) levels in the Caucasian and Chinese populations (Kruskul-Wallis, 
p=O.21). In the African-Americans, the median plasma concentration of Lp(a) 
was, however, 2-3-fold higher than in the other two racial groups. 
4.4 Analysis of APO(a) gene 
The K-4 encoding region of the APO(a) alleles was analyzed using 
pulsed-field gel electrophoresis and genomic blotting (Lackner et aI., 1993) as 
described in chapter 2. The alleles were classified according to the estimated 
total number of K-4 repeats contained within their sequences (APO( a)12-
APO(a)51). The observed genotype frequencies in each of the racial groups 
was consistent with Hardy-Weinberg expectations (Guo & Thompson, 1992). 
The distributions of APO(a) allele sizes in the three groups are shown in Figure 
4.2. In both the Caucasians and African-Americans, the distributions of 
APO( a) alleles were remarkably symmetrical and they were not significantly 
different from each other (Fisher exact test, p=0.17). However, the 
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Table 4.1 
Description of the samples from each of the 3 populations 
Age Plasma levels (mmo!. L-I) 
Race n (years) TC* TG LDL-C HDL-C 
Caucasian 174 38 (9) 5.1 (1.6) 1.45 (1.05) 3.1 (0.9) 1.3 (0.4) 
Chinese 101 44 (16) 4.9 (0.9) 1.59 (1.22) 3.0 (0.8) 1.3 (0.3) 
Aflican- 106 39 (10) 5.1 (1.0) 1.13 (0.63) 3.3 (1.0) 1.4 (0.3) 
American 
* All values are given as means (SO). 
TC total cholesterol; TG triglyceride; LDL-C low density lipoprotein cholesterol; HDL-
e high density lipoprotein cholesterol. 
Table 4.2 
Description of plasma Lp(a) concentrations in U.S. Caucasians. Chinese and African-
Americans. 
Standard 
Mean Median Deviation Skew Kurtosis Min. Max. 
Race (mg. dL-I) (mg. dL-l) 
Caucasian 17.9 9.0 19.1 1.33 4.22 <1 88.0 
Chinese 14.7 8.0 21.1 3.77 22.27 <1 156.0 
African- 37.7 33.0 26.9 0.84 3.33 <1 120.0 
American 
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Figure 4.1 
Frequency distributions of plasma Lp(a) concentrations in three populations. 
Plasma Lp(a) levels were measured in 381 subjects by a sandwich ELISA, as 
described in Section 2.4.3. The width of each bar corresponds to a plasma 
Lp(a) concentration interval of 7.8 mg. dL-l. Figures in parentheses show 
number of subjects studied. Individual plasma Lp(a) levels for all subjects are 
shown in appendix II. 
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Figure 4.2 
Frequency distributions of APO(a) alleles in three populations. APO(a) allele 
size (number of K-4 repeats) was estimated using pulsed-field gel 
electrophoresis and genomic blotting, as described in Section 2.6. Figures in 
parentheses show number of alleles studied. Individual APO(a) allele sizes for 
all subjects are shown in appendix II. 
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distributions of APO( a) alleles in the Caucasians and African-Americans were 
significantly different from the Chinese (p<O.OOl). In the Chinese population, 
the mean size of the apo(a) alleles was significantly larger than in the other two 
groups. 
Due to the large number of different sized alleles in these populations, 
post hoc statistical comparisons of the frequencies of individual alleles must be 
viewed with caution. Nonetheless, some striking differences were apparent. A 
single APO( a) allele, APO( a)-33, comprised 20% of the alleles in the Chinese 
sample, whereas the most frequent allele in either the Caucasians or African-
Americans contributed only 10% to the alleles in these populations. The high 
frequency of a single A PO ( a) allele in the Chinese suggests that the 
heterozygosity index in this population should be lower. This was indeed the 
case. The observed frequency of individuals homozygous for APO(a) alleles of 
identical size was highest in the Chinese (5.5%) and lowest in the Caucasians 
(2.9%) with the African-Americans having an intennediate level (4.7%). 
4.5 Relationship between apo(a) genotype and plasma 
concentration of Lp(a) 
The relationship between apo(a) genotypes and plasma concentrations of 
Lp(a) was examined in each population [Figure 4.3]. The apo(a) genotypes are 
represented on the floor (x and y axes) of the 3-D diagram. The vertical bars (z 
axis) represent the median plasma concentrations of Lp(a) for all individuals 
with a given apo(a) genotype. Although the patterns of apo(a) genotypes 
differed among the 3 populations, there was a similar inverse relationship 
between the size of the APO( a) alleles and the plasma concentration of Lp(a), as 
indicated by the decrease in the height of the bars from left to right. The 
Spearman rank correlation values for the relationship between the sum of the 
APO( a) allele sizes (i.e. total number of K-4 repeats) and the plasma levels of 
Lp(a) were remarkably similar in the three populations: -0.49 (Caucasians and 
African-Americans) and -0.53 (Chinese). The Chinese group had a 
significantly different "footprint pattern" on the floor of the graph from the other 
two populations, reflecting the difference in APO(a) allele frequencies (noted 
above). The Caucasians and African-Americans had more similar "footprint 
patterns", but had distinctly different "skyline patterns", that is, for almost all 
apo(a) genotypes, the African-Americans had higher median plasma Lp(a) 
levels than the Caucasians. While not apparent fmm this figure [4.3], it should 
be noted that the variance in plasma Lp(a) levels for each genotype was 
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Relationship between apo(a) genotype and plasma Lp(a) concentration in three 
populations. In each 3D plot, the number of K-4 repeats of the smaller 
APO(a)allele (Allele 1) is given on the x-axis. The number of K-4 repeats in the 
larger APO(a) allele (Allele 2) is shown on the y-axis. The vertical bars (z-axis) 
represent the median plasma Lp(a) concentration of individuals with each 
genotype. Individual data for all subjects are shown in appendix II. 
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higher in African-Americans (s2 = 664) than in the Caucasians (s2 = 166) or 
Chinese (s2 = 133). 
The higher variance in plasma Lp(a) levels in the African-Americans is 
made more obvious if the total number of K-4 repeats is related to the plasma 
concentrations of Lp(a) [Figure 4.4]. In all three populations distribution of 
plasma Lp(a) levels vs. total number of K-4 repeats was triangular in 
appearance. The relationship between APO(a) allele size and plasma Lp(a) level 
is not linear over the entire range. The relationship appears to be biphasic; 
Caucasian and Chinese individuals with greater than approximately 65 K-4 
repeats had uniformly low plasma concentrations of Lp(a) [Figure 4.41. The 
variability in plasma Lp(a) concentrations was greater among individuals with 
fewer rather than more K4 repeats, and the variability was greatest in the 
African-Americans. This effect may be explained in part by the fact that those 
individuals with fewer K-4 repeats comprise more than one group of 
individuals: those with one large and one small APO(a) allele, or those with two 
medium sized alleles. In contrast, almost all the individuals with a larger total 
number of K-4 repeats e.g., > 65, constituted a more uniform group because 
their K-4 complement could only result from the addition of two large alleles, 
and not a very small plus a very large allele because such alleles «12 or >51 K-
4 repeats) were not observed in this study. 
4.6 Relationship between A P 0 ( a) allele size and apo(a) 
glycoprotein 
Next, the relationship between APO( a) allele size and the presence of detectable 
apo(a) glycoprotein in plasma was examined. The apo(a) isoforms were analyzed by 
immunoblotting, as described in chapter 2, in the entire Chinese group, in all but six of 
the African-Americans, and in 155 of the 174 Caucasians. Immunoblotting data were 
not obtained in 25 subjects (6 African-Americans and 19 Caucasians) because blood 
samples were obtained from these individuals prior to the development of the more 
sensitive immunoblotting technique. The alleles were classified into two groups based 
on whether or not there was clearly detectable plasma apo(a) protein present on 
immunoblotting. The analysis of serial dilutions of plasma samples of known Lp(a) 
concentration, reported in chapter 3, revealed that APO( a) alleles associated with a 
plasma concentration of Lp(a) ;;:: 0.05 mg. dL-I were invariably detectable. Only those 
APO( a) alleles in which no protein product was identified by immunoblotting (i.e., 
associated with plasma Lp(a) concentrations < 0.05 mg. dL-I) are referred to as "null" 
alleles and are included in Figure 4.5. 
Figure 4.4 
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Frequency distributions of expressing and non-expressing APO( a) alleles in 
three populations. APO(a) allele and isoforrn sizes were both determined in 
each subject. The relative frequencies of APO( a) alleles associated with 
detectable protein [i.e. ~ 0.05 mg. dL-l plasma Lp(a)] and non-detectable 
protein [i.e. < 0.05 mg. dL-l plasma Lp(a)] are plotted according to race. In all 
popUlations, the non-expressing alleles are spread throughout the entire 
spectrum of APO(a) allele sizes. Individual APO(a) allele and apo(a) isofonn 
sizes for all subjects are shown in appendix II. 
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Since future refinement of the immunoblotting technique may reveal 
protein products that are presently undetectable, the designation of null alleles 
is qualified by using quotation marks. 
The frequency of APO(a) alleles with undetectable protein products was 
highest in the Caucasians (28.6%), and was similar in the African-Americans 
and Chinese (14.0% and 13.4%, respectively). The frequency of individuals 
who had no detectable apo(a) protein by immunoblotting was 5.7% in the 
Caucasians, 2.0% in the Chinese and 2.8% in the African-Americans. In all 
three populations, the frequency distribution of alleles associated with trace to 
no detectable apo(a) protein [i.e. < 0.05 mg. dL-l Lp(a)] was similar to the 
frequency distribution of alleles associated with detectable apo(a) protein [i.e. 
~0.05 mg. dL-I Lp(a)]. Thus, despite the overall relationship between APO(a) 
allele size and plasma Lp(a) level in all three populations, the frequency of low 
expressing alleles was not skewed towards the larger alleles, as might have 
been expected based on the overall relationship between APO(a) allele size and 
plasma level of Lp(a). 
4.7 Relationship between APO( a) allele size and plasma level of 
Lp(a) 
Finally, the relationship between APO(a) allele size and plasma level of 
Lp(a) was examined in the subset of individuals who had one allele which 
expressed no, or only trace amounts of, immunodectable apo(a) protein. For 
this analysis, we assume that essentially all of the plasma Lp(a) measured by the 
ELISA is the product of a single expressing allele [Figure 4.6]. Again, in the 
Caucasians, there was a distinct triangular relationship between Lp(a) level and 
the size of the expressing allele. APO(a) alleles with less than 25 K-4 repeats 
showed much greater variability in the associated plasma Lp(a) levels. APO(a) 
alleles with greater than 28 K-4 repeats consistently were associated with 
plasma Lp(a) levels less than 10 mg. dL-l. There were too few individuals with 
single expressing alleles in the Chinese or African Americans to make any 
definitive comments about the relationship to plasma Lp(a) level, although the 
pattern in both groups also appears to be triangular, especially in the African-
American subset [Figure 4.6]. 
Figure 4.6 
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Relationship between the size of a single expressing APO(a) allele and plasma 
Lp(a) concentration in three populations. A number of individuals in each racial 
group had only a single expressing APO(a) allele (Caucasians, n=68; Chinese, 
n=23; African-Americans, n=27). The sizes (number of K-4 repeats) of these 
APO(a) alleles are plotted against the corresponding plasma Lp(a) 
concentrations revealing a similar pattern for each racial group as that illustrated 
in figure 4.4. 
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4.8 Discussion 
4.8.1 Insights into the general control of plasma Lp(a) levels 
This is the first study in which the APO( a) gene structure, apo(a) 
glycoprotein size, and plasma concentration of Lp(a) have been compared in 
any popUlation. The apo(a) genotype frequencies in all three racial groups were 
in accordance with Hardy-Weinberg equilibrium, which is consistent with the 
samples studied being representative of the popUlations from which they were 
drawn. This is in contrast to the findings of previous studies that examined the 
size distribution of APO(a) alleles indirectly by examining the apo(a) isoforms 
(Sandholzer et aI., 1991; Helmhold et ai. 1991). In those studies, not all 
APO( a)allele protein products were detected, as indicated by the high estimated 
frequency of null alleles and the large number of subjects with only a single 
visible isoform. Direct analysis of the APO( a) gene obviates the problems 
associated with non-detection of APO(a) allele protein products when trying to 
assess the apo(a) genotype frequency. Consequently, in this study two APO( a) 
alleles of different sizes were observed in 97% of Caucasians, 95% of Chinese 
and 94% of African-Americans. 
A major finding of this study is that the differences in plasma 
concentrations of Lp(a) between Caucasians, Chinese and African-Americans 
are not due to in differences in the APO( a) allele size distributions. This 
conclusion is evident from the following observations: 1) The Caucasians and 
Chinese had very similar distributions of plasma Lp(a) levels and yet had 
significantly different APO(a) allele distributions and 2) The African-Americans 
had a distinctly different plasma Lp(a) distribution from the other two groups, 
yet their APO(a) allele size distribution was not significantly different from the 
Caucasians. The similarity in the distribution of APO(a) alleles in Caucasians 
and African-Americans cannot be solely attributed to genetic admixture, since it 
has been estimated that only approximately 25% of the genes in African-
Americans are Caucasian in origin (Chakraborty et aI., 1992). Admixture may 
contribute to the observed modest skewing of African-American plasma Lp(a) 
concentrations to lower levels [Figure 4.1]. 
It is striking that the relationship between APO(a) allele size and plasma 
Lp(a) level was so similar in all three ethnic groups. The uniformity of this 
relationship suggests a fundamental underlying biological mechanism. 
Interestingly, we found that the relationship between APO( a) allele size and 
plasma level of Lp(a) was almost identical with previous reports based on the 
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analysis of the apo(a) isofonns (Marcovina et aI., 1993a, 1993b; Sandholzer et 
aI., 1991; Helmhold et aI., 1991). The reason for this concordance has been 
elucidated by simultaneous analyses of the APO(a) gene and apo(a) isoforms. 
It had been anticipated, given the inverse relationship between APO( a) allele 
size and plasma Lp(a) level, that the APO( a) alleles associated with no 
detectable circulating apo(a) would have been of larger size, but this was not the 
case. The APO(a) alleles which were associated with little to no apo(a) protein 
had a very similar size distribution to those alleles with detectable protein 
products. Therefore, the APO( a) alleles undetected by immunoblotting in prior 
studies (Marcovina et aI., 1993a, 1993b; Sandholzer et aI., 1991; Helmhold et 
aI., 1991) did not bias the relationship between APO( a) allele size and plasma 
Lp(a) level. 
There are two possible explanations for the fact that APO( a) alleles 
associated with little or no plasma apo(a) protein are distributed throughout the 
entire size spectrum. First, the APO( a) alleles associated with very low 
concentrations of plasma protein may be the result of several different mutations 
that interfere with apo(a) synthesis or secretion. Given the cysteine-rich nature 
of this protein, it is likely that even rather conservative amino acid substitutions 
could disrupt proper folding and subsequent transport of this protein out of the 
hepatocyte (Amara, Cheng & Smith, 1992). Alternatively, there may be a few 
common mutations in the APO( a) gene which arose early in the gene's 
evolution and now are associated with APO( a) alleles of widely varying sizes 
due to subsequent recombination at the locus. 
It is interesting that the plasma levels of Lp(a) in the Chinese population 
were not lower than the Caucasians, given the shift of the APO( a) alleles to the 
larger sizes [Figure 4.2]. This is probably due to the fact that a much larger 
percentage of APO( a) alleles in the Caucasian population were associated with 
little to no circulating apo(a) protein. 
Despite the overall inverse relationship between APO( a) allele sizes and 
plasma concentrations of Lp(a) in all 3 populations, there were notable 
exceptions to this general trend. APO(a) alleles containing fewer K-4 repeats 
tend to be associated with higher plasma concentrations of Lp(a) but they can 
also be associated with little to no detectable plasma apo(a). There is 
considerably less variation in the plasma levels associated with APO(a) alleles at 
the high end of the size spectrum. In both the Caucasians and the Chinese, the 
APO(a) alleles containing more than 25 K-4 repeats were uniformly associated 
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with low plasma levels of Lp(a) (i.e. less than 10 mg. dL-l) [Figure 4.6]. This 
is consistent with the observation that apo(a) isoforms of large size are 
processed inefficiently and secreted at very low levels in primary cultures of 
baboon hepatocytes (White et aI., 1993, 1994). However, it must be noted that 
in the African-Americans, some very large alleles are associated with significant 
amounts of plasma Lp(a) protein (> 20 mg. dL-l). Therefore, there is no 
intrinsic property of large apo(a) isoforms that precludes their synthesis and 
secretion. 
A possible confounding factor in this study is the relative excess of 
women in the African-American sample. In all populations studied to date there 
has been no significant difference between plasma Lp(a) levels in men and 
women. The one exception is post-menopausal women where plasma 
concentrations of Lp(a) are increased by an average of 15% (Heinrich et aI., 
1991). To ensure that the higher plasma Lp(a) levels in the African-American 
popUlation were not due to a relative excess of women in the sample, the 
median plasma Lp(a) levels were compared in the African-American men and 
women and were found not to be statistically different (30.5 men vs. 33.5 mg. 
dL-l women). Similarly, when the sample was stratified to exclude African-
American post-menopausal women and compared to the total female group of 
African-Americans, the median level was almost identical (32.5 vs. 33.5). 
Therefore, the results of this study are not biased significantly by the 
differences in sex ratios. 
In previous studies, the contributions of APO( a) allele SIze 
polymorphism to inter-individual variations in plasma Lp(a) levels have been 
calculated. However, these calculations are based on the ratio between the 
variance in APO(a) allele size and the variance in plasma Lp(a) level. As noted 
previously, for almost every genotype, the plasma concentrations of Lp(a) vary 
much more in the African-Americans than in either of the two other popUlations. 
Accordingly, the size polymorphism appears to contribute much less to the 
inter-individual variability in plasma concentrations of Lp(a) in the African-
Americans due to the greater variance in plasma Lp(a) levels in this population. 
Therefore, the significance of such calculations is not clear. 
A compelling question that remains unanswered by this study is why 
African-Americans have higher plasma concentrations of Lp(a) than Caucasians 
despite the similar APO(a) allele distributions. We can definitively state that the 
higher plasma concentrations of Lp(a) in African-Americans are not due to a 
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higher frequency of APO( 0) alleles with fewer K-4 repeats. Nor. do African-
Americans have fewer APO( a) alleles associated with little or no circulating 
apo(a) protein. Rather, high Lp(a) levels in African-Americans appear to be due 
to a more general mechanism. For almost every apo(a) genotype, the African-
Americans had higher median plasma levels of Lp(a) than did Caucasians or 
Chinese. To date, little is known about the genetics of plasma Lp(a) 
concentrations in African-Americans. In Caucasians. the APO( a) gene, or 
sequences linked to it. contribute> 90% to the inter-individual variation in 
plasma Lp(a) levels (Boerwinkle et al., 1992). The relative contribution of the 
APO( a) locus to plasma levels of Lp(a) in individuals of African descent has not 
been determined. The fact that the relationship between APO( a) allele size and 
plasma Lp(a) level is similar in the African-Americans and the Caucasians 
suggests that sequences at the APO( a) locus contribute importantly to plasma 
levels of Lp(a) in the African-American population. If indeed the APO(a) gene 
is a major determinant of plasma Lp(a) levels in African-Americans. there 
appear to be additional factors, genetic or non-genetic. that modify the effect of 
the APO( a) allele size in this group. 
4.8.2 Insights into human evolution 
The enormous polymorphism of the APO(a) gene offers us a useful 
marker with which to study other genetic and evolutionary problems. The 
evolution of the APO( a) gene itself has been the subject of much debate. 
Workers have attempted to resolve the discontinuity of the the APO(a) gene in 
the mammalian lineages while trying to date the duplication event that led to the 
separation of the ancestral plasminogen and APO(a) genes in antiquity. Early 
attempts placed this event 40 million years ago during primate evolution 
(Mclean et aI., 1987) but more detailed studies push the event back into a much 
more distant past, some 90 millon years ago, immediately before the radition of 
the mammals (Pesole et aI., 1994). 
The comparative analysis of the APO( a) gene and its product presented 
here may be used to examine a much more recent event, in geological terms; the 
evolution of man. By studying racial differences at a genetic level, as has been 
done here, it is possible to offer supportive evidence for the 'out of Africa' 
model of Homo sapiens evolution as set forth by Stringer and Andrews (1988). 
Figure 4.7 
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Phyllogenetic tree for 26 representative human populations. Major groups of 
human populations are Africans (A), Caucasians (B), Greater Asians (C), 
Amerindians (D) and Australopapuans (E). As noted in the main text the 
African-Americans in the present study represent an approximate genetic mix of 
African: Caucasian of 3: 1. The American Caucasians in the study are all the 
descendants of West and East Europeans with little if any genetic admixture 
from other races. The Chinese in the study were all born in mainland China or 
Taiwan and again have little or no genetic admixture. The scale of each branch 
length is shown in D A (modified Cavalli-Sforza units of genetic distance). 
Adapted fron Nei & Roychoudhury (1993). 
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In this theory it is proposed that H. sapiens originated approximately 
200,000 years ago in Africa and later populated the globe by migration. A rival 
theory, the multiregional theory (Wolpoff et al., 1984) contends that H. sapiens 
evolved from a predecessor, H. erectus , simultaneously in several different 
areas in the world over the last one million years. Recent calculations of 
genetic distances between living human races (Nei & Roychoudhury, 1993) 
demonstrate a closer caucasoid/mongoloid than negroid/mongoloid relationship, 
with the caucasoid/negroid genetic distance intermediate between the two 
[Figure 4.7]. This suggests a population splitting in early human evolution 
between Africans and non-Africans and a further second level split later 
between Caucasians and other non-Africans, including Chinese. 
In the present study, the greater similarity between Caucasian and 
African-American APO(a) allele distributions than that between Chinese and 
African-Americans is consistent with this phyUogeny. There is, as mentioned 
above, considerable genetic admixture between Caucasian and African-
American populations and it has been estimated that approximately 25% of the 
African-American genome is in fact Caucasian (Chakraborty et al., 1992). 
However, if the gentic distances between West Africans and Western 
Europeans, as reported by Nei and Roychoudhury (1993) are corrected for this 
admixture rate, the African-American/Caucasian distance is still intermediate 
between the Caucasian/Chinese and the African-American/Chinese and the 
conclusion remains intact. 
When plasma Lp(a) distributions are examined in this light it becomes clear 
that the same phyllogenetic tree derived from APO( a) allele distributions is not 
sustained. This apparent paradox has also been observed with many other 
protein and enzyme polymorphisms where a consistent negroid split from all 
other populations has been reported (Stringer & Andrews, 1988; Nei & 
Roychoudhury, 1993) but there is currently no accepted explanation. 
However, because the plasma Lp(a) phenotype is largely, though not 
exclusively attributable to the apo(a) length polymorphism, the distinctly 
different pattern of Lp(a) plasma concentrations in African-Americans in this 
study must mean that in this population other controlling factors, genetic and/or 
environmental are at play. 
Chapter 5 
The influence of LDL receptor gene defects on 
plasma Lp(a) levels 
Democracy loosens social ties, but it tightens natural ones. At the same time as 
it separates citizens, it brings kindred closer together. 
Alexis de Tocqueville. 1835. 
Democracy in America 
5.1 Study background 
Many fundamental questions remain unanswered about the metabolism 
of Lp(a) largely because there are no stable cell lines or simple, accessible 
animal models that express the APO(a) gene in an authentic genomic context. 
Because Lp(a) is closely related in structure to LDL, the metabolism of LDL has 
been used as a paradigm to study the metabolic control of Lp(a). The LDL 
receptor plays a pivotal role in determining the plasma LDL concentration. 
Considerable efforts have therefore been made to define the role of the LDL 
receptor in the control of plasma Lp(a) concentrations. Many factors, both 
genetic and non-genetic impact on the function of the LDL receptor. The 
activity of this transmembrane protein not only effects the clearance, but also the 
production rates of LDL (Gaw et ai., 1993). Thus, mutations in this protein are 
associated with dramatic elevations in plasma concentrations of LDL-cholesterol 
and are the cause of the autosomal codominant disorder familial 
hypercholesterolemia (FH) (Goldstein & Brown, 1989). To date over 150 
different mutations of the LDL receptor gene have been identified (Hobbs et aI., 
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1992). FH heterozygotes have a two-three fold increase in plasma LDL-
cholesterol levels associated with tendon xanthomas and premature coronary 
heart disease. FH homozygotes may have as much as a six-fold elevation in 
plasma LDL-cholesterol and often develop clinical atherosclerosis in childhood 
(Goldstein & Brown, 1983). 
Metabolic and cell culture studies have provided conflicting results as to 
whether the LDL receptor binds and internalizes Lp(a). In vitro studies of LDL 
receptor mediated binding and uptake of Lp(a) by cultured cells have produced 
equivocal results (Floren et aI., 1981, Hofmann et aI., 1990, Krempler et al 
1983, Armstrong et aI., 1985). Krempler et aI., (1983) demonstrated that Lp(a) 
may be specifically bound with high affinity to human fibroblast LDL 
receptors, but added that the affinity and maximal binding capacity of Lp(a) was 
lower than that of LDL. Most recently Snyder and her colleagues (1994) 
demonstrated variable binding characteristics of Lp(a) in different cell types and 
concluded that in fibroblasts Lp(a) and LDL had equal affinities, but because of 
markedly different physiological plasma concentrations it would be unlikely that 
the hepatic LDL receptor could contribute significantly to the degradation of 
Lp(a) in vivo. 
In contrast to these in vitro studies, analysis of Lp(a) metabolism in 
mice expressing a human LDL receptor transgene revealed rapid catabolism of 
native human Lp(a) (Hofmann et aI., 1990). Thus, Lp(a) can bind to and be 
internalized by the LDL receptor in vivo, but the physiological relevance of 
these studies remain to be detennined. 
Another approach that has been taken to examine the role of the LDL 
receptor in Lp(a) metabolism is to analyse the plasma levels of Lp(a) in FH 
subjects. Utermann and his colleagues (1989) reported that FH heterozygotes 
have 2-3 fold higher plasma levels of Lp(a). These findings were supported by 
the results from other groups (Wiklund et aI., 1990; Leitersdorf et aI., 1991; 
Mbewu et aI., 1991). However, all these studies were flawed since there was 
no control for the possible effect of differences in apo(a) isoform distributions 
between the two groups being compared. Also, in some cases the sample of 
patients with FH were from a lipid clinic and the control sample was not. Thus, 
there may have been selection bias as those FH patients with high plasma Lp(a) 
levels may have overt CHD and may be more likely to be seen in lipid clinics. 
In addition, analysis of a large rhesus monkey pedigree with FH (Neven et aI., 
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1990) disclosed no difference in the plasma levels of Lp(a) between the affected 
and unaffected animals. 
In humans, recent evidence suggests that the LOL receptor may not play 
a major role in the catabolism of plasma Lp(a). Up-regulation of the LDL 
receptor by pharmacological agents such as bile acid sequestrant resins or 
HMG-CoA reductase inhibitors, has no appreciable effect on the plasma 
concentration of Lp(a) (Vessby et al., 1982, Thiery et al., 1988, Jurgens et al., 
1989, Kostner et al., 1989, Wiklund et al., 1990, Hunninghake et al., 1993), 
however, these studies are relatively small and there is considerable inter-
individual variation in response to therapy. Hypothyroidism, which is 
associated with a decrease in LOL receptor activity (Salter et al., 1991) and 
elevated plasma LOL-cholesterol levels, is not associated with a significant 
change in plasma Lp(a) levels (Klausen et al., 1992a). 
In normal individuals, kinetic studies have revealed that the plasma level 
of Lp(a) appears to correlate with the production rate, rather than the 
degradation rate of Lp(a) (Rader et al., 1993) and the fractional catabolic rates 
of 12SI-Iabelled Lp(a) in FH heterozygous individuals, who have 50% of 
normal LOL receptor activity, and normal indivduals were not significantly 
different (Knight et al., 1991). 
In addition, three human family studies have failed to demonstrate a 
significant difference in the plasma levels of Lp(a) of FH heterozygotes when 
compared to their unaffected relatives (Soutar et al., 1991, Ghiselli et al., 1992, 
Hegele et al., 1990). In two of these studies (Ghiselli et al., 1992, Hegele et al 
1990), the plasma Lp(a) levels were compared in family members who did or 
did not have FH. In both studies there was no control for the effect of the 
APO(a) allele size on the plasma level of Lp(a). In the other study (Soutar et 
al., 1991) the apo(a) isoforms were analyzed and it was demonstrated that the 
size distribution of apo(a) isoforms between the FH and non-FH groups were 
similar and there was no difference between the plasma levels of Lp(a) of the 
two groups. It is still possible, however, that the lack of difference in this 
study is due to variations at the APO( a) locus not revealed by simple sizing of 
the apo(a) isoforms. 
Apo(a) isoforms of the same size can be associated with very different 
levels of plasma Lp(a) (Cohen et al., 1993). Therefore, even if there is a 
similar distribution of apo(a) isoforms sizes in the comparison groups as was 
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the case in the study by Soutar and her colleagues (1991), this does not control 
for inter-individual differences in plasma Lp(a) due to the APO( a) gene. The 
only way to show rigorously that the APO( a) allele distributions between the 
two groups are similiar is to compare Lp(a) levels in family members with 
APO( a) alleles identical by descent (ibd). By examining APO( a) alleles that are 
identical in sequence (i.e., sibling pairs who inherit alleles ibd), the effect of a 
decrease in LDL receptor activity on plasma levels of Lp(a) can be 
unequivocally detennined. 
In this study such sibling-pair analyses of FH and non-FH siblings 
were used to examine the hypothesis that the LDL receptor plays a key role in 
the control of plasma Lp(a) levels. The results show that mutations in the LDL 
receptor do influence the plasma levels of Lp(a). 
5.2 Methods 
The general methods used in this study are described in detail in chapter 
2. Here, specific details of the protocol and genetic analysis are described. 
5.2.1 Subjects 
Venous blood samples were obtained from 162 subjects from 9 large 
well-defined FH kindreds from Utah. The plasma was separated and the 
leukocytes isolated for DNA extraction. Lipid and lipoprotein assays were 
performed on fresh plasma aliquots, obtained by low speed centrifugation 
(1000 xg, 40C) , using Lipid Research Clinics protocols (1982) as described in 
chapter 2. The plasma Lp(a) was measured using a commercial kit Macra Lp(a) 
(Strategic Diagnostics Inc.). 
Some of these large families with well-defined FH have been used in 
other studies and their pedigrees have been published elsewhere (Emi et aI., 
1991). The diagnosis of FH was confirmed by following the co-segregation of 
DNA polymorphisms at the LDL receptor locus with the hypercholesterolaemia 
as described in chapter 2. In each kindred at least one family member had 
clinical evidence of tendon xanthomata. The plasma lipid and lipoprotein levels 
of each family member used in the sibling pair analysis are given in appendix 
III. The apo(a) isoforms were sized, based on their migration in an SDS-
agarose gel relative to standards, as decribed in section 2.5 in chapter 2. From 
-------------------~~~-~--~-----.-~-.---
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the screening of 162 subjects in the FH kindreds 51 informative sibling pairs 
were identified. The characteristics of these sibling pairs are shown in tables 
5.1, 5.2 and 5.3. 
5.2.2 Statistical Methods 
Plasma Lp(a) concentrations are not normally distributed but are highly 
skewed towards lower plasma levels. Therefore, a comparison of median 
plasma Lp(a) concentrations was made between sibling groups using the non-
parametric test of significance, the Wilcoxon signed rank test. As previously 
used in a similar analysis by Boerwinkle and his colleagues (1992) all analyses 
were performed on the raw and square-root transformed data. For each 
analysis. the primary inferences were identical irrespective of which data format 
was used and only the raw data are presented here. 
Even though the sibships were often larger than size two, the above 
method has been shown to be valid when overlapping sibling pairs are analysed 
as though they were independent (Amos et al.. 1989). 
5.2.3 Apo(a) phenotyping vs. apo(a) genotyping 
In the present study high resolution apo(a) phenotyping is used as a 
surrogate for apo(a) genotyping. This approach provides equally valid 
information on APO( a) alleles in all but one situation. This exception is 
important and merits further discussion. Where a parent has an apparent (n,X) 
phenotype and all the offspring have inherited only the 'X' allele it is not 
possible to differentiate the parent's genotype as a (n,X) or an (X.X). If the 
parent is indeed a homozygote with two APO( a) alleles of equal size, but which 
are not necessarily identical, it is not possible to state unequivocally that two 
offspring, such as subjects 3 and 5 in figure 5.1, have inherited identical 
APO( a) alleles. 
However, as only approximately 3% of the Caucasian population are 
homo zygotes with two APO( a) alleles of the same size (chapter 2 , section 
4.8.1), virtually all of the parents asigned as (n,X) will indeed be (n,X) and not 
(X,X). 
Figure 5.1 
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Hypothetical pedigree showing apo(a) phenotypes. Circles denote females and 
squares denote males. The numbers below each symbol denote the subjects' 
identification numbers. n designates a null allele while X, Y and Z designate 
expressed isoforms of different sizes. 
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The analyses were also performed on the subgroup of sibling pairs in 
which APO( a) alleles were unequivocally inherited identical by descent 
(normal/normal, n=2; FH/FH, n=8; normal/FH, n= 12). 
5.3 Results 
From the screening of 162 subjects in the FH kindreds 51 informative 
sibling pairs were identified. The characteristics of these subjects are shown in 
appendix III. Two examples of the apo(a) phenotyping gels for two of the FH 
familes studied are shown in figures 5.2 and 5.3. 
Fifteen pairs of normal siblings who had inherited the same apo(a) 
phenotype from their parents were identified from the FH families. As 
expected, there was no significant difference between the plasma Lp(a) levels of 
the siblings in this group (12.9 mg. dL-I vs. 13.2 mg. dL-I, p=0,47). Only 
two of these sibling pairs had APO( a) alleles ibd and in view of the small 
number these were not further analysed. 
Ten pairs of siblings both of whom had inherited a defective LDL 
receptor allele from one of their parents and who were consequently FH 
heterozygotes, were also identified from these families. These FH siblings had 
inherited the same apo(a) phenotype from their parents. Again there was no 
significant difference between the plasma Lp(a) levels of the siblings in this 
group (29.5 mg. dL-I vs. 23.0 mg. dL-I, p=0.50). When the 8 sibling pairs 
who had had APO(a) alleles ibd were examined separately this conclusion was 
upheld. 
Twenty-six sibling pairs were identified in which one sibling was an FH 
heterozygote, while the other was normal with respect to LDL receptor 
function, but both of whom had inherited the same apo(a) phenotype from their 
parents. These sibling pairs were used to evaluate the impact of reduced LDL 
receptor function on the plasma Lp(a) concentration. When the median plasma 
Lp(a) level in the FH heterozygotes was compared to that of their normal 
siblings the result just failed to reach statitisical significance (21.5 mg. dL-l vs. 
19.0 mg. dL-I, p=0.08). With a more rigorous analysis including only those 
sibling pairs who had inherited APO(a) alleles unequivocally ibd (n=12), the 
difference was now strongly significant (22.0 mg. dL-I vs. 12.0 mg. dL-l, 
p=0.005). 
Figure 5.2 
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Example 1 of apo(a) immunoblot showing the inheritance of apo(a) isofonns in 
family 653-4. The gel was run, blotted and developed exactly as described in 
chapter 2 section 2.5. The exposure time was 5 min. Sibling pairs with 
identical apoCa) phenotypes andAPO(a) alleles ibd are shown in lanes 3, 7, 8 
and 9 (*) and lanes 4 and 6 (t). Size markers shown on the left side of the gel 
are in numbers of K4 repeats. In the pedigrees the numbers denote the ages of 
the family members in years at the time of sampling. The squares and circles 
represent males and females, respectively. while open symbols and shaded 
symbols represent normal and FR, respectively. The characteristics of the 
family members and the full pedigree are shown in appendix III. 
Lp(a) and the LDL Receptor 96 
15 17 20 22 24 
1234567 
25-
21-
15-
Isoform 1 n n 14 n n n n 
Isoform 2 22 14 22 14 22 22 14 
1 Lp(a) mgldl 19 136136118113/10122/ 
t * * t 
Figure 5.3 
Example 2 of apoCa) immunoblot showing the inheritance of apoCa) isofonns in 
family 26. The gel was run, blotted and developed exactly as described in 
chapter 2 section 2.5. The exposure time was 5 min. Two sibling pairs with 
identical apoCa) phenotypes and APO(a) alleles ibd are shown in lanes 4 and 7 
(t) and lanes 5 and 6 (*). Size markers shown on the left side of the gel are in 
numbers of K4 repeats. In the pedigrees the numbers denote the ages of the 
family members in years at the time of sampling. The squares and circles 
represent males and females, respectively, while open symbols and shaded 
symbols represent normal and FR, respectively. The characteristics of the 
family members and the full pedigree are shown in appendix III. 
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5.4 Discussion 
In this study, plasma Lp(a) levels are compared in siblings from 9 
families with FH. In the non-FH (n=15), and FH sibling pairs (n=1O) the 
plasma Lp(a) levels were very similar. The plasma Lp(a) levels in the sibling 
pairs with the same apo(a) phenotype and with APO(a) alleles ibd in which one 
member had FH and one member did not (n=12), were significantly different 
[median plasma Lp(a) 22.0 vs. 12.0 mg. dL-l, p=O.005], which would be 
expected if the LDL receptor played an important role in the control of plasma 
Lp(a) levels, as it does for LDL. 
As described in chapter 1, it has been estimated that approximately 90% 
of the inter-individual variation in plasma Lp(a) concentrations is attributable to 
sequences at, or closely linked to, the APO( a) gene (Boerwinkle et aI, 1992). 
In family studies, siblings who inherit the same APO( a) alleles from their 
parents have strikingly similar plasma levels of Lp(a) (r=0.95), whereas those 
who shared no APO( a) alleles had different plasma levels (r=-0.23). This 
would not be expected if normal variations in other genes contributed 
importantly to the plasma concentrations of Lp(a). However, major defects in 
key genes controlling lipoprotein metabolism such as the LDL receptor have 
been proposed as additional controlling factors of the plasma Lp(a) level. 
Attempts to explain the variable extent of atherosclerosis in subjects with 
FH have focussed on the adverse impact of environmental influences, as well as 
the influence of an LDL receptor defect on lipoprotein levels other than LDL 
(Seed et al 1990). Studies on the impact of FH on plasma Lp(a) levels have 
been conflicting. Initial observations that FH heterozygotes had increases in 
plasma Lp(a) approaching three-fold over normal controls (Utermann et al 
1989) have been supported by other workers who studied FH heterozygotes 
and age and sex matched controls (Wiklund et al 1990) or unaffected first 
degree relatives (Mbewu et a 1991). Other groups have, however, reported that 
there is no difference in the plasma Lp(a) level between FH heterozygotes and 
their unaffected siblings when low resolution apo(a) phenotyping is used to 
match subjects and controls (Soutar et al 1991). As a corollary Knight and his 
colleagues (1991) found that the clearance rates for trace-labelled Lp(a) were the 
same in subjects with FH and normal controls. 
In the present study the influence of the APO( a) gene, which has 
previously been shown to be the principle determinant of plasma Lp(a) levels 
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(Boerwinkle et al 1992), has been nonnalized by examining sibling pairs who 
share APO( a) alleles that are identical by descent. The influence of a second 
gene, the LDL receptor can therefore be examined in relative isolation. When 
26 FH/non-FH sibling pairs were examined in this way there was a significant 
difference in the plasma Lp(a) levels between the two groups (p=0.005). 
These results suggest that the LDL receptor is playing a role in the 
control of plasma Lp(a) levels. The level of this control remains unclear and 
there are two distinct mechanisms that may be invoked to explain this 
phenomenon. 
1. The LDL receptor may play an important physiological role in the 
clearance of Lp(a) from the plasma. 
2. The LDL receptor is known to be an important controlling factor in 
determining the plasma LDL concentration. Dysfunction of the LDL 
receptor may then increase the available LDL substrate for Lp(a) 
assembly and indirectly increase plasma Lp(a) levels. 
The pool of any plasma constituent is determined by the combined 
effects of its production rate and its catabolic rate. Previous published 
discussions on the influence of the LDL receptor on plasma Lp(a) have 
focussed on the putative clearance of Lp(a) from the circulation via the LDL 
receptor. There is clear in vitro evidence that the LDL receptor can indeed bind 
to and intemalise the Lp(a) particle (Krempler et aI., 1983; Snyder et aI., 1994). 
Furthermore, ill vivo studies with mice over-expressing a human LDL receptor 
transgene have demonstrated that Lp(a) clearance in this situation can be 
increased (Hofmann et aI., 1990). 
However, human metabolic studies have demonstrated that it is the 
production rate rather than the catabolic rate that primarily detennines the plasma 
Lp(a) level. Here, we must consider a more indirect mechanism by which 
defective LDL receptor function may impact upon plasma Lp(a) concentrations. 
From the work of White and her colleagues (1993,1994) we know that 
Lp(a) assembly most likely takes place extracellularly on the hepatocyte surface. 
This assembly requires the interaction of the secreted, and possibly 
immmobilised, apo(a) glycoprotein with free LDL particles in the extracellular 
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fluid (ECF). This interaction, in common with all chemical reactions, must be 
bound by the laws of mass action as shown below: 
Apo(a) + LDL ........ _-- Lp(a) 
If we assume the apo(a) secretion rate to be invariate because it is directly 
dependent on the length of the apo(a) isoform, which in turn is determined by 
the length of the APO( a) gene, then the only factor that can increase k I would 
be the concentration of LDL in the ECF. If this LDL concentration is increased 
k I will be increased and the mass action equation will be pushed to the right in 
favour of Lp(a) production. In FH the plasma and ECF LDL concentrations are 
increased. Therefore, we may hypothesise that in this condition the plasma 
Lp(a) concentration will be higher. not because of any effect on Lp(a) clearance 
by the defective LDL receptor. but rather an in indirect effect of the elevated 
LDL pool which leads to an increased availability of one of the two components 
for Lp(a) assembly. 
Further supportive evidence for the role of the plasma LDL pool as a 
controlling factor of the Lp(a) production rate comes from groups who have 
examined plasma Lp(a) concentrations in subjects with familial combined 
hyperlipidaemia (Fonda et aI., 1993) and in patients with type IIa 
hyperlipoproteinaemia (Bartens et aI., 1995). In both these studies those 
subjects with elevated plasma cholesterol levels had higher plasma Lp(a) levels 
when compared to controls. However, it is important to note that in neither of 
these studies was the contribution of the APO( a) gene polymorphism 
completely controlled and the results must remain tentative. 
Clearly, this hypothesis is consistent with some but not all of the 
available evidence. We know that the Lp(a) production rate is more important 
than its clearance rate in determining the plasma Lp(a) level, but we would also 
expect kl to be lowered by decreasing the plasma LDL level by pharmacological 
means such as statin therapy. There are no good data to support an Lp(a) 
lowering effect of the statins although as noted above the available studies are 
relatively small and there is a degree of inter-individual variability in therapeutic 
response. When the LDL-C concentrations of the normal and FH siblings are 
compared there is an average difference of 50% (Mean (SEM) for normals 2.7 
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(0.1) mmol. L-I vs. for FH 5.4 (0.2)mmol. L-I). Simvastatin, the most potent 
of the currently available statins, will lower LDL-C by approximately 35% 
(Scandinavian Simvastatin Survival Study Group, 1994). Perhaps in order to 
alter the kinetics of Lp(a) assembly significantly we may have to lower plasma 
cholesterol by a similar percentage to its corresponding increase in FH. 
Currently, the only available therapy to do this is LDL apheresis. This 
proceedure also directly removes Lp(a) from the plasma (GroB et aI., 1994) 
and would therefore be unhelpful in trying to ascertain the effect of dramatic 
LDL lowering on plasma Lp(a) concentration. Recently, phase III trials of a 
second generation statin called atorvastatin, have been reported (Nawrocki et al. 
1995) revealing very impressive LDL-C reductions of more than 60%. Further 
testing of the hypothesis presented here for plasma Lp(a) level control may soon 
be possible by lowering LDL-C levels by this novel phannacological modality. 
An alternative way to test this hypothesis would be to examine the 
effects of a genetically controlled reduction in plasma LDL levels on plasma 
Lp(a) levels. This experiment may be perfOlmed by examining families with 
the condition, hypobetalipoproteinaemia, in a similar fashion to that described 
here. This proposed study has now been performed and is the subject of 
chapter 6. 
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Table 5.1 
Comparison of plasma Lp(a) levels in nonnal sibling pairs with the same apo(a) 
phenotype. 
Sibling pair Apo(a) APO(a) Plasma 
ID numbers phenotype alleles Lp(a) mg. dL-I WSR 
ibd 
Nonnal Nonnal 
26-397/399 17/34 21.0 33.0 
26-394/395 32/34 2.0 4.0 
653-1-268/272 n/28 + 14.0 14.0 
653-2-102/104 n/30 4.0 5.0 
653-2-102/105 n/30 4.0 5.0 
653-2-105/104 n/30 5.0 5.0 
625-30/42 28/39 8.0 12.0 
625-52/59 26/28 17.0 22.0 
625-52/69 26/28 17.0 20.0 
625-52nO 26/28 17.0 16.0 
625-59/69 26/28 22.0 20.0 
625-59nO 26/28 22.0 16.0 
625-69nO 26/28 20.0 16.0 
71002076-265/266 n/27 9.0 3.0 
653-4-103/109 26/34 + 12.0 7.0 
Median 12.9 13.2 P=0.47 (NS) 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
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Table 5.2 
Comparison of plasma Lp(a) levels in FH sibling pairs with the same apo(a) 
phenotype. 
Sibling pair Apo(a) 
ID numbers phenotype 
659-125/127 n/20 
659-139/140 15/24 
659-143/147 n/20 
653-1-81/83 21/28 
653-1-1/41 20/26 
653-1-1/5 20/26 
653-1-5/41 20/26 
653-1-28/29 n/20 
653-4-108/110 26/34 
26-496/527 22/30 
Median 
Median (only ibd pairs) 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
APO(a) 
alleles 
ibd 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
FH 
47.0 
56.0 
4.0 
10.0 
31.0 
31.0 
28.0 
24.0 
22.0 
57.0 
29.5 
26.0 
Plasma 
Lp(a) mg. dL-l WSR 
FH 
42.0 
62.0 
4.0 
18.0 
10.0 
28.0 
10.0 
28.0 
17.0 
87.0 
23.0 P=0.50 (NS) 
17.5 P=0.12 (NS) 
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Table 5.3 
Comparison of plasma Lp(a) levels in normal and FH sibling pairs (i.e. one sibling 
with FH and one normal) with the same apo(a) phenotype. 
Sibling pair Apo(a) APO(a) Plasma 
ID numbers phenotype alleles Lp(a) mg. dL-l WSR 
ibd 
FH Normal 
625-64/52 26/28 20.0 17.0 
659-152/151 0/21 21.0 36.0 
659-61/63 n/15 + 45.0 37.0 
659-144/145 15/20 + 40.0 45.0 
26-393/397 17/34 29.0 21.0 
26-393/399 17/34 29.0 33.0 
625-64/59 26/28 20.0 22.0 
625-64/69 26/28 20.0 20.0 
625-64nO 26/28 20.0 16.0 
653-4-108/103 26/34 + 22.0 12.0 
653-4-110/103 26/34 + 17.0 12.0 
653-4-107/104 n/19 + 41.0 39.0 
653-1-12/24 20/26 37.0 60.0 
653-1-31/30 n/19 + 3.0 2.0 
653-5-102/109 29/31 + 11.0 7.0 
653-6-105/103 20/33 + 63.0 46.0 
71002076-264/265 0/27 14.0 9.0 
71002076-264/266 n/27 14.0 3.0 
26-726n21 n/n 1.0 1.0 
26-719n23 0/20 35.0 56.0 
26-527/497 22/30 87.0 64.0 
26-496/497 22/30 57.0 64.0 
26-343/342 0/22 + 13.0 10.0 
26-341/344 n/14 + 22.0 18.0 
653-4-108/109 26/34 + 22.0 7.0 
653-4-110/109 26/34 + 17.0 7.0 
Median 21.5 
19.0 P=0.08 (NS) 
Median (only ibd pairs) 22.0 12.0 P=0.005 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
Chapter 6 
The influence of defects in the APOBgene on 
plasma Lp( a) levels 
Let us read and recollect and impress upon our souls the views and ends of our 
own immediate forefathers in exchanging their native country for a dreary, 
inhospitable wilderness. 
John Adams, 1765. 
A Dissertation on the Canon 
6.1 Study Outline 
Familial hypobetalipoproteinaemia (FHB) is an autosomal codominant 
disorder characterized by abnormally low circulating LDL-cholesterol 
concentrations, which can be caused by mutations in the APOB gene (Young et 
aI., 1988, Collins et aI., 1988). Approximately 25 mutations in the APOB 
gene resulting in FHB have been described (Linton et a\., 1993). FHB 
heterozygotes typically have LDL-cholesterol and apoB levels 25-50% of 
normal (Linton et aI., 1993) and due to the low levels of atherogenic 
lipoproteins may be protected from the development of coronary artery disease 
(Kahn & Glueck, 1978). 
As detailed in chapter 1, apoB is one of the two main proteins in Lp(a). 
The APO( a) gene accounts for> 90% of the variation seen in plasma Lp(a) 
concentrations (Boerwinkle et aI., 1992), but relatively little is known about 
post-transcriptional and post-translational control of Lp(a) levels. The impact of 
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APOB gene mutations on plasma Lp(a) levels have not been previously studied 
and the apoB-67 mutation described here provides a unique opportunity to 
examine the relationship between decreased production of apoB-l 00 and Lp(a) 
levels. 
ApoB-67 is a truncated form of apoB previously reported in a large 
Amish kindred in which affected family members have plasma apoB and LDL-
C levels approximately 25% of normal, low plasma triglyceride levels, elevated 
plasma HDL cholesterol levels and the absence of CHD (Welty et a\., 1991). 
The production rates of both apoB-67 and apoB-IOO in these FHB subjects is 
<10% of normal subjects, however, catabolism of apoB-IOO in both the VLDL 
and LDL fractions is identical in both groups. Because these FHB subjects 
catabolize apoB-100 at normal rates, the association between decreased 
production of apoB-IOO and Lp(a) levels should be independent of LDL 
receptor activity. As there is only approximately one quarter of the normal 
amount of apoB-100 in the FHB subjects to complex with apo(a), it is 
hypothesised that Lp(a) levels would be lower in the FHB subjects when 
compared to their normal siblings 
In the present study the influence of the APO( a) gene, which has 
previously been shown to be the main determinant of plasma Lp(a) levels 
(Boerwinkle et al., 1992), has been normalized by examining sibling pairs who 
share APO( a) alleles that are identical by descent. The influence of a second 
gene, APO B, can therefore be examined in relative isolation. When 
FHB/normal sibling pairs were examined it was clear that those subjects who 
had inherited the apoB defect had significantly lower plasma Lp(a) levels. 
6.2 Methods 
The general methods used in this study are described in detail in chapter 
2. Here, specific details of the protocol and genetic analysis are described. 
6.2.1 Subjects 
Venous blood samples were obtained from 80 subjects from large well-
defined FHS kindreds from Ohio. The plasma was separated and the 
leukocytes isolated for DNA extraction. Lipid and lipoprotein assays were 
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performed on fresh plasma aliquots, obtained by low speed centrifugation 
(1000 xg, 40C) , using Lipid Research Clinics protocols (1982) as described in 
chapter 2. The plasma Lp(a) was measured using ELISA I as described in 
section 2.4.1. 
Some of these large families with well-defined FHB have been used in 
other studies and some of their pedigrees have been published elsewhere (Welty 
et aI., 1991). The diagnosis of FHB was confirmed in the proband of each 
family by RFLP analysis as described in chapter 2. Thereafter, the presence or 
absence of the mutation in other family members was assessed by analysing 
freshly prepared lipoprotein samples for the presence of apoB-67 by SDS-
PAGE. The plasma lipid and lipoprotein levels of each family member used in 
the sibling pair analysis are given in appendix IV. The apo(a) isoforms were 
sized, based on their migration in an SDS-agarose gel relative to standards, as 
described in section 2.5 in chapter 2. From the screening of 80 subjects in the 
FH kindreds 33 informative sibling pairs were identified. The characteristics of 
these sibling pairs are shown in tables 6.1, 6.2 and 6.3. 
6.2.2 Statistical Methods 
The statistical methods used in this study were exactly as described in 
chapter 5 section 5.2.2. 
6.3 Results 
From the screening of 80 subjects in the FHB kindreds 33 informative 
sibling pairs were identified. The characteristics of these subjects are shown in 
appendix IV. Two examples of the apo(a) phenotyping gels for two of the 
FHB families studied are shown in figures 6.1 and 6.2. 
Thirteen pairs of normal siblings who had inherited the same apo(a) 
phenotype from their parents were identified from the FHB families. As 
expected, there was no significant difference between the plasma Lp(a) levels of 
the siblings in this group (22.8 mg. dL-l vs. 19.6 mg. dL-I, p=0.15). Twelve 
of these sibling pairs had APO(a) alleles ibd and when only these groups were 
included in the analysis the conclusion was the same: no significant difference 
(45.5 mg. dL-l vs. 47.9 mg. dL-l, p=O.1l). 
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Six pairs of siblings both of whom had inherited a defective APOB 
allele from one of their parents and who were consequently FHB heterozygotes. 
were also identified from these families. These FHB siblings had inherited the 
same apo(a) phenotype from their parents. Again there was no significant 
difference between the plasma Lp(a) levels of the siblings in this group (11.3 
mg. dL-I vs. 10.8 mg. dL-I, p=O.25). Only 5 of these sibling pairs 
unequivocally had APO( a) alleles ibd and because of this small number this 
group could not be examined separately. However. simple inspection of the 
median Lp(a) levels in this group shows no difference (18.6 mg. dL-1 VS'. 18.6 
mg. dL-i). 
Fourteen sibling pairs were identified in which one sibling was an FHB 
heterozygote. while the other was normal with respect to apoB function. but 
both of whom had inherited the same apo(a) phenotype from their parents. 
These sibling pairs were used to evaluate the impact of reduced apoB-lOO 
production on the plasma Lp(a) concentration. When the median plasma Lp(a) 
level in the FHB heterozygotes was compared to that of their normal siblings 
there was a highly significant difference (4.8 mg. dL-I vs. 1.8 mg. dL-I, 
p=O.002). Once again. when only those sibling pairs who had inherited 
APO(a) alleles unequivocally ibd (n=13). the difference was equally significant 
(4.6 mg. dL-I vs. 1.8 mg. dL-i. p=0.003). 
6.4 Discussion 
In this study. plasma Lp(a) levels were compared in 33 sibling pairs 
identified from the study of 80 subjects in large Amish pedigrees with FHB 
from Ohio in which an apoB-100 mutation has been identified and thoroughly 
characterized (Welty et al .• 1991). The APOB mutation causing FHB in these 
families is a frameshift that results in the formation of a truncated apoB-lOO that 
contains approximately 67% of the apoB sequence. The mutation results in the 
production of only U·ace amounts of circulating apoB-67 and these individuals 
have markedly reduced levels of circulating apoB-lOO. In the non-FHB 
(n= 13). and FHB sibling pairs (n=6) the plasma Lp(a) levels were very similar. 
The plasma Lp(a) levels in the sibling pairs with the same apo(a) phenotype and 
with APO(a) alleles ibd in which one member had FHB and one member did 
not (n=13). were significantly different [median plasma Lp(a) 4.6 vs. 1.8 mg. 
dL-l, p=0.003], which would be expected if the APOB gene played an 
important role in the control of plasma Lp(a) levels. 
Figure 6.1 
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Example 1 of apo(a) immunoblot showing the inheritance of apo(a) isofonns in 
family 145. The gel was run, blotted and developed exactly as described in 
chapter 2 section 2.5. The exposure time was 10 min. Two informative sibling 
pairs with identical apo(a) phenotypes and APO( a) alleles ibd are shown in 
lanes 4 and 8 (*) and lanes 6 and 7 (t). Size markers shown on the left side of 
the gel are in numbers of K4 repeats. In the pedigrees the numbers denote the 
ages on the family members in years at the time of sampling. The squares and 
circles represent males and females, respectively, while open symbols and 
shaded symbols represent nonna! and HlB, respectively. The characteristics of 
the family members and the full pedigree are shown in appendix IV. 
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Example 2 of apo(a) immunoblot showing the inheritance of apo(a) isofonns in 
family 174-l. The gel was run, blotted and developed exactly as described in 
chapter 2 section 2.5. The exposure time was 5 min. One infOlmative sibling 
pairs with identical apo(a) phenotypes and APO( a) alleles ibd is shown in lanes 
3 and 7 (t). Size markers shown on the left side of the gel are in numbers of 
K4 repeats. In the pedigrees the numbers denote the ages on the family 
members in years at the time of sampling. The squares and circles represent 
males and females, respectively, while open symbols and shaded symbols 
represent normal and FHB, respectively. The characteristics of the family 
members and the full pedigree are shown in appendix IV. 
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ApoB occupies a central role in lipid metabolism and normally exists as 
two isoforms in plasma, apoB-IOG and apoB-48. ApoB-IOG is the principal 
protein component of LDL. FHB is an autosomal codominant disorder 
characterized by low plasma concentrations of apoB and LDL cholesterol. Most 
cases of FHB have been shown to be due to mutations in the APOB gene 
resulting in the production of a truncated form of apoB-IOG (Linton et aI., 
1993). 
The results presented in chapter 5 suggested that the LDL receptor plays 
playing an important role in the control of plasma Lp(a) concentrations. The 
level of apoB, the other main apolipoprotein apart from apo(a) in Lp(a), also 
appears to be a limiting factor in the control of plasma Lp(a) levels. Those 
siblings who had lower circulating apoB levels due to a defect in one of their 
APOB alleles had significantly lower levels of plasma Lp(a). This may be due 
to a defect in Lp(a) production. Diminished availability of apoB at the 
hepatocyte surface, where Lp(a) assembly has been hypothesized to occur after 
secretion of free apo(a) (White et aI., 1994), may limit the assembly of the 
apo(a):apoB dipeptide. These findings are therefore entirely consistent with the 
previously stated hypothesis that plasma Lp(a) levels are controlled by 
production rather than degradation rates of the particle. 
As described above in section 5.4 the size of the circulating Lp(a) pool 
will be a function of both the rate of Lp(a) production and Lp(a) catabolism. In 
FHB there is a clearly defined defect in apoB production but no defect in the 
clearance rate of apoB-containing lipoproteins. We may therefore hypothesise 
that the diminished plasma concentration of Lp(a) observed in those individuals 
with FHB was due to a decreased production rate of Lp(a). This finding is 
consistent with the findings presented in chapter 5 and adds further weight to 
the hypothesis describing a general control mechanism for the plasma Lp(a) 
concentration dependent on substrate availability. If we re-examine the 
equilibrium equation describing Lp(a) assembly: 
Apo(a) + LDL ..... ~--- Lp(a) 
it is immediately obvious that if the concentration of LDL is decreased then 
there will be a shift towards the left, i.e. not favouring Lp(a) production. This 
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again assumes the apo(a) production rate to be invariant, which will be the case 
in those sibling pairs where the powerful effects of the APO( a) gene 
polymorphisms have been normalised by studying siblings with identical 
APO(a) alleles. This is the exact opposite of the situation observed in FH, as 
described in chapter 5, where the LDL concentration was increased and Lp(a) 
assembly was favoured by a shift to the right. 
Study of these FHB kindreds has therefore provided further evidence to 
support the hypothesis that the plasma concentration of Lp(a) while 
predominately controlled by polymorphisms at the APO( a) locus is also 
influenced by other genes that code for key proteins that control the plasma 
concentrations of LDL, viz. the LDL receptor and apoB-IOO. 
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Table 6.1 
Comparison of plasma Lp(a) levels in nonnal sibling pairs with the same apo(a) 
phenotype. 
Sibling pair 
ID numbers 
174-1-29/36 
174-1-28/29 
174-2-20/22 
174-2-3/5 
174-2-6/11 
174-2-5/6 
174-2-5/11 
174-2-3/6 
174-2-3/11 
174-1-28/36 
174-2-2/16 
174-1-26/32 
174-1-36/39 
Median 
Apo(a) 
phenotype 
22/34 
22/34 
17/29 
14/17 
14/17 
14/17 
14/17 
14/17 
14/17 
22/34 
13/22 
23/34 
22/34 
Median (only ibd pairs) 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
APO(a) 
alleles 
ibd 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Plasma 
Lp(a) mg. dL-l WSR 
Nonnal 
3.4 
4.6 
22.8 
68.2 
79.8 
76.2 
76.2 
68.2 
68.2 
4.6 
15.6 
1.9 
2.5 
22.8 
45.5 
Nonnal 
2.5 
3.4 
19.6 
76.2 
78.0 
79.8 
78.0 
79.8 
78.0 
2.5 
19.0 
1.0 
1.8 
19.6 P=0.15 (NS) 
47.9 P=0.11 (NS) 
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Table 6.2 
Comparison of plasma Lp(a) levels in hypobetalipoproteinaemic sibling pairs with 
the same apo(a) phenotype. 
Sibling pair 
ID numbers 
174-2-4/10 
174-2-4/7 
174-2-7/10 
174-2-17/41 
153-4/5 
144-4/5 
Median 
Apo(a) 
phenotype 
17/27 
17/27 
17/27 
27/29 
34/34 
23/34 
Median (only ibd pairs) 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
APO(a) 
alleles 
ibd 
+ 
+ 
+ 
+ 
+ 
Plasma 
Lp(a) mg. dL-l 
FHB FHB 
20.7 35.2 
20.7 18.6 
18.6 35.2 
1.2 2.5 
4.0 1.0 
3.0 3.0 
11.3 10.8 
18.6 18.6 
WSR 
P=0.25 (NS) 
Insufficient 
data for 
WSR 
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Table 6.3 
Comparison of plasma Lp(a) levels in nOl111al and hypobetalipoproteinaemic sibling 
pairs (i.e. one sibling with hypobetalipoproteinaemia and one nOl111al) with the 
same apo(a) phenotype. 
Sibling pair Apo(a) APO(a) Plasma 
ID numbers phenotype alleles Lp(a) mg. dL-l WSR 
ibd 
NQrmal FHB 
174-1-39/37 22/34 + 1.8 1.8 
174-2-21/17 27/29 + 2.0 1.2 
174-2-21/41 27/29 + 2.0 2.5 
174-1-31/19 22/28 + 11.2 2.0 
174-1-29/37 22/34 + 3.4 1.8 
174-1-36/3 7 22/34 + 2.5 1.8 
174-1-28/37 22/34 + 4.6 1.8 
174-2-20/44 17/29 + 22.8 20.0 
174-2-22/44 17/29 + 19.2 20.0 
153-3/4 34/34 + 5.0 4.0 
153-3/5 34/34 + 5.0 1.0 
145-6n 19/26 + 37.7 24.6 
145-8/4 25/34 + 3.0 1.0 
144-3/6 23/30 18.0 1.0 
Median 4.8 1.8 P=0.002 
Median (only ibd pairs) 4.6 1.8 P=O.003 
ibd: identical by descent 
WSR: Wilcoxon Signed Rank Test 
Chapter 7 
Conclusions 
Though our challenges are fearsome, so are our strengths. Americans have 
ever been a restless, questing, hopeful people. And we must bring to our task 
today the vision and will of those who came before us .... Our democracy must 
be not only the envy of the world but the engine of our own renewal. There is 
nothing wrong with America that cannot be cured by what is right with 
America. 
President William 1. Clinton, 1993. 
Inaugural Address 
7.1 Introduction 
It was while performing one of the many apo(a) phenotyping Western 
blots in Dallas that I listened to the new President's words on the lab. radio as 
they were being spoken in Washington DC. The rhetroic, so essential to any 
inaugural speech, was punctutated with an uncommon wisdom and there truly 
was a sense of a new beginning in America that day. 
Words of a new beginning are appropriate for the final chapter of a 
thesis for all that has gone before in science is merely the prelude to that which 
will follow. In this chapter I shall review the findings presented in this thesis 
and offer some direction for the next stage of the still extensive work to be done 
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on Lp(a). This chapter is then the starting point for my work and hopefully the 
work of others in the months and years ahead. 
Most theses will present some interesting data, some conclusions, but 
many more interesting questions. This work has been no different. In chapter 
1 the aims of this thesis were set forth. It is the purpose of this final chapter to 
assess the extent to which these aims have been satisfied and, in turn, the 
overall contribution made to this field. 
7.2 The APO(a) "null" allele may be any size 
The inverse relationship between the length of the apo(a) glycoprotein 
and the plasma concentration of Lp(a) with which it is associated has been 
thoroughly documented (Utermann et aI., 1987). With the knowledge that 
many APO( a) alleles were apparently associated with no detectable plasma 
protein product it was hypothesised that these non-expressing alleles would be 
clustered at the large end of the apo(a) size spectrum. With the analyses 
presented in chapter 4 this hypothesis was found to be incorrect. APO( a) alleles 
that are non-expressing or "null" may be any size. This conclusion was only 
made possible by simultaneous investigation of the APO( a) gene and its 
glycoprotein product apo(a), using apo(a) genotyping by pulsed-field gel 
electrophoresis and apo(a) phenotyping by high resolution immunoblotting. 
These findings have stimulated interest in the search for controlling sequences 
in and around the APO(a) locus that may be responsible for the transcriptional 
regulation of this gene. 
7.3 The APO( a) allele size polymorphism does not explain 
inter-racial differences in plasma Lp(a) 
A major finding of the studies presented in chapter 4 is that the inter-
ethnic differences in plasma concentrations of Lp(a) are not due to in differences 
in the APO( a) allele size distributions. This conclusion is evident from the 
following observations: 
1) The Caucasians and Chinese groups studied had very similar 
distributions of plasma Lp(a) levels and yet had significantly different 
APO( a) allele distributions. 
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2) The African-Americans had a distinctly different plasma Lp(a) 
distribution from the other two groups. yet their APO( a) allele size 
distribution was not significantly different from the Caucasians. 
It was also a striking finding that the relationship between APO( a) allele 
size and plasma Lp(a) level was so similar irrespective of ethnic origin. As 
described in chapter 4. the uniformity of this relationship suggests a 
fundamental underlying biological mechanism controlling the plasma Lp(a) 
concentration. 
7.4 Plasma Lp(a) levels are affected by defects m the LDL 
receptor and APOB genes 
The importance of the APO(a) gene in controlling plasma Lp(a) levels is 
without dispute. In Caucasians. Boerwinkle and his colleagues (1992) have 
quantified this contribution as >90% of the inter-individual variability in plasma 
Lp(a) concentration. However. the subjects used to define that figure were 
normolipidaemic and there has been considerable controversy in the literature on 
the contribution on other candidate genes that may control plasma Lp(a) levels 
in abnormal situations. Most notably the role of the LDL receptor has received 
considerable attention. 
FH heterozygotes. who have a defective LDL receptor allele. have 
variably been described as having either normal or elevated plasma Lp(a) levels. 
Because the contribution of the enormous inter-individual varaiblity at the 
APO(a) locus may override any controlling factors this has to be removed from 
the analysis. In order to normalise the contribution of the APO( a) gene it is 
necessary to study and compare individuals with identical APO(a) alleles. It is 
quite insufficient merely to rely on equalizing the size variability between 
individuals for we know that there are further levels of heterogeneity at the 
APO( a) locus beyond the length of the gene. The only way to ensure that 
APO(a) alleles are identical. and their effect normalised. is to study sibling pairs 
who have inherited the same APO(a) alleles from their parents. These studies 
are difficult to perform for many subjects and families have to be examined 
before sufficiently large numbers of appropriate sibling pairs are identified. 
In the studies presented in chapters 5 and 6 the LDL receptor and the 
APOB genes were studied respectively. The results were consistent and 
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allowed the formulation of the following hypothesis: Lp(a) plasma 
concentrations are in part determined by the availability of the LDL moiety. 
When LDL is present in the ECF in significantly higher concentrations than 
normal (as in FH) the assembly of Lp(a) is favoured and the plasma level rises. 
On the other hand, if the ECF LDL level is significantly lower than normal (as 
in FHB) the assembly of Lp(a) is not favoured and plasma levels fall. This is 
shown schematically in figure 7.1. 
If this hypothesis is true then plasma Lp(a) levels should be lowered by 
pharmacological means that lower plasma LDL concentrations. To date most 
lipid lowering drugs have failed to lower plasma Lp(a) levels consistently. 
However, as argued in chapter 6, it may be that we have not yet used 
sufficiently powerful drugs to shift the equilibrium equation. Studies using 
new agents, which are already underway in different centres may provide useful 
new data in support of this hypothesis. 
7.5 The case for high resolution apo(a) phenotyping 
Lp(a) is without doubt one of the most fascinating of the human 
lipoproteins. The locus structure of the gene encoding the complex 
glycoprotein, apo(a), presents us with two major intellectual challenges. Its 
highly repetitive structure and close similarity to adjacent loci in the human 
genome pose difficult technical problems for those wishing to study 
polymorph isms and mutations in this stretch of DNA. Elegant solutions have 
been found by a number of key workers in this field, most notably Lackner and 
her colleagues (1991, 1993), whose methods provided a foundation for the 
work presented here. In addition, nature presents us with a gene of such 
startling inter-individual variation that it is clear that the range of apo(a) protein 
sizes begs the question: can all these APO(a) gene products be regarded as the 
same protein, at least in functional terms. 
The high degree of apo(a) heterogeneity may be regarded as going 
beyond mere polymorphism. The largest isoform thus far described has 51 K4 
repeats while the smallest has 12. These two proteins, although sharing all the 
key motifs in common, differ in size by approximately 480 kDa. 
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The extension of this argument is that the resulting Lp(a) particles 
containing such differently sized apo(a) isoforms must be viewed as equally 
diverse in their potential function(s) and atherogenicity. Thus. it is quite simply 
insufficient to define an individual's Lp(a) status or phenotype on the basis of a 
plasma estimation of the circulating mass of Lp(a) particles. Some measure of 
the type and potentially the quality of these particles must be taken into account. 
Early attempts at characterising the apo(a) constituent of Lp(a). based on 
SDS-PAGE gave useful but limited information. This form of low resolution 
apo(a) phenotyping has been used by many groups and features as a an 
analytical tool throughout the literature. However. the originator of this method. 
Utermann (1989). has even now adopted the higher resolution methods 
developed by others (Lackner et a1.. 1991). The clear advantage of a high 
resolution system is that it provides complete definition of the apo(a) size range. 
which ascends in discrete steps of single K4 units. This system therefore 
provides the investigator with a tool to define the Lp(a) / apo(a) phenotype of an 
individual with much improved accuracy. As this system separates the apo(a) 
isoforms solely on the basis of size it tells us nothing of the potential 
compositional heterogeneity that may exist in Lp(a). The sugar content of the 
apo(a) and the lipid complement of the LDL moiety are not defined by this 
method and this may be seen as a potential drawback. Apart from these 
obvious manifestations of Lp(a) heterogeneity that are unresolved by this 
method there is also a more subtle characteristic of the apo(a) protein that is not 
touched on by this method. 
As we know that APO( a) alleles of the same length have differences in 
sequence. albeit silent polymorphisms. we may hypothesise that there may also 
be differences in DNA sequence that lead to amino acid changes and potentially 
to changes in the tertiary structure and perhaps glycosylation pattern of the 
apo(a) protein. which may in tum lead to differences in function. This would 
result in the presence of apo(a) isoforms. which have the same length and 
therefore the same migration on the SDS-agarose gel used in high resolution 
apo(a) phenotyping. but which may have differences in composition and 
therefore. potentially. differences in function. 
The apo(a) phenotyping system presented is therefore a major advance 
over simple plasma Lp(a) concentration measurements but it does not provide 
absolute differentiation of all individual apo(a) isoform types. Collectively. the 
different levels of polymorphism in the APO( a) gene are known to contribute 
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>90% of the inter-individual variability of plasma Lp(a) levels. The length 
polymorphism, which is controlled solely by the corresponding length 
polymorphism of the APO(a) gene is known to contribute approximately 42% 
of the variability in Lp(a) levels. As such it is probably the single most 
important controlling factor of plasma Lp(a) concentrations. 
The research presented in this thesis was performed to contribute new 
information to our understanding of the mechanisms controlling plasma Lp(a) 
levels. I believe the results presented are useful additions to our existing 
knowledge base, especially the discovery that so-called "null" APO(a) alleles 
are independent of allele size as was previously thought, and that the functions 
of the APOB and LDL receptor genes do have an important impact on the 
plasma Lp(a) level. 
7.6 Full circle 
This thesis began at the very beginning of the Lp(a) story with the 
words KAre Berg used to name his fascinating lipoprotein. It is fitting then that 
Prof. Berg should have the lasts words in this thesis, which has tried to extend 
our knowledge of his discovery. Over more than three decades Berg has 
published extensively on Lp(a) and, although by his own admission he would 
not claim to have dominated the field, he has always been present supporting 
and nudging research in the right direction like the proud father of a developing 
child. His most recent paper (Berg, 1994) has called investigators throughout 
the world to task over the most basic element of Lp(a) research: its 
measuremen t. 
"Lp(a) lipoprotein determination should now be included in any clinical 
or scientific study of CHD risk. Lp(a) lipoprotein measurements must be based 
either on methods used in research laboratories or on techniques firmly 
validated and monitored against such methods and reagents." 
KAre Berg, 1994 
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Appendix II 
Individual plasma Lp(a) concentrations, APO( a) allele sizes and 
apo(a) isoform sizes of the subjects reported in chapter 4. 
Caucasians 
Subject Subject's Plasma APO(a) APO(a) Apo(a) Apo(a) 
No. initials Lp(a) allele 1 allele 2 isoform I isoform 2 
(mg.dl- i ) 
1 KS 44 21 25 21 25 
3 NR 5 24 28 - -
4 CL 32 18 33 18 33 
6 RK <1 24 30 24 n 
7 LE 30 26 32 - -
9 GB 83 19 27 - -
12 LF 6 27 28 - -
15 MB 29 18 24 18 24 
18 HH 20 24 31 24 31 
21 GM 19 26 33 - -
22 MD 7 24 29 n 29 
24 TO 7 25 27 25 n 
26 RB 9 28 30 - -
27 KN 8 20 24 - -
29 DJ 7 27 32 - -
30 JM 20 24 30 24 30 
31 ON 7 32 34 32 34 
32 FP 33 23 28 23 28 
33 KP 1 25 33 25 33 
35 BB 16 28 28 28 28 
36 JL 1 28 31 n 
31 
37 KL 3 27 29 27 n 
38 OS 16 31 33 31 33 
39 ST 8 20 22 - -
40 PO 2 26 38 n 38 
41 DR 47 18 29 - -
42 SH 5 22 28 22 n 
43 TO 9 22 31 22 31 
44 WC 5 22 33 - -
45 RM 5 22 30 -
-
46 PM <1 25 34 -
-
47 VR 19 20 29 -
-
48 OS <l 29 30 n 
n 
49 OS 61 19 34 19 
34 
50 SS 66 19 26 19 
26 
51 ET 1 26 26 26 
26 
52 AT 47 19 21 
19 21 
53 MD 17 26 31 26 
n 
54 LO 7 20 33 20 
33 
55 ML 18 25 51 
25 51 
56 MM 1 27 39 
27 39 
57 PC 10 26 39 
26 n 
58 JG 29 31 32 31 
32 
59 RL 2 19 24 19 
n 
60 CO 29 20 21 
n 21 
61 MP 62 20 24 
20 n 
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Caucasians contd 
Subject Subject's Plasma APO(a) APO(a) Apo(a) Apo(a) 
No. initials Lp(a) allele 1 allele 2 isoform I isoform 2 
(mg.dl-1) 
64 SG 9 28 33 28 n 
65 RT 36 15 23 15 23 
66 ER 4 33 34 33 n 
67 JC <1 25 34 n 34 
68 MB 8 23 30 23 n 
69 KN 13 28 30 28 30 
70 LA 38 18 26 18 26 
71 ES 4 28 29 n 29 
72 RW 34 19 23 19 n 
73 KS 17 26 27 26 n 
74 LW 14 26 37 26 n 
75 KM 33 23 23 23 23 
76 HP 2 19 28 19 n 
77 MT 4 24 26 24 n 
78 VT 22 26 27 - -
79 DH 7 25 25 25 25 
80 BJ 1 24 36 n 36 
81 BC 15 27 30 27 30 
82 ML 3 22 32 22 32 
83 JH 7 29 33 29 n 
84 KH 25 24 24 24 24 
85 CM 27 22 24 22 24 
86 MF <1 26 30 26 30 
87 MF 32 21 33 21 n 
88 MP 54 19 33 19 33 
89 MP 27 18 23 18 23 
90 KH 7 23 25 23 25 
91 SS 39 16 32 16 n 
92 RC 6 28 31 28 31 
93 DS 5 IS 28 n 28 
94 DS 9 26 30 n 30 
97 TC 28 22 27 22 27 
98 LS 74 29 35 29 n 
99 LC 24 28 29 23 26 
101 HW 3 29 30 29 n 
102 JB 36 20 31 20 n 
103 SS 4 20 21 n n 
104 GT 42 16 26 16 n 
105 JT 18 23 26 - -
106 EP 88 14 37 14 
n 
107 MS 3 26 32 26 32 
108 ES <l 23 37 n 
n 
109 BH 10 22 29 22 
29 
110 MH 7 26 26 26 
26 
III RF 9 27 32 27 
n 
112 RW 4 20 30 n 
30 
113 KW 15 19 33 19 
33 
114 MC 3 26 28 n 
28 
115 VE 7 26 27 26 
27 
116 CN <l 29 40 29 
40 
117 AN <l 19 30 19 
30 
118 PW 8 30 36 30 
36 
119 CW <I 30 32 30 
n 
120 EH 7 28 30 -
-
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Caucasians contd 
Subject Subject's Plasma APO(a) APO(a) Apo(a) Apo(a) 
No. initials Lp(a) allele I allele 2 isofonn I isoform 2 
(mg.dl- l ) 
121 BH 10 27 27 27 27 
122 JC <1 - - - -
123 JC 48 13 28 13 28 
133 NC 15 23 32 23 32 
134 HC 3 32 33 32 n 
135 MR 4 32 33 32 n 
136 BR 45 19 30 19 n 
137 LW 1 28 36 n n 
138 LW 9 31 34 - -
139 HG <1 24 29 n n 
140 NG 2 28 30 28 n 
141 TM 4 28 29 n 29 
142 MM 2 26 27 n 27 
143 XX 29 19 32 19 n 
145 GH 36 16 33 16 n 
146 SH 6 27 32 n 32 
147 SP 71 19 33 19 33 
148 TP 21 23 24 23 24 
149 CL 28 21 32 21 n 
150 CL <1 26 30 n n 
151 KT <1 30 33 n 33 
152 CT 51 23 23 23 23 
153 1B 47 19 33 19 33 
154 JB 5 25 26 25 26 
155 DS 22 21 23 21 n 
156 JS 9 25 36 25 36 
157 RL 14 27 28 27 28 
158 SL 41 21 21 21 21 
159 SH 12 22 30 22 30 
160 JH 10 22 30 22 30 
161 KM 6 21 31 20 31 
162 PM 15 28 34 28 34 
163 RT 5 32 33 32 33 
164 IT 5 21 22 21 22 
165 CE 1 29 32 n 32 
166 SE I 28 29 28 n 
167 CS I 26 28 n n 
168 CS 30 22 30 22 n 
169 GD 52 21 33 21 n 
170 DD 1 26 32 n 
32 
171 CR 32 26 32 26 32 
172 DR 52 18 27 18 27 
173 RC 4 30 32 30 
32 
174 LC 3 26 26 26 26 
175 RM 4 30 32 n 
32 
176 MM 42 18 25 18 
n 
177 JF 4 32 35 32 
n 
178 EF 51 20 33 20 
33 
179 JT 48 18 22 18 
22 
180 CT 7 30 31 30 
31 
181 EM <1 33 36 n 
n 
182 BM 6 23 32 n 
32 
183 CJ 27 24 26 24 
26 
184 JJ 10 30 31 30 
n 
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Caucasians conld 
Subject Subject's Plasma APO(a) APO(a) Apo(a) A(X>(a) 
No. initials Lp(a) allele 1 allele 2 isoform I isoform 2 
(mg.dl- l) 
185 JH 50 18 27 18 27 
186 SH 9 28 29 28 29 
187 PP 38 19 30 19 30 
188 LP 19 18 29 18 n 
189 MP 60 19 25 19 26 
190 SP 41 19 20 19 n 
191 SS 2 25 33 n 33 
192 OS 4 22 32 22 32 
193 JB 16 28 30 28 30 
194 MB <l 24 35 n n 
195 PQ 9 23 27 n 27 
196 DQ 10 25 31 n 31 
197 WM 12 28 40 28 40 
198 SM 1 26 28 n n 
199 OW 40 20 35 20 n 
200 KW 54 15 26 15 26 
201 OW 3 22 26 22 n 
202 OW 7 25 32 n 32 
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Chinese 
Subject Subject's Plasma APO(a) APO(a) Apo(a) Alx>(a) 
No. initials Lp(a) allele I allele 2 isoform I isoform 2 
(mg.dl-1 ) 
CI WC 5 33 33 33 33 
C2 KL 15 33 33 33 33 
C4 YH 26 23 34 23 34 
C5 BZ 3 27 29 n 29 
C6 HZ 8 23 27 23 n 
C7 ST 10 28 35 28 35 
C8 XX 14 26 33 26 33 
C9 SP 2 34 36 34 36 
CIO MY 31 24 36 24 36 
CII yy 8 34 36 34 36 
CI2 GS 33 15 34 15 34 
CI3 JC 13 31 32 n 32 
CI4 LH 33 22 33 22 33 
CI5 SW 8 33 35 33 35 
CI6 BG 45 21 33 21 33 
CI7 XZ 5 34 34 34 34 
CI8 XW 13 23 41 23 41 
CI9 JL 3 22 33 n 33 
C21 QJ 6 32 35 32 35 
C22 JC 63 15 32 15 32 
C23 JC 4 33 35 33 n 
C24 JL 4 33 34 n 34 
C25 KL 11 28 34 28 34 
C26 PL 2 33 37 33 37 
C27 XL 30 25 33 25 33 
C29 BZ 5 34 38 34 38 
C30 XT 34 24 34 23 34 
C31 CZ 3 32 33 n 33 
C32 WT 10 32 33 32 33 
C33 YS 26 29 34 29 34 
C34 CM 7 30 30 30 30 
C35 YX 3 32 33 n 33 
C36 KL 32 19 33 19 33 
C37 MZ 8 25 33 25 33 
C38 CL 5 33 34 33 n 
C39 yy 3 36 36 36 36 
C40 LF 49 20 26 20 n 
C41 MZ 6 34 35 34 35 
C42 yz 13 31 34 31 34 
C44 ZG 17 24 33 24 
33 
C45 YH 14 31 35 31 35 
C46 YW I 33 33 33 33 
C47 EG 3 35 35 35 
35 
C48 CY 13 28 32 28 
32 
C50 ST 9 30 31 n 
31 
C51 SN 7 32 37 32 
37 
C52 GT 5 32 33 32 
33 
C53 CH 11 32 34 32 
34 
C54 SH 5 31 37 31 
37 
C55 CS 27 25 35 25 
35 
C57 HT 6 32 40 32 
40 
C58 CY 4 32 36 32 
n 
C59 WF II 31 43 31 
n 
C60 yy 13 30 32 30 
32 
C61 PT 32 30 32 30 
32 
C62 MD 68 19 40 19 
40 
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Chinese conld 
Subject Subject's Plasma APO(a) APO(a) Apo(a) Apo(a) 
No. initials Lp(a) allele I allele 2 isoform 1 isoform 2 
(ml!..dl-1) 
C63 HY 1 26 34 n 34 
C64 YL 13 29 34 29 34 
C65 HC 3 35 39 35 39 
C66 PC 9 32 34 32 34 
C67 FC 3 33 35 33 35 
C68 YC 17 21 34 21 34 
C69 CY 2 32 34 32 34 
C71 HC <1 35 36 n n 
cn LW 26 26 31 26 31 
C73 SW 68 22 33 22 33 
C74 LY 9 30 33 30 33 
C75 yy <1 32 36 32 36 
C76 11.. <1 31 31 31 31 
cn BY I 28 35 28 n 
C78 SL 9 29 30 29 30 
C79 CL 7 28 35 28 35 
C80 PL 14 28 36 28 36 
C81 TC 10 23 32 23 32 
C82 TC 2 32 44 32 44 
C83 DS 4 18 33 n 33 
C84 CH <1 38 41 n 41 
C85 MC 6 29 33 29 33 
C86 JW 6 29 37 29 37 
C87 SS 21 23 33 23 33 
C88 SS 3 25 33 n 33 
C89 MC 5 33 33 33 33 
C90 FC 3 33 37 33 37 
C93 GC 14 33 33 33 33 
C94 HC <1 28 35 n n 
C96 LK 2 21 32 n 32 
C97 JK 3 31 31 31 31 
C98 CY 14 25 29 25 29 
C99 CC 54 28 33 28 33 
CIOO YW 3 33 33 33 33 
CIOI EL 3 32 34 32 34 
ClO2 CF 16 28 35 28 35 
C103 HH 156 18 27 18 27 
CI04 IC 73 19 33 19 33 
CI05 TC 10 28 38 28 38 
African 
Americans 
Subject Subject's 
No. initials 
BI JJ 
B2 RG 
B3 RM 
B4 LB 
B5 PM 
B6 MJ 
B7 OK 
B8 JT 
B9 AF 
B10 BH 
Bll MO 
BI2 RT 
BI3 NW 
B14 BW 
BI5 AE 
BI8 RM 
BI9 BJ 
B20 BH 
B21 FE 
B22 AT 
B23 CH 
B24 DB 
B25 CJ 
B26 CA 
B27 CD 
B28 MT 
B29 JS 
B30 MC 
B31 U 
B32 SJ 
B33 PW 
B34 JH 
B35 11 
B36 NB 
B37 CB 
B38 RW 
B39 JH 
B40 BN 
B41 JG 
B42 BG 
B43 JW 
B44 JR 
B45 OL 
B46 DT 
B47 CL 
B48 BB 
B49 KN 
BSO SH 
B51 TS 
B52 SP 
B54 CB 
B55 GW 
B56 SC 
B57 AW 
B58 BW 
B59 AH 
Plasma 
Lp(a) 
(mg.dl-I) 
3 
71 
50 
34 
10 
43 
8 
22 
4 
24 
23 
120 
30 
44 
64 
40 
68 
12 
31 
72 
32 
41 
65 
7 
29 
14 
37 
17 
36 
32 
90 
63 
24 
33 
58 
37 
25 
52 
13 
86 
51 
49 
1I8 
29 
53 
<l 
8 
12 
11 
39 
49 
26 
32 
51 
10 
2 
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APO(a) APO(a) Apo(a) Apo(a) 
allele I allele 2 isoform I isoforrn 2 
24 27 n n 
20 23 20 23 
19 31 19 31 
25 32 25 32 
30 36 30 36 
23 26 23 26 
22 25 32 38 
26 35 26 n 
25 29 n 29 
27 33 27 33 
24 32 24 32 
21 24 21 24 
24 26 24 n 
18 20 - -
16 18 16 18 
22 24 22 24 
21 32 21 32 
26 29 26 29 
29 31 29 31 
20 24 - -
25 27 25 27 
23 28 23 28 
23 37 23 37 
25 32 n 32 
24 27 24 27 
26 26 26 26 
23 28 23 n 
28 29 28 29 
20 30 20 n 
22 32 22 32 
18 18 - -
23 23 23 23 
29 30 29 30 
21 24 21 n 
27 28 27 28 
23 31 23 31 
27 33 27 33 
25 26 n 26 
30 33 30 33 
18 23 18 23 
21 28 21 28 
20 24 - -
19 19 19 19 
18 27 18 27 
24 27 24 27 
30 30 30 30 
21 33 21 33 
27 28 n 28 
25 33 25 n 
26 28 26 28 
20 30 20 30 
26 29 26 29 
26 27 26 27 
24 28 24 28 
23 26 23 n 
25 26 n n 
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African 
Americans conld 
Subject Subject's Plasma APO(a) APO(a) Apo(a} Apo{a} 
No. initials Lp(a) allele I allele 2 isoform I isoform 2 
(mg.d1-1) 
BOO NY 35 20 28 20 28 
B61 CS 29 22 29 22 29 
B62 JW 22 18 29 n 29 
B63 GJ 9 29 42 29 42 
BM JM 39 21 33 21 33 
865 JS 24 26 26 26 26 
B66 BP 18 18 29 18 29 
B67 MT 27 19 28 n 28 
B68 AT 54 27 29 27 29 
B69 VJ 5 20 23 - -
B70 RS 90 25 25 25 25 
B71 EK 92 18 26 18 26 
B72 SS 1 18 30 n n 
B73 MS 64 21 31 21 31 
B74 KS 23 23 26 - -
B75 DP 25 24 33 n 33 
B76 JD 42 21 29 21 29 
B77 EJ 41 18 22 18 22 
B78 PR 4 29 37 29 n 
B79 MK 32 27 33 27 33 
B80 BD 91 22 25 22 25 
B81 MC 45 27 28 27 28 
B82 PR 76 22 30 22 30 
B83 IR 51 21 28 21 28 
B84 CW 17 27 27 27 27 
B85 GJ 21 28 28 28 28 
B86 RL 33 23 25 n 33 
B87 LB 12 27 28 27 28 
B88 NB 49 22 25 22 25 
B89 JH 10 26 30 n 30 
B90 AL 5 29 34 n 
34 
B91 TA 36 19 37 19 37 
B92 AS 5 31 31 31 31 
B93 LP 33 23 30 23 30 
B94 WS 84 23 26 23 26 
B95 MS 52 25 31 25 31 
B96 1M 12 26 27 26 
27 
B97 DB 14 18 21 18 
n 
B98 EP 34 27 39 27 
39 
B99 JC 19 13 34 13 
34 
BlOO VH 59 22 25 22 
25 
BIOI AR 60 17 25 17 
25 
B102 WC 62 21 27 25 
29 
BI04 CB 74 24 28 24 
28 
B105 IC <I 35 38 35 
38 
BI06 JW 81 21 23 21 
23 
B200-1 MK 5 26 40 26 
n 
B200-2 WI( 45 22 24 
22 24 
B201-1 EC 97 21 27 
21 n 
B201-2 SC 37 13 24 
n 24 
Appendix III 
Characteristics of the FH family members subjects reported in 
chapter 5. 
Subject No. Age Sex TC TG LDL-C Lp(a) Apo(a) phenotype 
26-341 24 M 9.0 1.9 7.0 22.0 n/14 
26-342 22 M 3.5 0.8 2.4 10.0 n/22 
26-343 20 F 7.9 2.0 5.6 13.0 n/22 
26-344 17 M 4.8 1.2 3.2 18.0 n/14 
26-393 24 F 6.3 1.3 4.6 29.0 17/34 
26-394 23 M 4.1 0.7 2.4 2.0 32/34 
26-395 21 F 4.4 0.9 2.7 4.0 32/34 
26-397 18 F 4.5 0.6 3.0 21.0 17/34 
26-399 13 M 4.7 0.6 3.2 33.0 17/34 
26-496 17 M 4.1 * 1.2* 3.1 * 57.0 22/30 
26-497 8 M 4.0 0.6 t 64.0 22/30 
26-527 28 M 6.4 l.8 5.3 64.0 22/30 
26-719 24 M 6.4 l.5 4.7 35.0 n!20 
26-721 20 F 4.9 1.9 2.2 1.0 n/n 
26-723 16 F 4.0 0.7 2.3 56.0 n/20 
26-726 8 M 7.7 1.0 6.4 1.0 n/n 
625-30 44 M 6.7 1.9 4.0 8.0 28/39 
625-42 35 M 4.0 1.2 2.5 12.0 28/39 
625-52 32 M 4.8 2.1 3.3 17.0 26/28 
625-59 29 F 4.7 1.2 2.4 22.0 26/28 
625-64 28 F 6.5 0.6 5.1 20.0 26/28 
625-69 24 F 4.1 0.7 1.8 20.0 26/28 
625-70 22 F 4.0 0.6 2.5 16.0 26/28 
653-1-1 43 M 10.7 1.5 5.8 31.0 20/26 
653-1-5 37 F 7.8 1.1 5.5 28.0 20/26 
653-1-12 68 M 9.4 4.6 5.0 37.0 20/26 
653-1-24 79 M 5.0 2.4 3.0 60.0 20/26 
653-1-28 17 M 6.6 1.2 5.1 28.0 n/20 
653-1-29 16 F 8.3 1.8 t 24.0 n/20 
653-1-30 14 F 3.9 1.0 2.1 2.0 n/19 
653-1-31 10 M 6.9 1.1 5.2 3.0 n/19 
653-1-41 42 M 11.7 0.9 4.8 10.0 20/26 
653-1-81 18 F 7.2 0.9 5.6 10.0 21/28 
653-1-83 11 M 8.6 0.7 7.2 17.5 21/28 
653-1-268 66 F 5.9 1.3 3.7 13.6 n/28 
653-1-272 52 F 7.5 1.2 2.8 14.4 n/28 
Age: in years at time of sampling, Sex: F female, M male. 
TC (total cholesterol), LDL-C and TG (triglyceride): in mmol. L-i 
Lp(a): in mg. dL-l 
FH (familial hypercholesterolaemia): + FH, - normal. 
* lipid values on lipid lowering drug therapy 
t sample for LDL-C measurement lost during analysis. 
FH 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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Characteristics of the FH family members reported in chapter 5 
( continued). 
SUbject No. Age Sex TC TG LDL-C Lp(a) Apo(a) FH 
phenotype 
653-2-102 31 M 5.6 2.0 3.4 4.6 n/30 
653-2-104 28 M 5.5 l.7 3.6 3.7 nJ3() 
653-2-105 26 F 4.3 l.0 2.5 5.0 n/30 
653-4-103 21 F 4.2 0.5 2.5 11.8 26/34 
653-4-104 18 F 4.1 0.8 2.5 38.9 n/19 
653-4-107 11 M 6.5 1.4 4.8 40.7 n/19 + 
653-4-108 10 M 7.1 0.9 5.1 22.0 26/34 + 
653-4-109 7 F 3.9 0.9 2.2 7.2 26/34 
653-4-110 6 F 6.7 1.3 4.9 16.7 26/34 + 
653-5-102 36 M 9.8 6.2 4.2 10.7 29/31 + 
653-5-109 18 F 4.1 l.3 2.7 7.0 29/31 
653-6-103 20 M 5.3 1.5 3.1 45.9 20/33 
653-6-105 13 F 12.6 2.7 9.9 63.0 20/33 + 
659-61 46 M 15.8 5.4 6.2 45.0 n/15 + 
659-63 40 M 4.1 4.1 1.5 37.0 n/15 
659-125 29 M 8.1 1.4 7.0 47.0 n/20 + 
659-127 20 M 7.9 1.9 5.8 42.0 n/20 + 
659-139 15 F 4.8 2.3 3.2 56.0 15/24 + 
659-140 12 F 5.1 1.9 3.9 62.4 15/24 + 
659-143 18 M 6.8 1.7 4.5 4.4 nl20 + 
659-144 16 M 5.5 1.6 4.9 39.9 15/20 + 
659-145 12 F 3.6 1.9 2.3 45.1 15/20 
659-147 7 M 5.9 1.3 4.6 3.9 n/20 + 
659-151 23 F 5.0 1.2 2.7 36.0 nl21 
659-152 20 M 8.0 3.1 5.2 21.0 n/21 + 
71002076-264 16 F 6.4 1.0 4.8 14.0 nl27 + 
71002076-265 14 F 3.2 0.4 2.2 9.0 nl27 
71002076-266 9 F 3.4 0.4 2.0 3.0 n/27 
Age: in years at time of sampling, Sex: F female, M male. 
TC (total cholesterol), LDL-C and TG (triglyceride): in mmol. L-i 
Lp(a): in mg. dL-i 
FH (familial hypercholesterolaemia): + FH, - normal. 
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Family 26 
670 718 
719 720 721 722 723 724 725 
n/20 nln n/20 
FH pedigree 1. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
726 
nln 
Appendix III 15X 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
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Family 26 
493 
527 497 498 496 499 494 495 
22/30 22/30 22/30 
FH pedigree 3. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH. respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (lD) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
713 
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FH pedigree 4. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
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Family 653-1 
(n/31) (28/36) 
1-268 
n/28 
FH pedigree 5. 
168 1-270 
n/36 
1-265 1-271 1-272 
n/31 28/31 n/28 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (JD) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
FH pedigree 6. 
Family 653-1 
81 
80 
21/30 
82 
79 
28/30 
83 
21/28 21/30 21/28 
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The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
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Family 653-1 
1-28 
n/20 
FH pedigree 7. 
1-24 
20/26 
1-12 
20/26 
1-13 
20/28 
1-8 1-1 1-41 1-27 1-36 
20/28 20/26 20/26 20/28 n/19 
1-29 1-30 1-31 
n/20 n/19 n/19 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
1-5 
20/26 
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Family 653-2 
2-1 2-101 
n/30 n/26 
2-102 2-104 2-105 
n/30 n/30 n/30 
FH pedigree 8. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
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Family 653-4 
4-101 4-1 
19/34 n/26 
4-102 4-103 4-104 4-105 4-106 4-107 4-108 4-109 4-110 
26/34 n/19 n/34 n/19 26/34 26/34 26/34 
FH pedigree 9. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
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FH pedigree 10. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (lD) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
FH pedigree 11. 
Family 653-6 
6-103 
20/33 
6-1 
25/33 
6-101 
16/20 
6-105 
20/33 
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6-106 
16/33 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
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FH pedigree 12. 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (10) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) allele. 
168 
FH pedigree 13. 
Family 659 
124 
n/31 
60 123 
n/20 n/31 
125 
n/20 
126 
n/n 
127 
n/20 
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128 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO(a) allele. 
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Family 71002076 
260 
259 261 262 263 264 265 266 
n/27 n/27 n/27 
FH pedigree 14. 
The squares and circles represent males and females. respectively. while open 
symbols and shaded symbols represent normal and FH, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (10) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. Where an 'n' is recorded this denotes a null or non-
expressing APO( a) aIIele. 
267 
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Characteristics of the FHB family members reported in chapter 6. 
SUbject No. Age Sex TC TG LDL-C Lp(a) Apo(a) FHB phenotype 
144-3 10 F 3.9 0.5 2.1 18.0 23/30 
144-4 9 F 3.9 0.7 1.7 3.0 23/34 + 
144-5 7 F 3.3 0.9 1.2 3.0 23/34 + 
144-6 5 F 2.6 1.1 1.1 1.0 23/30 + 
145-4 14 F 3.3 2.0 1.3 1.0 25/34 + 
145-6 10 M 4.9 1.8 2.7 37.7 19/26 
145-7 8 F 3.5 2.1 1.4 24.6 19/26 + 
145-8 4 M 3.4 0.8 1.8 3.0 25/34 
153-3 14 F 3.5 0.9 2.1 5.0 34/34 
153-4 12 F 2.1 0.4 0.6 4.0 34/34 + 
153-5 11 F 1.9 0.3 0.4 1.0 34/34 + 
174-1-19 24 M 2.2 0.1 0.6 2.0 22/28 + 
174-1-26 17 F 4.6 0.9 3.0 1.9 23/34 
174-1-28 27 M 4.8 2.7 2.7 4.6 22/34 
174-1-29 30 F 4.5 0.4 2.5 3.4 22/34 
174-1-31 31 F 7.1 1.6 5.2 11.2 22/28 
174-1-32 20 M 4.1 2.6 1.5 1.0 23/34 
174-1-36 34 M 4.6 0.1 3.1 2.5 22/34 
174-1-37 22 F 3.8 2.1 1.2 1.8 22/34 + 
174-1-39 28 M 8.3 1.3 6.5 1.8 22/34 
174-2-2 58 F 5.6 1.8 3.4 15.6 13/22 
174-2-3 38 F 5.6 0.1 2.4 68.2 14/17 
174-2-4 70 F 2.5 1.0 0.8 20.7 17/27 + 
174-2-5 36 F 6.0 1.8 4.0 76.2 14/17 
174-2-6 42 M 7.4 15 5.0 79.8 14/17 
174-2-7 65 F 4.0 1.3 1.4 18.6 17/27 + 
174-2-10 66 M 3.4 1.8 0.9 35.2 17/27 + 
174-2-11 35 F 4.9 0.9 3.2 78.0 14/17 
174-2-16 69 M * * * 19.0 
13/22 
174-2-17 40 F 3.5 1.1 0.9 1.2 27/29 + 
174-2-20 20 F 4.1 0.6 2.4 22.8 17/29 
174-2-21 41 M 4.7 1.3 2.7 2.0 27/29 
174-2-22 36 M 5.2 4.0 2.2 19.6 17/29 
174-2-41 39 F 3.3 1.0 0.8 2.5 27/29 + 
174-2-44 24 F 3.0 0.6 1.0 20.0 
17/29 + 
Age: in years at time of sampling, Sex: F female, M male. 
TC (total cholesterol), LDL-C and TG (uig1yceride): in mmol. L'! 
Lp(a): in mg. dL-! 
FHB (familial hypobetalipoproteinaemia): + hypobetalipoproteinaemic, -
normal. 
* sample for lipid measurement lost during analysis, but subject 174-2-16 
previously documented as normolipidaemic. 
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Family 144 
3 
23/30 
FUB pedigree 1. 
4 
23/34 
1 
30/34 
5 
23/34 
2 
23/23 
6 
23/30 
7 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FHB, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. 
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Family 145 
3 4 
26/34 25/34 
FHB pedigree 2. 
1 
19/34 
5 
19/25 
2 
25/26 
6 
19/26 
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7 8 
19/26 25/34 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FHB, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (ID) number. The pairs of numbers below the ID numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. 
Family 153 
3 
33/33 
FUB pedigree 3. 
4 
33/33 
1 
21/33 
5 
33/33 
2 
26/33 
6 
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7 
21/33 
8 
The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FHB, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (lD) number. The pairs of numbers below the 10 numbers denote 
the apo(a) phenotye of the subject as assessed by high resolution 
immunoblotting. 
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The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FHB, respectively. The 
number immediately below the subject symbol denotes that subject's family 
identification (1D) number. The pairs of numbers below the ID numbers den.ote 
the apo(a) phenotye of the subject as assessed by high resolutIOn 
imrnunoblotting. 
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The squares and circles represent males and females, respectively, while open 
symbols and shaded symbols represent normal and FHB, respectively. The ~um'?er i~mediately below the subject symbol denotes that subject's family 
IdentJficatJon (lD) number. The pairs of numbers below the ID ~umbers den.ote ~he apo(a) phenotye of the subject as assessed by hIgh resolutIon 
Immunoblotting. 
Glossary 
r . A po ........................................................................ apo Ipoproteln 
Apo(a) ........................................................ apolipoprotein(a) protein 
A PO ( a) .......................................................... apolipoprotein(a) allele 
BSA .............................................................. bovine serum albumin 
cDNA .............................................................. complimentary DNA 
CHD ............................................................. coronary heart disease 
CV ................................................................ coefficient of variation 
d .................................................................................... density 
[)a .................................................................................. Dalton 
EDT A .................................................... ethylene diamine tetra-acetate 
EIA ................................ " ............................... electroimmunoassay 
EID .......................................... , .................. electroimmunodiffusion 
ELISA .......................................... enzyme linked immunosorbent assay 
FH. '" .................................................. familial hypercholesterolaemia 
F H B ................................................ familial hypobetalipoproteinaemia 
GRIPS ............................ '" Gottingen risk incidence and prevalence study 
H D L ............................................................ high density lipoprotein 
HMG CoA ..... " ............................. hydroxy methyl glutaryl coenzyme A 
HNF 1 (l •••••.•••••.••••••.••.••.•.••••.•••••••....•..•••• hepatocyte nuclear factor 1 a 
H R PO ........................................................... horseradish peroxidase 
IRMA ...................................................... , . immunoradiometric assay 
K .......................................................... '" ...................... kringle 
k b ................................................................................. kilobase 
illL ............................................................. low density lipoprotein 
L M P ................................................................... low melting point 
Lp(a) ...................................................................... lipoprotein (a) 
M A b ............................................................... monoclonal antibody 
mRNA ...................................... '" ......................... messenger RNA 
n .................. " ............................................. null or non-expressing 
NP-40 ....................................................................... nonidet P-40 
PAGE ............................................. polyacrylamide gel electrophoresis 
PBS .......................................................... phosphate buffered saline 
PCR .......................................................... polymerase chain reaction 
PMSF ................................................ phenylmethylsulphonyl fluoride 
PTCA ............... , .............. percutaneous transluminal coronary angioplasty 
RFLP ..................................... restriction fragment lengt~ ~olymorphism 
R I A ................................................................... radIoImmunoassay 
SDS ........................................................... sodium dodecyl sulphate 
SS ....................................... signal sequence 
T . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . .. . ........................................... tail region 
TBS' : :: : : : : : : : : : : : : : :: : : : : : : : : : :: : : : .... , .................... " ....... tris buffered saline 
TC ........................................................................ total choleste!ol 
TG .............................................. ::::::::: :tr~~·;i~~i~g·g~~~g?a~~~.~~ 
TGF-B . .......... .. ................ ............ tissue t e plasminogen activator 
tP A ....................................... : : : : : : : : : : : ...... ve~ low density lipoprotein 
VLDL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . east artificial chromosome 
yAC .................................................... · .. ·y 
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